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Abstract 
 
RASSF7 is part of a novel group of proteins, the N-terminal RAS-
association domain family, which has been recently described as a distinct 
and evolutionary conserved group of Ras association domain containing 
members. The biological function of these members is still unclear, but at 
least some of these proteins may play a role in oncogenesis.  
The aim of this project was to understand the role of mammalian RASSF7, 
which is up-regulated in a variety of cancers but whose direct contribution 
to tumour progression has still to be proved. RASSF7 was found to be an 
integral centrosomal component which is broadly expressed during mouse 
embryogenesis and in adult tissues. It is also expressed in every human 
cell line tested so far. Knockdown of RASSF7 severely impairs cell growth 
in H1792 and HeLa cells and causes major mitotic defects in HeLa cells. 
In fact, RASSF7 depletion compromises spindle formation and 
choromosomal congression in these cells. Furthermore Aurora B, which 
plays a fundamental role in the maintenance of genome integrity, is not 
activated in the knockdowns. Finally microtubule re-growth assays show 
that RASSF7 is a key regulator of microtubule dynamics.  
Overall, the data presented in this thesis provide the first functional 
analysis of human RASSF7, indicating that this protein has a key role in 
regulating microtubules during mitosis, and suggest that the misregulation 
of RASSF7 in cancer cells might promote genomic instability. 
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1  Introduction 
Aberrant control of cell division is closely related to tumour formation and 
many cell cycle regulators are tumour suppressors or oncogenes and 
potential targets of anti-cancer therapies. This thesis will test the 
hypothesis that RASSF7 is a new mitotic regulator. Therefore, the 
introduction will focus on two areas, mitosis and the RASSF family.  
 
1.1 An overview of mitosis 
 
1.1.1 Mitotic stages 
The cell cycle is composed of two main phases termed interphase and 
mitosis. Genome replication (synthesis or S-phase) and the accumulation 
of  cellular material (gap-phases G1 and G2) take place during interphase. 
Mitosis leads to the segregation of the duplicated genome into daughter 
cells and comprises the following stages: prophase, prometaphase, 
metaphase, anaphase and telophase. These mitotic phases are shown in 
a schematic diagram (Figure 1.1A), and in confocal images (Figure 1.1B). 
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A 
     
B 
      
Figure 1.1: Mitotic phases. Diagram of the mitotic phases (A). Immunofluorescent 
images of pig kidney epithelial cells (LLC PK) stained for DNA (red) and tubulin (green) 
(B). Adapted from http://royaleb.wordpress.com/2009/04/27/mitosis/ and Earnshaw 
Laboratory’s website 
(http://www.biology.ed.ac.uk/research/groups/earnshaw/Mitosis.htm).  
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During prophase, condensins are involved in condensing nuclear 
chromatin into chromosomes (Strunnikov, 2003). Cohesins keep 
chromosomes  (which are namely sister chromatids) connected (Michaelis 
et al., 1997) from S phase to mitosis the metaphase-to-anaphase 
transition takes place (Waizenegger et al., 2000).  An other important 
event during phophase is the formation of the mitotic spindle. This event is 
concomitant to the movement of the centrosomes, also referred to as 
spindle poles, to the opposite ends of the cell. This occurs in parallel with 
the nuclear envelope breakdown, which marks the beginning of 
prometaphase. 
In prometaphase, the microtubules originating from the centrosomes reach 
the chromosomes and start their movement torwards the centre of the cell. 
The microtubules are extremely active components of the cytoskeleton  
and capture the chromosomes in the cytoplasm with their plus-ends 
(Hayden et al., 1990; Holy and Leibler, 1994). Chromosomes initially bind 
along the microtubules via kinetochores by forming temporary “lateral 
attachments” (Rieder and Alexander, 1990; Merdes and De Mey, 1990; 
Hayden et al., 1990). Such transient attachments become subsequently  
stable when the chromosome-microtubule attachment occurs via the 
interaction of  microtubules with kinetochores. 
In the amphitelic attachment, microtubules that originate from opposite 
centrosomes become attached to sister kinetochores in a bipolar fashion 
(Figure 1.2). Namely, each sister kinetochore is attached through 
microtubules to the spindle pole facing that kinetochore. However, since 
sister kinetochores attachment occurs via microtubules from one pole first 
and then from the other pole, monotelic, syntelic or merotelic attachments 
often precede amphitelic attachments (Figure 1.2B). These are improper 
attachments and need to be made unstable in order to make the cell 
proceed with the amphitelic attachments (Tanaka, 2008). As illustrated in 
figure 1.2B, they either lead to only one sister kinetochore bound or both 
sister kinetochores bound to the same pole or one of the sister 
kinetochores bound to both poles. 
19 
 
 
Figure 1.2:: Possible kinetochore attachment errors and subsequent incorrect 
chromosome inheritance. A) Unattached kinetochores generate a “wait” signal and 
recruit the spindle checkpoint proteins. The levels of mitotic-arrest deficient homologue-2 
(MAD2) are high at unattached kinetochores (right) and moderately high in case of 
monotelic attachment (left) (see section 1.1.4.2). B) Correction mechanisms exist to 
prevent incorrect chromosome division, which would occur if improper attachments 
(syntelic, merotelic) persisted until anaphase. Monotelic attachment is a normal condition 
during prometaphase before bi-orientation. Modified from (Musacchio and Salmon, 2007). 
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During metaphase, chromosomes align at the centre of the cell to form the 
metaphase plate. Forces that originate from the spindle microtubules and 
the kinetochores counterbalance each other and make this alignment 
possible (Inoue and Salmon, 1995). This is a necessary condition for the 
correct segregation of the duplicated DNA into daughter cells. 
Following the removal of cohesin, sister chromatids separate from each 
other after and anaphase takes place (de Gramont and Cohen-Fix, 2005). 
Anaphase comprises an initial phase during which sister chromatids are 
pulled in opposite directions towards their respective mitotic poles 
(Anaphase A), and a subsequent stage (Anaphase B) when further 
separation of the sister chromatids occurs. Microtubules with opposite 
orientation, that form the spindle midzone where the metaphase plate 
used to lie, and microtubule motor proteins mediate the accomplishment of 
this process.  
In the last mitotic phase, telophase, the cleavage furrow develops where 
the metaphase plate used to be and segregates the separated chromatids 
and cytoplasm into new daughter cells in a process called cytokinesis 
(Barr and Gruneberg, 2007). Numerous regulatory proteins contribute to 
the correct progression of  cytokinesis, which is successfully completed via 
the abscission of the last element of the cytokinetic furrow, called 
midbody.  
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1.1.2 Centrosomes and mitotic spindle  
In proliferating animal cells, centrosomes organise microtubules to form 
the mitotic spindle. This requires nucleation of microtubules at their minus 
end which stabilises and anchors them at the centrosome. Centrosomes 
consist of two centrioles, barrel shaped structures consisting of 
microtubule triplets, arranged perpendicularly to one another (Luders and 
Stearns, 2007). Traditionally, the centrioles were considered to be the 
structures which organise the microtubules, but studies in which the 
centrioles have been removed have shown that they have a non-essential 
role in mitosis (Luders and Stearns, 2007). The other main component of 
the centrosome is a mass of proteins termed the pericentriolar material 
(PCM). It is thought that the PCM is responsible for microtubule 
organisation, and not the centrioles.  
γ-tubulin is one of the main components of the PCM and the key protein in 
microtubule organisation (Stearns et al., 1991; Stearns and Kirschner, 
1994; Zheng et al., 1995). γ-tubulin nucleates the α and β-tubulin subunits 
of microtubules, without being incorporated itself. It does this by forming, 
with a number of other proteins, a ring complex (γTuRC) which mimics the 
plus end of the microtubules, causing the latter to bind to them via their 
minus end. The minus ends are capped which stabilises the microtubules. 
Other proteins found in the PCM are also involved in the organisation of 
microtubules, including pericentrin and ninein (Doxsey, 2001; Bornens, 
2002; Blagden and Glover, 2003). 
Centrosomes undergo a series of events including duplication, separation, 
and maturation to form the poles of the bipolar spindle [reviewed in (Nigg, 
2001)], which are controlled by numerous centrosomal effectors. Polo-like 
Kinase 1 (PLK1) localises to spindle poles to control these early mitotic 
events (Lane and Nigg, 1996; McInnes et al., 2006). In fact, It may affect 
microtubule nucleation at spindle poles through phosphorylation of the Nlp 
(Ninein –like protein) and recruitment of γ-tubulin, thus contributing to the 
formation of the mitotic spindle (Lane and Nigg, 1996; McInnes et al., 
2006). The activity of another important centrosome controller, Aurora A, is 
closely correlated with the maturation of mitotic centrosomes (see section 
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1.1.5.1). Aurora A assists in the centrosome maturation by recruiting 
proteins such as γ-tubulin (Berdnik and Knoblich, 2002), D-TACC 
(Drosophila-Transforming, Acidic, Coiled Coil containing protein) (Giet et 
al., 2002), SPD-2 (Kemp et al., 2004), centrosomin (Terada et al., 2003) 
and chTOG (colonic and hepatic tumour overexpressed protein) (Conte et 
al., 2003), and consequently, participates in spindle assembly and 
stability. Aurora A localisation and kinase activity is controlled by TPX2 
(Kufer et al., 2002; Bayliss et al., 2003), a microtubule binding protein 
involved in the Ran-GTP mediated pathway, which is not only critical for 
spindle organisation and function but also for directional microtubule 
growth (Roscioli et al., 2010). 
 
Many more proteins, which have not yet been identified and/or 
characterised, may also be involved in co-ordinating the centrosome’s role 
in microtubule organisation. In fact, over 100 regulatory proteins are 
known to bind to centrosomes (Doxsey et al., 2005). However, the function 
of many of these proteins is unknown, indicating that cellular processes 
mediated by centrosomes are complex and must be carefully controlled. 
More investigation of centrosome proteins is therefore required. 
In multicellular eukaryotes, the mitotic spindle is made up of microtubules 
extending from two opposing spindle poles (Figure 1.3). The less dynamic 
minus ends of microtubules are located at the spindle poles, while the 
more dynamic plus ends extend away from the poles (Figure 1.3). A 
portion of the microtubules’ plus ends attaches to sister chromatids at the 
kinetochore. Kinetochore microtubules form morphologically distinct 
bundles called K fibers (Figure 1.3), which maintain attachment of 
chromosomes to the spindle and allow them to align and segregate 
(Rieder and Salmon, 1998; McIntosh et al., 2002). The remainder of the 
spindle consists of interpolar microtubules (Figure 1.3). In addition, 
systems with centrosomes as the primary microtubule organising centre 
(MTOC) at the spindle poles have astral microtubules extending away 
from the spindle (Figure 1.3) and play an important role for positioning the 
mitotic spindle. 
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Figure 1.3: Mitotic spindle components. The schematic diagram shows the basic 
components of the mitotic spindle in somatic cells. Microtubules (MT) are shown in gray, 
centrosomes in green, kinetochores in red, and chromosomes in blue. Positions of the 
microtubule minus (-) ends versus (+) ends are indicated. Adapted from (Kline-Smith and 
Walczak, 2004). 
 
1.1.3 Centromeres and kinetochores 
Centromeres are the most condensedand constricted regions of a 
chromosome, to which the spindle fibers are attached during mitosis 
(Figure 1.4). Repetitive DNA sequences, called -satellite DNA, form the 
centromeres. Besides, in the centromeric chromatin a specific histone 
CenpA, substitutes the normal nucleosomal subunit H3 at certain intervals 
(Blower et al., 2002). Another peculiar feature of this region is the 
presence of heterochromatin, which is tightly packed and not transcribed 
(Pidoux and Allshire, 2005). The structural conformation of the centromere 
chromatin determines the sites at which the kinetochore proteins and 
centromere proteins (Cenps) are assembled (Zinkowski et al., 1991; 
Blower et al., 2002). It is plausible that forms of epigenetic controls 
determine where the assembly of the proteins mentioned above occurs 
(Karpen and Allshire, 1997). 
The inner, middle and outer layers constitute the vertebrate kinetochore 
structure (Brinkley and Stubblefield, 1966) (Figure 1.4). It is important to 
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note the presence of a fourth region called the fibrous corona that 
originates from the outer kinetochore. The importance of kinetochores  is 
due to the role they have in mediating and monitoring microtubule-
chromosome attachments. 
 
 
Figure 1.4: Organisation of the centromere-kinetochore region showing the 
location of some of its protein constituents. The kinetochore is composed of several 
distinct layers. Innermost is an inner plate, a chromatin structure containing nucleosomes 
with at least one specialised histone, auxiliary proteins and DNA. Outside this is an outer 
plate composed primarily, if not solely, of proteins (Cooke et al., 1993). Adapted from 
(Maiato et al., 2004).  
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The centromere and inner kinetochore regions (Figure 1.4) are made of 
proteins involved in mediating the binding of the kinetochore to DNA, and 
in kinetochore assembly (Maiato et al., 2004; Cheeseman and Desai, 
2008). Amongst those proteins there the Chromosomal Passenger 
Complex (CPC) molecules. Molecules that are thought  to play a role in 
sensing tension across the kinetochore as a result of microtubule pulling 
forces (3F3/2 antigen) reside in the middle kinetochore. The most external 
layer of the kinetochore and  the fibrous corona contain numerous proteins 
ascribed as part of the spindle checkpoint system (Bub1, Bub3, BubR1, 
Cdc20 and Mad2), involved in microtubule attachment (CenpE and F, 
Ndc80/Hec1 and microtubule associated proteins EB1 and CLASPs), or 
crucial for chromosome movements along microtubules (motor proteins 
CenpE and dynein).  
Kinetochore proteins are differently regulated during mitosis. Some 
components, such as the microtubule motor proteins CenpE, dyneins and 
spindle checkpoint proteins (Mad1, Mad2, BubR1 and Cdc20), differ in 
concentration at the kinetochore depending on the presence of 
microtubule attachments. In fact during early mitosis, they are higly 
present at the kinetochores, but their concentrations are reduced by 
interactions with spindle microtubules in late prometaphase and 
metaphase (King et al., 2000; Hoffman et al., 2001; Shah et al., 2004; 
Howell et al., 2004). Kinetochore components’ response is further 
regulated by the turnover of the proteins. In fact, some proteins, such as 
Cdc20 and Mad2 (Kallio et al., 2002a; Shah et al., 2004; Howell et al., 
2004), are frequently synthetised and degraded so that new molecules 
can bind to the kinetochore.  
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1.1.4 The spindle checkpoint system 
1.1.4.1 The function of the spindle checkpoint 
The spindle checkpoint monitors the presence of errors in the attachment 
of the microtubules to chromosomes during mitosis, in order to guarantee 
that the correct number of chromosomes is inherited by daughter cells 
(Figure 1.2). It delays cell cycle progression from metaphase to anaphase 
until all chromosomes have aligned in a bipolar fashion at the metaphase 
plate [Figure 1.5; reviewed in (Musacchio and Salmon, 2007)].  
The activation of the spindle checkpoint occurs in early mitosis when few 
kinetochores exhibit correct attachment to the microtubules and this 
activation persists until the establishment of proper bipolar attachments. 
The presence of one single improperly attached chromosome could  inhibit 
mitotic progression (Rieder et al., 1995). Incorrecly attached kinetochores 
release inhibitory signals in the cytoplasm therefore preventing all 
chromosomes from initiating anaphase (Rieder et al., 1994; Rieder et al., 
1995). 
The spindle checkpoint releases cell cycle inhibitory signals in response to 
lack of attachment between the kinetochore and the microtubules (Rieder 
et al., 1994; Rieder et al., 1995). Another aspect of kinetochore 
microtubule interaction that determines the activation of the spindle 
checkpoint is the lack of tension (Figure 1.2; synthelic attachment) (Nicklas 
et al., 1995; Li and Nicklas, 1995). Tension is the result of opposite 
directional forces generated by kinetochore microtubules attached to 
chromosomes aligned at the metaphase plate. At this point the spindle 
checkpoint is switched off. The generation of tension was reported to 
increase the number of kinetochore microtubule attachments (Nicklas and 
Ward, 1994; King and Nicklas, 2000). It was suggested that in the 
absence of tension a small number of unattached kinetochores is 
generated, so that the spindle checkpoint is maintained active (Pinsky et 
al., 2006). 
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Figure 1.5: The spindle checkpoint and the cell cycle machinery. In prometaphase, 
the lack of microtubule attachment or tension at the level of the kinetochore contributes to 
the creation of the mitotic checkpoint complex (MCC). The MCC prevents Cdc20 
mediated activation of the APC/C. Separase is kept inactive by securin. In metaphase, 
kinetochores are attached and under tension and no longer originate MCC. Cdc20 can 
therefore activate the APC/C allowing ubiquitination of securing and cyclin B. Separase is 
activated and can cleave sister chromatids to promote anaphase onset. Modified from 
(Musacchio and Salmon, 2007). 
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1.1.4.2 The inhibitory complexes 
The lack of attachment or tension that activates the spindle checkpoint 
generates inhibitory signals consisting of various proteins. Bubs and Mads 
genes (Li and Murray, 1991; Hoyt et al., 1991) were identifired as part of of 
the inhibitory complexes that prevent Cdc20 (cell division cycle 20) 
mediated activation of the anaphase promoting complex/cyclosome 
(APC/c) (Figure 1.5) (Kallio et al., 1998; Sudakin et al., 2001). Free Cdc20 
activates APC/c, which subsequently triggers entry into anaphase by 
polyubiquitination of mitotic substrates, such as cyclin B and securin, 
which leads to their degradation (Peters et al., 2006).  
BubR1 (Bub1 related protein 1), Mad2, Bub3 and Cdc20 proteins form 
mitotic checkpoint complex, or MCC (Kallio et al., 1998; Sudakin et al., 
2001) and diffuse from the incorrectly attached kinetochores throughout 
the cell to inhibit the APC/c. When kinetochore microtubules are not 
attached properly, MCC proteins accumulate at kinetochores. Lack of 
tension triggers BubR1 accumulation to kinetochores, whereas Mad2 
levels respond to in the lack of attachment (Skoufias et al., 2001; 
Logarinho et al., 2004).  
Other proteins are thought to contribute to the formation of inhibitory 
signals at the kinetochores. CenpE, a plus end kinetochore microtubule 
protein (Abrieu et al., 2000) regulates BubR1 kinase activity and is 
involved in Mad1 and Mad2 recruitment to the kinetochores (Chan et al., 
1998; Mao et al., 2003; Mao et al., 2005). CenpE activity is, in turn, 
controlled by Bub1 and Mps1 (monopolar spindle 1) kinases, as they are 
essential for the checkpoint because they are involved in retaining CenpE 
at kinetochores (Sharp-Baker and Chen, 2001; Abrieu et al., 2001; Mao et 
al., 2003). Moreover, Bub1 kinase contributes to the MCC-APC/c 
interaction and Cdc20 phosphorylation (Tang et al., 2004; Morrow et al., 
2005). Finally, Aurora B promotes the creation of detached kinetochores 
that activate the spindle checkpoint (see section 1.1.5.2) (Pinsky et al., 
2006) and cooperate with CenpE, BubR1 and Mad2 at the kinetochores 
(Ditchfield et al., 2003). 
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1.1.4.3 Inactivation of the spindle checkpoint and entry into 
anaphase  
When correct attachments and tension are established, Cdc20 is relieved 
from inhibition and binds to the APC/c (Figure 1.5). The APC/c 
ubiquitinates securin which becomes degraded, thus eliminating the 
inhibition of separase, a cysteine protease responsible for the separation 
of sister chromatids through the hydrolysis of cohesin. Following APC/c 
activation, also cyclin B becomes degraded, which leads to CDK1 
inactivation and exit from mitosis. Consequently, the initiation of anaphase 
is promoted only by the concomitant cleavage of cohesin and inhibition of 
CDK1. 
However, it is not clear what  individual events trigger the inactivation of 
the spindle checkpoint and the MCC production, as multiple events 
contribute to switching off the spindle checkpoint signaling pathway. 
Proper microtubule attachment, modulation of BubR1 kinase activity 
(Putkey et al., 2002; Mao et al., 2003), Dynein mediated silencing of the 
spindle checkpoint (Howell et al., 2001), and degradation of Cdc20 (Reddy 
et al., 2007), are all events required for stopping the inhibitory signal 
production. 
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1.1.5 Aurora B and the Chromosomal Passenger Complex   
1.1.5.1 CPC components and localisation 
Aurora B kinase is part of the CPC with Incenp, Survivin and Borealin 
(Figure  1.6A). The localisation of the complex is subject to cell cycle 
phases (Figure 1.6B). In early mitosis it localises to the chromosome arms, 
then it is detected at the inner centromeres until metaphase-to-anaphase 
transition. CPC proteins then relocate to the spindle midzone and to the 
cell cortex (Cooke et al., 1987). Aurora B and Incenp were first shown to 
be part of the CPC complex when co-immunoprecipitated from different 
model systems and the study of the phenotypes derived from their 
knockdown showed similar defects, such as failure of chromosome 
segregation and inhibition of cytokinesis (Kim et al., 1999; Kaitna et al., 
2000; Adams et al., 2000). Later on Survivin and Borealin were ascribed 
as components of  the same complex (Bolton et al., 2002; Gassmann et 
al., 2004).  
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Figure 1.6: The chromosomal passenger complex (CPC). Schematic structure of the 
CPC (A) and mitotic functions (B). In B) the localisation (green boxes) is correlated with 
the relevant functions (blue boxes) and principal targets (red boxes) during the different 
phases of mitosis relative to tubulin and chromosome dynamics. Adapted from (Klein et 
al., 2006) and (Ruchaud et al., 2007). 
32 
 
Three proteins are considered members of the Aurora kinase family: 
Aurora A, B and C that are Ser/Thr kinases involved in diverse  functions 
during mitosis. Aurora A controls bipolar spindle assembly and the 
maturation of the centrosomes, where it resides (Glover et al., 1995; 
Kimura et al., 1997). Moreover, It promotes entry into mitosis by activating 
PLK1 and CDK1 (Seki et al., 2008; Macurek et al., 2008). Aurora C 
expression appears to be testis specific and in fact regulates 
spermatogenesis along with Aurora B (Kimmins et al., 2007). Aurora C 
could interact with other CPC proteins (Sasai et al., 2004; Li et al., 2004b; 
Yan et al., 2005), but its role during somatic cell mitosis needs more 
investigations. 
Aurora B kinase is the principal component of the CPC. Incenp is required 
for Aurora B activation and the recruitment of the other CPC members. 
The N-terminus of Incenp, which  determines the centromere and midzone 
targeting, interacts with Survivin and Borealin, whereas the region 
adjacient to the C-terminus of Incenp binds to Aurora B (Figure 1.6A) 
(Ainsztein et al., 1998; Bolton et al., 2002; Klein et al., 2006). The 
interaction between Aurora B and Incenp is crucial for the complete 
activation of the kinase (Bishop and Schumacher, 2002; Sessa et al., 
2005).  
The site of action and role of the CPC members is determined by their 
interaction. In fact RNA knockdown experiments or dominant negative 
mutations showed tha the depletion of one of these proteins compromises 
the localisation and function of other CPC molecules (Kaitna et al., 2000; 
Wheatley et al., 2001; Adams et al., 2001; Honda et al., 2003).  
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1.1.5.2 CPC functions 
The localisation of the CPC during the different mitotic phases is in line 
with the functions of the complex (Figure 1.6B). At the beginning of 
mitosis, the CPC is involved in chromosome condensation, spindle 
assembly, correction of improper kinetochore microtubule interactions and 
control of spindle checkpoint activity. In late mitosis the CPC monitors the 
completion of cytokinesis. 
 
Chromosome condensation and cohesion 
Following entry into mitosis, chromosomes acquires the necessary rigidity  
for chromosome segregation in anaphase. Aurora B promotes the 
recruitment of condensin via its phosphorylation, therefore facilitating 
chromosome condensation (Giet and Glover, 2001; Lipp et al., 2007). 
Aurora B provides further contribution to chromosome condensation 
through the phosphorylation of histone H3 (Wei et al., 1998; Hsu et al., 
2000; Giet and Glover, 2001; Adams et al., 2001). 
Aurora B plays a crucial role in controlling cohesion between duplicated 
sister chromatids. As illustrated above, cohesin is lost in two distinct 
phases during mitosis of vertebrate cells (Waizenegger et al., 2000). 
Aurora B determines the removal of cohesin from chromosomes arms 
(Sumara et al., 2002; Losada et al., 2002; Gimenez-Abian et al., 2004) at 
the onset of mitosis, but it restricts cohesin to centromeres during later 
phases of mitosis (McGuinness et al., 2005; Resnick et al., 2006). 
The error correction system and the regulation of CPC activity 
Aurora B plays a vital role in the re-organisation of incorrect microtubule-
kinetochore attachments (Tanaka et al., 2002; Lampson et al., 2004). This 
is achieved via the destabilisation of improper attachments via inhibitory 
phosphorylations that regulate the activity of MCAK (Mitotic centromere-
associated kinesin) (Sampath et al., 2004; Lan et al., 2004; Andrews et al., 
2004).  
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Aurora B has been also involved in the regulation of Ndc80/Hec1, which 
contributes to the formation of stable kinetochore microtubule attachments 
at the outer kinetochore (McCleland et al., 2003; McCleland et al., 2004; 
DeLuca et al., 2005). In fact, the interaction of Ndc80/Hec1 with 
microtubules may be affected by the phosphorylation of Ndc80/Hec1 by 
Aurora B, therefore leading to microtubule release (DeLuca et al., 2006; 
Cheeseman et al., 2006; Emanuele et al., 2007). 
Aurora B plays an important role in correcting merotelic attachments. In 
these erroneous attachments, one of the two sister kinetochores of a 
chromosome is attached to both spindle poles (Figure 1.2), causing the 
kinetochore to be under tension by microtubule pulling forces. If merotelic 
attachments were not detected by the spindle checkpoint, anaphase could 
initiate leading to the formation of lagging chromatids. For this reason 
merotely has been linked to aneuploidy (Cimini et al., 2001). The 
importance of Aurora B in correcting these erroneous connections was 
highlighted by the higher rate of merotelic attachments observed in cells 
where Aurora B activity had been partially inhibited (Cimini et al., 2006). It 
seems that Aurora B activity is mediated by MCAK, which in turn 
destabilises inappropriately attached kinetochore microtubules (Knowlton 
et al., 2006). 
The activity of Aurora B is determined by activating and inhibitory proteins 
(Rosasco-Nitcher et al., 2008). Rosasco-Nitcher and colleagues have 
proposed that Aurora B is first recruited to centromeres as a result of  the 
phosphorylation mediated by other kinases such as PLK1 (Rosasco-
Nitcher et al., 2008). At the centromeres, activating proteins, such as TD-
60 (telophase disk 60) and the interaction with the microtubules promote 
an increase of Aurora activity and autophosphorylation. Aurora B activity is 
suppressed by interactions with substrates that lack priming 
phosphorylations.  In particular, the model explains why the allosteric 
changes induced by the physical interaction with the microtubules are 
necessary for Aurora B activation. The centromeres of unaligned 
chromosomes frequently make contact with microtubules, and such 
interaction persists for centromeres of merotelically attached 
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chromosomes even when they are aligned at the metaphase plate. 
However, once chromosomes are correctly aligned at the metaphase 
plate, centromeres detach from the microtubules and Aurora B cannot 
reach its targets. As a result, the activity of Aurora B would be higher at 
the centromeres of unaligned and merotelically attached chromosomes, 
whereas it would be reduced at the centromeres of metaphase 
chromosomes. 
Spindle checkpoint activity 
 Aurora B cooperates with the spindle checkpoint by destabilising incorrect 
attachments (Pinsky et al., 2006). It has also been suggested a more 
active role of Aurora B in the spindle checkpoint system. In fact, it is role is 
crucial for maintaining the mitotic arrest induced by drugs that promote 
microtubule disassembly (loss of attachment) or hyperstabilisation (loss of 
tension) and therefore trigger the spindle checkpoint activation (Kallio et 
al., 2002b; Hauf et al., 2003; Ditchfield et al., 2003). It is likely that Aurora 
B functions in the tension sensitive branch of the spindle checkpoint given 
that its chemical inhibition leads to more rapid escape from mitotic arrest 
induced by taxol (loss of tension) compared to nocodazole block (loss of 
attachment) (Hauf et al., 2003). Aurora B role has also been linked to the 
recruitment of checkpoint proteins such as Mad2 and BubR1 to 
kinetochores (Ditchfield et al., 2003). Besides, Aurora B would modulate 
BubR1 activity via phosphorylation upon entry into mitosis (Ditchfield et al., 
2003) and would therefore regulate the activity of the spindle checkpoint.  
Cytokinesis 
Aurora B and other CPC members have been shown to control 
chromosome segregation and cytokinesis (Terada et al., 1998; Kaitna et 
al., 2000; Giet and Glover, 2001; Adams et al., 2001): Aurora B controls 
contractile ring formation, an element that determines the site of the 
cytokinetic furrow development, as well as the function of the cytokinetic 
furrow in numerous ways. It phosphorylates Mklp1 and MgcRacGAP/CYK-
4 that are components of the centralspindlin complex, which contributes to 
the formation of the spindle midzone (Mishima et al., 2002; Minoshima et 
al., 2003; Guse et al., 2005). Aurora B  phosphorylation targets during 
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cytokinesis comprise components of the cleavage furrow, such as 
vimentin, myosin II regulatory light chain and desmin (Murata-Hori et al., 
2000; Kawajiri et al., 2003; Goto et al., 2003). 
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1.2 Introduction to the RASSF proteins 
 
1.2.1 The RAS-Association Domain Family 
Ras proteins are small GTPases which alternate between their active, 
GTP-bound state and their inactive, GDP bound state. Ras proteins 
mediate their downstream effects through binding to a variety of proteins, 
termed Ras effectors. Ras effectors bind via their Ras binding domain 
specifically to GTP-bound Ras proteins (van der Weyden and Adams, 
2007). A number of different Ras binding domains exist, including the 
RalGDS/AF6 Ras association (RA) motif which is supposed to form a 
three dimensional structure called an ubiquitin fold (Herrmann, 2003) and 
it is common to over 50 human proteins. One family of proteins which all 
contain a RA domain are the RAS-association domain family (RASSF). 
 
1.2.2 The domain architecture of the Classical and N-
terminal RASSF proteins 
1.2.2.1 Classical RASSFs 
The RASSF proteins have only been identified in the last 10 years. 
RASSF1 was first described in 2000 as 3 variants with high homology of 
their C terminus to the mouse gene, NORE1, which was a known Ras 
effector (Dammann et al., 2000). A human orthologue of NORE1 was later 
identified and termed RASSF5 due to its high homology with RASSF1. To 
date RASSF1 and RASSF5 are the best studied RASSF proteins and so 
far 10 RASSF members have been found in the human genome.  
RASSF1 to 6 are characterised by their RA domain at their carboxy (C)- 
terminal of the protein, and together these 6 proteins form the Classical 
RASSF family. A protein-protein interaction domain, the SARAH domain, 
was identified adjacent to the C terminal RA domain in RASSF1 to 6, as 
shown in Figure 1.7A . This domain is named after the 3 types of proteins 
that contain it Salvador (WW45 in vertebrates), RASSF and Hippo 
(MST1/2 in vertebrates) (Scheel and Hofmann, 2003). SARAH domains 
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have two α-helices which form a novel antiparallel helix conformation 
(Hwang et al., 2007). This fold allows dimerisation between SARAH 
domains so that Salvador, RASSF and Hippo can form homo and 
heterodimers. RASSF 1 and 5 also contain a diacylglycerol/phorbol ester 
binding (DAG) domain, known as protein kinase C conserved region (C1). 
RASSF proteins have no catalytic domain, but their RA domain allows 
them to bind to Ras proteins. Therefore they have the potential to function 
as adaptors which are recruited to activated Ras-GTPases to modulate 
GTPase activity or to mediate downstream actions of GTPases (Avruch et 
al., 2009). Several studies have investigated the ability of RASSF proteins 
to bind to different Ras family proteins. RASSF1 to 5 have been shown to 
bind Ras or Ras-like GTPases either directly or indirectly. For example, 
RASSF1A alone binds weakly to Ras, but when it dimerises with RASSF5, 
it is able to associate with Ras-like GTPases (Ortiz-Vega et al., 2002). 
Mixed reports exist on the ability of RASSF6 to bind to Ras and so this 
requires further investigation (Richter et al., 2009). 
1.2.2.2 N-terminal RASSFs 
More recently the N-terminal members of the family have been identified. 
RASSF7 to 10 do not contain the SARAH domain and their RA domain is 
located at their extreme amino terminus (Figure1.7A) (Sherwood et al., 
2008). N-terminal RASSFs contain coiled coil domains, and it is 
speculated that these are involved in protein-protein interactions to 
mediate downstream signaling, as SARAH domains may do in classical 
RASSFs. The presence of an RA domain is the defining feature of 
classical and N-terminal RASSF proteins. However, the RA domains of the 
two groups have quite different sequences. In fact, the RA domains of 
RASSF7-10 form a phylogenetically distinct group from the RA domains of 
the classical RASSF proteins (Figure 1.7B). The separation between 
groups is not a recent event, Drosophila melanogaster and Caenorhabditis 
elegans have both classical (dmRASSF (Polesello et al., 2006) and 
T24F1.3 respectively (Khokhlatchev et al., 2002)) and N-terminal RASSF 
homologues [Table 1.1  and (Sherwood et al., 2008)].  
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Figure 1.7: Differences between Classical and N-terminal RASSF proteins. The 4 
members of the newly identified N-terminal RA domain family are both structurally (A) and 
phylogenetically (B) distinct from the 6 Classical RASSFs. Adapted from (Sherwood et al., 
2010). 
RASSF7, 8 and 10 are all located close to members of the Ras family in 
the genome (Weitzel et al., 1992; Falvella et al., 2006; Sherwood et al., 
2008). This suggests that the N-terminal RASSF proteins may have co-
evolved with members of the Ras family. No similar association has been 
found between the classical RASSF proteins and members of the Ras 
family, so this unusual juxtaposition of a Ras gene and a potential Ras 
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effector represents another distinction between the two groups (Sherwood 
et al., 2010). 
N-
terminal 
RASSF 
member 
    Chromosome Alternative names Potential 
Drosophila 
orthologue 
Potential 
C. elegans 
orthologue 
RASSF7 11p15.5 HRAS1 cluster1 (HRC1), 
C11orf13 
 
CG5053 
 
 
 
 
K05B2.2 
RASSF8 12p12.3 Human carcinoma 
associated HoJ-1(HoJ-1), 
C12orf2 
RASSF9 12q21.31 peptidylglycine alpha-
amidating monooxygenase 
(PAM) C-terminal interactor 
1 (P-CIP1), 
PAMC1 
CG13875 
RASSF10 11p15.2 similar to peptidylglycine 
alpha-amidating 
monooxygenase C-terminal 
interactor 1 
CG32150 
Table 1.1: The N-terminal RASSF family. The table summarises the nomenclature used 
for the N-terminal RASSF proteins and their genomic positions. Adapted from (Sherwood 
et al., 2010).  
1.2.2.3 RASSF7 
RASSF7 was first identified by Weitzel and colleagues in a cluster of three 
genes closely located to HRas in the genome and called HRC-1 (H-Ras1 
cluster 1) (Weitzel et al., 1992). HRC-1 was recently renamed RASSF7, 
presumably because the protein it encodes contains an RA 
domain/ubiquitin fold and was not part of a recognised family. Through 
alternative promoter usage and splicing of the exons, three different 
transcripts have been predicted by Vega- The Vertebrate Gene Annotation 
database (http://vega.sanger.ac.uk) (Figure 1.8).  
Given the close proximity to HRas in the genome, Weitzel and colleagues 
originally suggested that RASSF7/HRC-1 might be a growth regulator 
(Weitzel et al., 1992). They also suggested, based on Southern blotting, 
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that RASSF7/HRC-1 might be part of a large family of related proteins. 
Only recently the authors predictions about RASSF7 have begun to be 
confirmed.  
Interestingly, RASSF7 maps also near HRAS1 minisatellite which is 
immediately downstream of HRas. Rare alleles of this minisatellite were 
shown to be associated with cancer risk (Krontiris et al., 1985; Krontiris et 
al., 1993) and it was proposed that altered expression of RASSF7 might 
contribute to the increased risk (Weitzel et al., 2000). This generated a 
great deal of interest in the region, however subsequent studies using 
improved technology failed to find a link (Firgaira et al., 1999; Tamimi et 
al., 2003) and the idea that rare alleles of the minisatellite are associated 
with cancer risk is no longer the consensus.   
 
Figure 1.8: Human RASSF7 transcripts. Schematic diagram representing the 
transcripts produced from the RASSF7 locus due to use of different C-terminal exons. 
RASSF7A (Vega: RASSF7-003, OTTHUMT00000254972) is a 1,928 bp transcript that 
initiates transcription from the ATG present in exon 2 and utilises different C-terminal 
exons from the other RASSF7 transcripts. Its translated product is a 373 amino acid 
protein. RASSF7B (Vega: RASSF7-002, OTTHUMT00000254971) differs from RASSF7A 
for the last exon, and generates a 1,745 bp transcript that translates a 337 amino acid 
protein. RASSF7C (Vega: RASSF7-001, OTTHUMT00000254970) has the same number 
of exons of RASSF7B. Its transcript is 1,731 bp long and translates a 337 amino acid 
protein. Recently the number of RASSF7 spliced variants predicted by Vega- The 
Vertebrate Gene Annotation database- has raised to 7. Boxes are exons and lines 
connecting boxes are introns. Filled boxes are coding sequence, whereas empty, unfilled 
boxes are UTRs(untranslated regions).  Each of these proteins contains an N-terminal 
RA domain. Modified from (van der Weyden and Adams, 2007). 
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1.2.3 The function of the RASSF proteins 
1.2.3.1 The tumour suppressor activity of the classical RASSFs 
Several RASSF family proteins are tumour suppressors that are frequently 
down-regulated during the development of human cancer. However there 
are differences in the biological activity of the members (Table 1.2). 
In mammals, epigenetic inactivation of RASSFF1A is frequently reported 
in different tumour entities (Dammann et al., 2005; Agathanggelou et al., 
2005), suggesting RASSF1A functions as a tumour suppressor. In 
agreement with this, the constitutive over-expression of RASSF1A in 
different tumour cell lines (non small cell lung cancer (NSCLC), prostate, 
kidney, nasopharyngeal carcinoma and glioma cell lines) resulted in cells 
exhibiting less viability, suppressed growth, diminished invasiveness, and 
reduced anchorage independence (Dammann et al., 2000; Dreijerink et 
al., 2001; Burbee et al., 2001; Kuzmin et al., 2002; Hesson et al., 2004; 
Chow et al., 2004). In addition, forced expression of RASSF1A in lung, 
kidney, nasopharyngeal and prostate cancer cell lines caused a 
substantial attenuation of tumourigenicity both in vivo and in vitro 
(Dammann et al., 2000; Dreijerink et al., 2001; Burbee et al., 2001; 
Kuzmin et al., 2002; Ji et al., 2002; Li et al., 2004a; Chow et al., 2004). 
The characterisation of Rassf1a knockout mice (van der Weyden et al., 
2005; Tommasi et al., 2005) corroborated the analysis done in human 
tumour cell types. Rassf1a null mice exhibited increased tumourigenesis, 
reduced survival rate and higher physical/ chemical mutagen induced 
tumour susceptibility compared with controls (van der Weyden et al., 2005; 
Tommasi et al., 2005). Thus RASSF1A is a tumour suppressor that is 
frequently impaired in human tumours. 
 
Fragmented and contrasting information is available for another RASSF1 
isoform, RASSF1C. RASSF1C did not show hypermethylation of its 
promoter region and was expressed in almost all tumour cell lines tested 
(Dammann et al., 2000; Burbee et al., 2001). RASSF1C ectopic 
expression did not show any relevant effect on growth, anchorage 
independent colony forming activity and growth inhibitory activity of 
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various lung carcinoma cell lines (Burbee et al., 2001; Ji et al., 2002; Li et 
al., 2004a). However, RASSF1C expression was almost undetectable in 
the KRC/Y renal cell carcinoma cell line (Dreijerink et al., 2001) and 
RASSF1C was reported to exert growth inhibitory effects in the prostate 
cell line LNCaP, the renal cell carcinoma line KRC/Y (Li et al., 2004a), and 
embryonic kidney 293T cells upon the presence of activated RasG12V 
(Vos et al., 2000). In contrast, over-expressed RASSF1C was seen to 
activate osteoblast (Amaar et al., 2005) and MDA-MB231 and T47D 
breast cancer cell proliferation (Reeves et al., 2010). In accordance with 
these data, reduced RASSF1C expression levels led to decreased lung 
cancer (Amaar et al., 2006) and breast cancer (Reeves et al., 2010) cell 
proliferation. Therefore RASSF1C could exert any tumourigenic activity in 
a tumour type specific fashion, which raises questions over the role of 
RASSF1C in tumour suppression.  
Recently, an explanation for the different mechanism of action of 
RASSF1A and RASSF1C isoforms has been suggested by Estrabaud and 
colleagues (Estrabaud et al., 2007). Indeed, the two variants were shown 
to control the degradation of -catenin in different ways (Estrabaud et al., 
2007). -catenin links E-cadherin to the actin cytoskeleton through 
interaction with -catenin in adherens junctions. Abnormalities of cell 
adhesion molecules are known to play an important role in invasion and 
metastasis of cancer cells through loss of cell-to-cell adhesion. -catenin 
accumulation was reported to be promoted by over-expression of 
RASSF1C (Estrabaud et al., 2007) or inactivation of RASSF1A (Estrabaud 
et al., 2007; van der Weyden et al., 2008), which suggests that the 
inhibition of -catenin accumulation could be one of the mechanisms by 
which RASSF1A exerts its tumour suppressor function. RASSF1C 
expression in the absence of RASSF1A could promote tumourigenesis 
(Estrabaud et al., 2007). 
RASSF2 protein was shown to be frequently down-regulated in human 
lung cancer cell lines (Vos et al., 2003a) and RASSF2 promoter 
methylation was observed to occur at a higher incidence rate in primary 
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colorectal cancer cell lines compared to other RASSF genes (Akino et al., 
2005). Over-expression of RASSF2 in A549 human lung cancer cells and 
RKO colorectal cancer cells caused an inhibition of cell growth (Vos et al., 
2003a; Akino et al., 2005). In 293-T cells, this RASSF2 mediated growth 
inhibition was significantly enhanced by the presence of activated K-RAS, 
which binds directly to RASSF2 (Vos et al., 2003a). RASSF2 down-
regulation via siRNA was shown to increase the ability of K-Ras to 
transform rat kidney cells (Akino et al., 2005), suggesting that the 
inactivation of negative regulators of K-ras, such as RASSF2, could result 
in a growth advantage during tumour cell transformation (Akino et al., 
2005; Park et al., 2007; Nosho et al., 2007). 
RASSF3 promoter methylation has not been extensively studied and no 
systematic functional characterisation of RASSF3 has been performed to-
date. 
RASSF4 expression is down-regulated in some human tumour cell lines 
and primary tumours and this correlated well with methylation of the 
promoter (Eckfeld et al., 2004). RASSF4 was reported to inhibit cell colony 
formation when over-expressed in MCF-7 cells and A549 lung cancer cells 
(Eckfeld et al., 2004) and this effect could be enhanced by the presence of 
activated K-Ras, to which RASSF4 binds directly in a GTP dependent 
manner via the RA domain (Eckfeld et al., 2004). 
NORE1 (RASSF5) transcripts were shown to be expressed at very low 
levels in several cancer cell lines compared to normal tissues (Tommasi et 
al., 2002; Vos et al., 2003b), although promoter silencing by methylation 
was reported to be the likely mechanism behind the down-regulation of 
NORE1 expression only in some studies (Vos et al., 2003b; Hesson et al., 
2003). NORE1 is known to induce growth suppression. The expression of 
NORE1A or NORE1B inhibited cell growth in some NORE1 deficient 
cancer cell lines (namely A549 and G361) (Vos et al., 2003b; Aoyama et 
al., 2004), but not in others (NCI-H4460 and M14) (Aoyama et al., 2004) 
despite the RAS signaling being disrupted in all of them primarily due to a 
RAS activating mutation. Stable expression of NORE1A also impairs the 
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anchorage independent growth of A549 human lung cells and PC12 
pheochromocytoma cells (Aoyama et al., 2004; Li et al., 2005). A possible 
explanation for the growth suppressive effects of NORE1A  could be found 
in its cytoskeletal localisation and could occur through the ERK signaling 
pathway (Moshnikova et al., 2006). 
Similar to the other classical RASSFs, reduced levels of RASSF6 
transcripts were found in numerous primary tumour tissues (Allen et al., 
2007), but this phenomenon seemed to be only partially linked to 
epigenetic mechanisms of silencing (Allen et al., 2007). RASSF6 over-
expression caused a decrease in cell survival but this phenomenon was 
specific for particular tumour cell types. RASSF6 inhibited the growth and 
cell survival of MCF-7 human breast tumour cells and A549 human lung 
cancer cells, but not of H1299 human lung tumour cell line (Allen et al., 
2007). Conversely, RASSF6 siRNA knockdown (KD) in the H1792 NSCLC 
cell line enhanced their ability to grow in soft agar, relative to control cells 
(Allen et al., 2007). 
In Drosophila melanogaster, a “tumour suppressor” effect of dRassf was 
first observed by Polesello and colleagues in 2006 as dRASSF appeared 
to antagonise Ras1 signaling in growth control and Salvador mediated 
Hippo activation in vivo (Polesello et al., 2006). Recently, the same group 
has demonstrated the presence of a dRassf-Hippo containing complex, 
which associates with a Drosophila PP2A phosphatase complex, 
dSTRIPAK (Drosophila Striatin-interacting phosphatase and kinase), as a 
negative regulator of Hippo signaling (Ribeiro et al., 2010). 
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Classical 
RASSFs 
Effect caused on cell 
viability/cell growth following 
protein up-regulation 
Effect caused on cell 
viability/cell growth following 
protein down-regulation 
RASSF1A   
RASSF1C Contrasting data  
RASSF2   
RASSF3 Not known Not known 
RASSF4  Not known 
RASSF5   
RASSF6   
Table 1.2: The tumour suppressor activity of the classical RASSFs. Summary of 
effects caused by up or down- regulation of RASSF proteins on cell viability and cell 
growth. Arrows pointing upwards indicate enhanced cell ability to grow; arrows pointing 
downwards indicate reduction or inhibition of cell growth. 
1.2.3.2 The classical RASSFs and their microtubule activity 
RASSF1A was seen to induce microtubule stabilisation and protect cells 
from the actions of microtubule depolymerising agents, such as 
nocodazole, when re-expressed in a RASSF1A negative cell line (Liu et 
al., 2003; Vos et al., 2004; Rong et al., 2004; Dallol et al., 2004). Such a 
microtubule stabilising property of RASSF1A was shown to critically 
depend on RAN-GTP, via the MST2 (mammalian Sterile20-like 2) induced 
phosphorylation of RCC1 (Regulator of chromosome condensation 1) 
(Dallol et al., 2009a). The association of RASSF1A with the microtubules 
could well contribute to the tumour suppressor activity of this protein. In 
fact the interaction with C19ORF5, a microtubule-associated protein 
confirmed to interact with RASSF1 (Liu et al., 2002a; Song et al., 2004) 
was suggested to be required for the proper control of the APC/Cdc20 
complex during mitosis (Song et al., 2004), as explained in detail in the 
following section. Interestingly, RASSF1A was recently proposed by 
Verma and co-workers as a novel substrate of protein kinase C (PKC), 
which would play a key role in determining RASSF1A control of 
microtubule organisation via the RA domain phosphorylation sites (Verma 
et al., 2008). 
RASSF1C, the other RASSF1 isoform, was shown to hyperstabilise 
microtubules (Liu et al., 2005). However, when its expression was co-
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induced with C19ORF5, it did not associate with microtubules and did not 
hyperstabilise them (Liu et al., 2005). Therefore RASSF1C seems to be 
less effective at stabilising microtubules compared to RASSF1A. 
1.2.3.3 The classical RASSFs and their modulation of the cell cycle 
RASSF1A was demonstrated to play a role at the G1-S checkpoint (Figure 
1.9) and showed to modulate the levels of cyclin D1 in numerous human 
cell lines (Shivakumar et al., 2002; Agathanggelou et al., 2003). Cyclin D 
production may be induced by growth factors which stimulate the Ras-Raf-
Erk signaling cascade. RASSF1 was found to cause inhibition of the 
epidermal growth factor (EGF) dependent activation of the Erk pathway. 
When co-expressed with plasma membrane calmodulin dependent 
calcium ATPase 4b (PMCA4b) in mammalian cells, RASSF1 was indeed 
able  to impair proliferation (Armesilla et al., 2004). 
Other studies demonstrated that the RASSF1A induced G1 cell cycle 
arrest may occur via inhibition of the c-Jun-NH2-kinase (JNK) pathway 
(Whang et al., 2005) (Figure 1.9). RASSF1A directly interacts with the 
kinase MST1 (Khokhlatchev et al., 2002) which can modulate JNK activity 
(Ura et al., 2007). RASSF1A could also affect the G1 transition via its 
direct interaction with the transcription factor p120E4F (Fenton et al., 2004). 
RASSF1A enhances the ability of p120E4F to suppress cyclin A2 which in 
turn regulates CDK2 and thereby controls progression through S phase. In 
this way RASSF1A synergises with p120E4F to induce cell cycle arrest 
(Fenton et al., 2004; Ahmed-Choudhury et al., 2005).  
In addition to a G1 arrest, RASSF1A can block the cell cycle at G2/M. 
Over-expression of RASSF1A caused G2/M arrest in MCF-7 breast cancer 
cell line (Rong et al., 2004), in HeLa cells and 293T human embryonic 
kidney cells (Song et al., 2004; Rong et al., 2004). The RASSF1A 
mediated M phase arrest observed in 293T and HeLa cells was explained 
by Song and colleagues through the direct binding of RASSF1A with 
Cdc20 (Song et al., 2004; Song et al., 2005) (Figure 1.9), although it 
should be noted that this interaction is controversial (Liu et al., 2007). This 
blocks the ability of Cdc20 to activate the ubiquitin ligase activity of the 
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APC, and consequently the degradation of the mitotic cyclins A and B, 
which is essential for the progression of mitosis (Song et al., 2004). The 
negative effect exerted by RASSF1A on APC-Cdc20 activity during mitosis 
appeared to be independent of Mad2 and Emi1 (negative regulators of 
Cdc20 during mitotic progression) (Song and Lim, 2004; Song et al., 2004)  
and to be regulated by C19ORF5. The depletion of this RASSF1A-binding 
protein prevented both the localisation of RASSF1A to the spindle poles 
and its binding to Cdc20, which resulted in premature destruction of mitotic 
cyclins and acceleration of mitotic progression (Song et al., 2005). In 
addition C19ORF5 KD caused mitotic abnormalities and disrupted the 
MTOC (Dallol et al., 2007). However, in contrast with these data, Rassf1a 
null mouse embryonic fibroblasts (Rassf1a -/- MEFs) showed delayed 
mitosis (Guo et al., 2007). The protracted period of time observed for 
completing mitosis was also shown to be reverted to a normal period of 
time by the expression of either RASSF1A or components of the 
mammalian Hippo pathway (MST2, WW45 and LATS1) (Guo et al., 2007).  
The involvement of RASSF1A in mitosis is further underlined by the 
interaction with Aurora A, an established regulator of cell division. Aurora 
A phosphorylates RASSF1A on residues located in the microtubule-
binding domain, and mutations of these residues which mimic constitutive 
phosphorylation of RASSF1A disrupt its interaction with the microtubules, 
and suppress its ability to induce M phase cell cycle arrest (Rong et al., 
2007). Interestingly, RASSF1A was also reported to regulate Aurora A 
activation, as RASSF1A down-regulation, or conversely over-expression, 
resulted in a marked decrease or increase of Aurora A phosphorylation on 
Thr288, respectively (Liu et al., 2008).  
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Figure 1.9: RASSF1A and cell cycle control. Summary of some of the known partners 
and pathways of RASSF1A. Direct interaction between RASSF1A and microtubule-
associated proteins results in RASSF1A localising the microtubules, stabilising them and 
regulating mitosis. Repression of cyclins A and D1 by RASSF1A results in cell cycle 
arrest. Modified from (Donninger et al., 2007). 
RASSF1C contribution to cell cycle regulation has been less well studied 
compared to RASSF1A. RASSF1C over-expression induced cell cycle 
arrest in the renal cell carcinoma cell line KRC/Y (Li et al., 2004a), but not 
in HeLa cells (Song et al., 2004).  
Cell cycle arrest was suggested as a mechanism of growth inhibition also 
for RASSF2. RASSF2 expressing 293-T cells showed a 20% decrease in 
the G2/M phase of the cell cycle, suggesting the cells tended to arrest in 
the G0/G1 phase (Vos et al., 2003a). 
NORE1A was found to induce growth suppression through a mechanism 
independent of Ras or the MST1/2 kinases. As observed for RASSF1A, 
expression of NORE1A caused a significant decrease in the number of 
cells in S phase and a reciprocal increase of the fraction in G1 phase 
(Aoyama et al., 2004). 
1.2.3.4 Classical RASSFs mediated control of genomic stability 
Over-expression of RASSF1A or RASSF1C in the human embryonic 
kidney cell line 293T or human lung tumour cell line NCI-H1299 impaired 
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the ability of activated RAS to induce genomic instability (Vos et al., 2004), 
such as polyploidy, aneuploidy, and improper organisation of the nuclear 
structure (Denko et al., 1994; Saavedra et al., 2000; Vos et al., 2004). 
Human foreskin fibroblasts depleted of RASSF1A were reported to be 
bicentrosomal and showed various mitotic spindle abnormalities including 
the formation of multi-polar spindles, misalignment of chromosomes, and 
lagging chromosomes, indicative of chromosome instability (Song et al., 
2004). However, cultured fibroblasts from Rassf1a null mouse embryos 
(Rassf1a-/- MEFs) did not show a significant increase of polycentrosomal 
cells or any obvious chromosomal rearrangements by spectral karyotyping 
analysis (van der Weyden et al., 2005). It has to be noted though, that 
these cells exhibited delayed mitosis and subsequent cytokinesis failure 
albeit apparently genomically stable (Guo et al., 2007). Thus, RASSF1A 
could be potentially involved in the maintenance of genomic stability, but 
further detailed analysis will be required to determine the specific role of 
this gene in this context. 
1.2.3.5 The classical RASSFs and apoptosis 
Numerous lines of research report the RASSF family proteins to be pro-
apoptotic  (Vos et al., 2000; Vos et al., 2003a; Vos et al., 2003b; Vos et al., 
2004; Eckfeld et al., 2004). 
Over-expression of RASSF1A in MCF-7 breast cancer cells caused 
morphological and biochemical changes indicative of apoptosis (cell 
rounding, increased annexin V staining and appearance of a sub-G1 
population) (Baksh et al., 2005). Apoptosis was also triggered by 
temporary expression of RASSF1C in 293-T cells and enhanced by co-
expression with mutant active Ras (Vos et al., 2000), but others failed to 
observe this phenomenon in the same cell line over-expressing only wild 
type RASSF1A or RASSF1C (Rabizadeh et al., 2004).  
If the initiation of apoptosis by any over-expressed RASSF1 isoforms can 
be debated, there is strong evidence that RASSF1A can participate in pro-
apoptotic pathways (Figure 1.10). In a yeast two-hybrid assay RASSF1, as 
NORE1, was shown to specifically bind the pro-apoptotic MST1 
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(Khokhlatchev et al., 2002). MST1/2 over-expression promotes apoptosis 
and normally becomes activated by auto-phosphorylation, which can be 
inhibited by co-transfection with RASSF1A, RASSF1C, or NORE1 
(Praskova et al., 2004). NORE1A and RASSF1A are constitutively 
complexed with MST1 and when endogenous MST1/2 is prevented from 
associating with these proteins, Ras induced apoptosis is inhibited 
(Praskova et al., 2004; Avruch et al., 2006). 
Hippo, the Drosophila homologue of MST1, forms part of an important 
tumour suppressor network which is crucial for growth control (Saucedo 
and Edgar, 2007; Harvey and Tapon, 2007). Hippo functions by regulating 
the kinase Warts which in turn regulates the transcriptional activator 
Yorkie, which controls apoptosis-associated genes. Recent work shows 
that RASSF1A induced apoptosis acts via a similar pathway, which 
involves MST2 activating LATS (large tumour suppressor), causing the 
release of YAP (yes-associated protein 1) which promotes transcription of 
p73 (Matallanas et al., 2007). NDR (Nuclear Dbf2-related) kinases, which 
are related to LATS kinases, can also function downstream of MST1 to 
promote apoptosis (Vichalkovski et al., 2008). 
RASSF1A may also function as a scaffold for the assembly of an apoptotic 
complex containing CNK1, a pro-apoptotic adapter protein that can bind to 
RASSF1A or RASSF1C (Rabizadeh et al., 2004) and requires interaction 
with RASSF1A-MST1 in order to induce apoptosis (Rabizadeh et al., 
2004). Furthermore, RASSF1A could control apoptosis by regulating the 
activity of Bax, a Bcl2 family component involved in the apoptotic 
machinery (Tan et al., 2001; Sharpe et al., 2004). Stimulation of death 
receptors with TNF (tumour necrosis factor ) or TNF-related 
apoptosis-inducing ligand (TRAIL) was shown to cause the recruitment 
and subsequent interaction of RASSF1A and modulator of apoptosis-1 
(MAP-1), a Bax-binding protein (Tan et al., 2001), at the site of the 
receptor complexes (Baksh et al., 2005). Bax activation was further 
enhanced by the concomitant presence of K-Ras, RASSF1A, and MAP-1, 
and knocking down RASSF1A impaired the ability of oncogenic K-Ras to 
activate Bax (Vos et al., 2006).  
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Figure 1.10: RASSF1A and apoptosis. Schematic diagram of RASSF1A interactions 
with CNK1, MST1, Salvador and MAP-1, which may allow RASSF1A to modulate 
apoptosis. Modified from (Donninger et al., 2007).  
It was reported that RASSF1C binds to Daxx (involved in apoptosis and 
transcriptional repression) in nuclear protein complexes called 
promyelocytic leukaemia-nuclear bodies (Kitagawa et al., 2006). Following 
DNA damage, Daxx is degraded and RASSF1C translocates to the 
microtubules and participates in the activation of stress-activated protein 
kinase/c-Jun N-terminal kinase (SAPK/JNK) pathway, which plays a 
crucial role in the regulation of gene expression leading to apoptosis 
(Kitagawa et al., 2006). In contrast with these data however, Reeves and 
colleagues have recently published that RASSF1C down-regulates several 
pro-apoptotic genes, including Bax and Caspase 3, in breast cancer cells 
(Reeves et al., 2010). Caspase 3 down-regulation due to RASSF1C over-
expression was further shown to reduce the sensitivity of breast cancer 
cells to the apoptosis inducing agent etoposide (Reeves et al., 2010). 
Therefore it is debatable that RASSF1C has a pro-apoptotic role. 
When exogenously expressed, RASSF2 was found to induce actin 
polymerisation changes and suppression of the Ras-RhoA pathway in 
colorectal cancer cells. The subsequent loss of adhesion was seen to 
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cause a suspension dependent apoptosis, called anoikis (Akino et al., 
2005).  
Over-expressed RASSF4 induced caspase mediated cell death in 293-T 
cells, which was enhanced by the presence of activated K-Ras, and was 
shown to interact with exogenously expressed MST1 (Eckfeld et al., 
2004). 
There are conflicting reports about the ability of NORE1 on its own to 
induce apoptosis (Khokhlatchev et al., 2002; Vos et al., 2003b; Aoyama et 
al., 2004; Li et al., 2005). On the other hand, co-expression of NORE1 and 
MST1, to which NORE1 was shown to bind (Khokhlatchev et al., 2002; 
Hwang et al., 2007), has a greater pro-apoptotic effect than either protein 
alone (Khokhlatchev et al., 2002). Apoptosis caused by the over-
expression of constitutively active Ki-RasG12V in a variety of cell lines is 
counteracted by over-expression of either the NORE1-binding domains of 
MST1 or by the portion of NORE1 that binds MST1 (Khokhlatchev et al., 
2002). NORE1/RASSF1 proteins not only would mediate the Ras 
apoptotic effect, they would also direct MST1 to sites of activation and 
perhaps co-localisation with endogenous substrates (Praskova et al., 
2004). 
Similar to what has been found for RASSF1A, forced expression of 
RASSF6 caused apoptosis in both the MCF-7 cell line (Allen et al., 2007) 
and the HeLa cervical cancer cell line (Ikeda et al., 2007). On the other 
hand, RASSF6 KD was seen to partially block TNF induced cell death in 
HeLa cells (Ikeda et al., 2007). Furthermore RASSF6 was shown to 
activate Bax, induce cytochrome c release and initiate caspase dependent 
and caspase independent pathways of apoptosis (Ikeda et al., 2007). 
RASSF6 was found to interact with MAP-1 and this binding was made 
more stable by the presence of activated K-Ras (Allen et al., 2007).  
1.2.3.6 The classical RASSFs and cell migration/adhesion 
Agathanggelou and colleagues showed that genes for cell adhesion and 
motility, such as tropomyosin I and CDH2 were up-regulated in A549 
NSCLC cells stably expressing RASSF1A (Agathanggelou et al., 2003). 
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RASSF1A could well control cell migration given that RASSF1A 
methylation was more frequently observed in tumours showing metastasis 
(Byun et al., 2001; Calvisi et al., 2006). Over-expressed RASSF1A affects 
the ability of A549 NSCLC cells to migrate either through  a transwell filter 
or to close a wound (Dallol et al., 2005). If stably transfected with 
RASSF1A, the same cells exhibited increased cell-cell adhesion (Dallol et 
al., 2005). Rassf1a deficient MEFs and RASSF1A KD HeLa cells showed 
loss of cell-cell adhesion and increased cell migration. This last effect 
could be Phosphatidylinositol 3-kinase (PI3-K) mediated, given the ability 
of LY294002, a PI3K inhibitor, to abrogate that effect (Dallol et al., 2005). 
In addition, activation of the PI3K pathway was also suggested by the 
detection of increased phosphorylation of the PI3-K downstream effector 
AKT in the RASSF1A depleted cells (Dallol et al., 2005). Interestingly, 
Rassf1a-/- cells showed also increased levels of the small GTPase Rac1, 
but the mechanisms behind this phenomenon are still unknown (Dallol et 
al., 2005). 
Over-expressed RASSF1C was recently found to enhance T47D cell 
invasion/migration in vitro, which suggests a role for RASSF1C in 
stimulating metastasis in breast cancer cells (Reeves et al., 2010). 
1.2.3.7 The classical RASSFs in the immune system 
NORE1B has been found to regulate lymphocyte adhesion (under the 
name of RAPL- regulator of adhesion and polarisation enriched in 
lymphocytes) (Katagiri et al., 2003). In fact, NORE1B was found to 
associate with the Ras family member Rap1, which modulates integrin 
activity (Kinashi and Katagiri, 2005). Nore1B knockout mice exhibited 
defective adhesion and migration of lymphocytes and dendritic cells, which 
led to an impaired immune response (Katagiri et al., 2004). NORE1B was 
further linked to lymphocyte polarity and adhesion (via the interaction with 
the proapoptotic kinase MST1) (Katagiri et al., 2006), T cell migration 
(Miertzschke et al., 2007), and directional migration of vascular endothelial 
cells (Fujita et al., 2005). Endogenous NORE1B was also suggested to 
respond to T-cell receptor (TCR) stimulation by recruiting active Ras, 
which co-precipitates with NORE1B, to the plasma membrane and by 
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contributing to the localisation of Carma1, a regulator of TCR induced NF-
B activator (Ishiguro et al., 2006). 
RASSF6 was shown to suppress NF-B pathway in a lung epithelial cell 
line and suggested to play a role in dictating the degree of inflammatory 
response to the respiratory syncytial virus (Allen et al., 2007). 
In summary, as shown in Table 1.3, the biological function of the classical 
RASSF proteins is much too complicated to be ascribed to one process 
only. The members of this family have been linked to microtubule stability, 
cell cycle control and apoptosis, all of which may contribute to the tumour 
suppressor activity of these proteins. 
Function Classical RASSF proteins involved 
MICROTUBULE ACTIVITY 1A, 1C 
MODULATION OF CELL CYCLE 1A, 1C, 2, 5A 
APOPTOSIS 1A, 1C,2, 4, 5, 6 
CELL MIGRATION/ ADHESION 1A, 1C 
REGULATION OF IMMUNE SYSTEM 5B, 6 
Table 1.3: Functions of the classical RASSFs. A summary of what is currently known 
about the function of individual classical RASSFs in different cellular processes. 
1.2.3.8 The function of the N-terminal RASSF proteins 
The differences between RASSF7-10 and RASSF1-6 make it important 
that RASSF7-10 proteins are not assumed to be an extension of the 
classical RASSF proteins and may therefore have a different role. The N-
terminal RASSFs, whose name was given to refer to a distinctive group of 
proteins, represent a new family of potential Ras effectors which suggests 
they may have important and specific biological functions. In comparison 
with the classical RASSFs little is known about the function of the N-
terminal RASSF7-10. 
RASSF8 may be a tumour suppressor. The first studies that aimed to 
characterise the function of this protein found that the over-expression of 
RASSF8 protein in A549 lung cancer cell lines significantly reduced 
anchorage independent growth, which has been correlated with tumour 
progression and metastasis (Falvella et al., 2006). More recently, Langton 
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and colleagues started to shed light on the mechanism of action of the 
Drosophila RASSF8 orthologue, Boa (Langton et al., 2009). Boa acts in 
concert with dASPP (Ankyrin-repeat, SH3-domain, and Prolin-rich-region 
containing Protein) at the adherens junctions to promote dCsk (Drosophila 
C-terminal Src kinase) activity (Langton et al., 2009). Boa-dASPP 
mediated modulation of cell-cell adhesion was shown to be crucial for the 
normal cellular rearrangements and for normal localisation of the cell 
adhesion molecule E-cadherin in the Drosophila eye (Langton et al., 
2009). Boa-dASPP complex at the adherens juctions may be required to 
locally prevent inappropriate Src activation and in fact Boa mutants 
exhibited an overgrowth phenotype, reduced apoptosis and cell-cell 
adhesion defects (Langton et al., 2009). It is known that inappropriate 
disruption of cell-cell contacts can lead to excess proliferation and is a 
hallmark of the metastatic process in mammals (Vasioukhin et al., 2001; 
Yang and Weinberg, 2008). 
The regulation of cell-cell adhesion could also be key for understanding a 
possible tumour suppressor function of human RASSF8. Lock et al. found 
that endogenous RASSF8 interacted with endogenous E-cadherin in lung 
cancer cells, where E-cadherin, -catenin and NF-B p65 localisation at 
the adherens junctions was abolished following RASSF8 depletion (Lock 
et al., 2010). In RASSF8 KD lung cells, -catenin was seen to re-locate 
back to the nucleus, where the authors observed increased -catenin/ T-
cell factor (TCF) promoter activity, which suggested that RASSF8 
depletion may result in increased -catenin/TCF signaling as part of the 
canonical Wnt signaling pathway (Lock et al., 2010). A549 RASSF8 
depleted cells showed an increase in anchorage independent growth in 
soft agar when compared to controls and were able to form solid tumours 
when inoculated into severe combined immunodeficiency (SCID) mice 
(Lock et al., 2010). The authors of the study also observed that RASSF8 
KD led to enhanced cell proliferation in Xenopus embryos and A549 
confluent cells, indicating loss of contact dependent growth inhibition. 
Thus RASSF8 suppressed growth in a manner dependent on contact 
inhibition and was also suggested to control proliferation of NSCLC cells 
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by modulating Wnt and NF-B signaling pathway (Lock et al., 2010). 
Furthermore, there is evidence suggesting a role for RASSF8 in the 
organisation of the cytoskeleton. A549- RASSF8 RNAi cells exhibited a 
disorganised actin cytoskeleton and increased in vitro motility and 
migration abilities, which makes it plausible to speculate that a role of 
RASSF8 in regulating cell-cell adhesion may contribute to the 
maintenance of normal tissue architecture (Lock et al., 2010).  
RASSF9 has been linked to vesicle trafficking (Chen et al., 1998). Rat 
Rassf9 (also called P-CIP1) interacted with immunoprecipitated PAM-1 
(peptidylglycine -amidating monooxygenase), a transmembrane protein 
found in secretory vesicles of neurons and endocrine cells (Chen et al., 
1998). This result confirmed a previous yeast two-hybrid screen (Alam et 
al., 1996) and was further substantiated by the association of exogenously 
expressed Rassf9 with recycling endosomes (Chen et al., 1998). 
Interestingly, RASSF9 is the only member of the N-terminal RASSF 
proteins which has currently been shown to bind Ras proteins. Pull-down 
experiments with RASSF9 and Ras family GTPases showed that RASSF9 
binds N-Ras, K-Ras and R-Ras (Rodriguez-Viciana et al., 2004). 
RASSF10 was recently proposed as a candidate tumour suppressor gene  
in gliomagenesis. Hill et al. showed that forced expression of RASSF10 in 
glioma cell lines not expressing endogenous RASSF10 suppressed the 
ability to form colonies. Conversely, transient depletion of endogenous 
RASSF10 in U87 glioma cells exhibited an increased ability in their 
anchorage independent growth potential compared to control cells (Hill et 
al., 2010). The growth inhibitory effects of RASSF10 on cell proliferation 
were further confirmed by cell viability assay and 5-ethynyl-2′-deoxyuridine 
(EdU) incorporation (Hill et al., 2010). 
RASSF7 function has been linked to some key biological processes 
including the regulation of cell death and proliferation. A large scale RNAi 
screen suggested that RASSF7 is required for necroptosis (Hitomi et al., 
2008), a regulated form of necrosis which is distinct from apoptosis. To 
date the most informative work on the role of RASSF7 has been carried 
58 
 
out by my colleagues (Sherwood et al., 2008). Xenopus rassf7 was 
demonstrated to be essential for cell cycle progression and cell survival 
(Sherwood et al., 2008). In embryonic cells where rassf7 was not 
expressed, mitotic spindle defects and mitotic arrest occurred with 
subsequent nuclear fragmentation and apoptosis (Sherwood et al., 2008). 
However, the signaling pathways in which RASSF7 participates remain a 
mystery. The physiological functions of RASSF7 in mammals are also 
unknown, so further work is required. 
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1.3 Aims of the thesis  
The primary aim of this project was to understand the role of RASSF7 in 
mammalian, and in particular in human, cells. In order to address this 
fundamental question multiple approaches were used:   
1) Analysis of the expression pattern. This approach was intended 
for evaluating whether the expression of mammalian RASSF7 is 
restricted to developmental stages, specific to particular tissues 
and cell lines or, conversely, broadly expressed.  
2) Study of the subcellular localisation. This aimed to provide 
understanding of where RASSF7 functions within the human cells. 
This is key to understanding the function of the protein.    
3) Characterisation of the function. To test if human RASSF7 plays 
a role in mitosis, as its Xenopus counterpart (Sherwood et al., 
2008), and, more in general, to understand what the consequences 
of RASSF7 depletion are for the human cells. 
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2 Materials and Methods 
 
2.1 Materials 
Unless otherwise specified, all chemicals and general laboratory reagents 
were of molecular biology grade and were purchased from either Sigma-
Aldrich Chemical Company or Fisher Scientific UK Ltd. 
2.1.1 Reagents 
Phosphate Buffered Saline (PBS):  
Purchased from OXID. 
Phosphate Buffered Saline - Tween 20 (PBST):  
PBS 0.1% (v/v) Tween-20. 
Tris Buffered Saline - Tween 20 (TBST):  
10 mM Tris, (pH 7.4), 154 mM NaCl, 0.1% (v/v) Tween-20. 
Luria Broth (LB):  
1% (w/v) Bacto™ Tryptone (BD Biosciences), 0.5% (w/v) Bacto™ Yeast 
Extract (BD Biosciences), 0.5% (w/v) NaCl. Autoclaved. 
Agar Plates:  
1% (w/v) Bacto™ Tryptone (BD Biosciences), 0.5% (w/v) Bacto™ Yeast 
Extract (BD Biosciences), 0.5% (w/v) NaCl, 1.5% (w/v) Agar. Autoclaved  
and once cooled down, the appropriate antibiotic was added (100 g/ml 
ampicillin or 30 g/ml kanamycin) and poured into plastic plates. Kept at 
4°C. 
2.1.1.1 Buffers for in situ hybridisation  
Diethyl pyrocarbonate (DEPC)-treated water : 
0.1% (v/v) DEPC in distilled H20 (dH2O) was incubated overnight and 
autoclaved. 
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4% Paraformaldehyde (PFA): 
The PFA  4% (w/v) was dissolved in PBS, made with DEPC treated water 
(autoclaved) by heating at 65°C with stirring. When dissolved and cooled, 
it was adjusted to pH 7.4. 
20X Standard Saline Citrate (SSC) buffer: 
3M NaCl, 0.3 M sodium citrate in dH2O (pH 7, autoclaved). 
Tris-Glycine buffer: 
0.5 M Tris-Cl (pH 8, autoclaved), 0.5 M glycine in DEPC treated dH2O. 
100X Denharts: 
2% (w/v) ficoll, 2% (w/v) polyvinylpyrrolidone, 2% (w/v) Bovine Serum 
Albumin (BSA) (Fraction V, Sigma 85040C) in dH2O. When dissolved, it 
was sterilised. 
In situ hybridisation solution: 
40% (v/v) Formamide (Sigma 47671), 1X Denharts, 5X SSC, 100 g/ml 
tRNA (Sigma R8508), 100 mg/ml herring sperm (Sigma D7290) in DEPC 
treated dH2O. 
Post-hybridisation solution: 
20% (v/v) Formamide, 0.5X SSC in dH2O. 
RNase A solution: 
12.5 g RNase A (Sigma R5500) in 1 ml 2X SSC. 
10% Blocking solution: 
5% (v/v) sheep serum (Roche 11 096 176 001), 10 mg/ml BSA in PBST. 
NTMT: 
100 mM NaCl, 50 mM MgCl2, 100 mM Tris-HCl pH 9.5, 0.1% (v/v) TritonX-
100 in dH2O. 
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2.1.1.2 Buffers for immunohistochemistry 
Sodium Citrate Buffer: 
10 mM tri-sodium citrate (dehydrate) in dH20 with 0.05% (v/v) Tween-20. 
pH 6. 
Blocking solution: 
1% (w/v) BSA (Vector Laboratories SP-5050), 1.5% (v/v) goat serum 
(Vectastain Elite ® ABC Kit, Vector Laboratories PK-6101) in PBS. 
2.1.1.3 Solutions for cell culture 
RIPA buffer for protein extraction: 
50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.5% Na-deoxycholate, 0.1% 
sodium dodecyl sulphate (SDS), 0.1% NP40 and 10M protease inhibitor 
cocktail for mammalian cell extracts (Sigma P8340). 
2X DMEM solution for soft agar assay: 
20% (v/v) 10X DMEM (Sigma), 0.75% (v/v) sodium bicarbonate, 20% fetal 
calf serum, 1% penicillin/streptomycin/glutamine (Sigma), 0.1 mg/ml 
Gentamicin (Sigma) in sterile water. 
4% PFA: 
As described above but dissolved in PBS made with dH2O. 
10% Blocking solution for immunocytochemistry: 
Blocking reagent (Roche) was dissolved in maleic acid buffer (100 mM 
maleic acid, 150 Mm NaCl, pH 7.5) to a final concentration of 10% (w/v) 
with shaking and heating on a heating block. Autoclaved. 
Propidium iodide buffer for flow citometry: 
20 g/ml propidium iodide (Sigma, kindly provided by Dr Asma Aroun, 
University of Bath), 200 mg/ml RNase A, 0.1% (vol/vol) Triton X-100 in 
PBS. 
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2.1.1.4 Buffers for Western blotting 
Sample Buffer:  
Protein samples were solubilised in 2% (w/v) SDS, 62.5 mM Tris HCl (pH 
6.8), 0.01% (w/v) bromophenol blue, 10% (v/v) glycerol with 100 mM 
Dithiothreitol (DTT) as reducing agent. 
Resolving Gel Buffer:  
1.5 M Tris HCl, 0.4% (w/v) SDS, (pH 8.8). 
Stacking Gel Buffer:  
0.5 M Tris HCl, 0.4% (w/v) SDS, (pH 6.8). 
Electrophoresis Running Buffer:  
25 mM Tris HCl, (pH 6.3), 0.1% (w/v) SDS, 0.2 M glycine. 
Transfer Buffer:  
39 mM glycine, 48 mM Tris, 0.0375% SDS (w/v), 20% methanol (v/v), (pH 
8.8). 
Ponceau S Stain:  
0.1% (w/v) Ponceau S (Sigma), 3% (w/v) trichloroacetic acid. 
Blocking buffer : 
5% (w/v) skimmed milk (Marvel®) in TBST. 
ECL Reagent (home made): 
Solution A – 100 mM glycine (pH 10), 0.4 mM luminol (Sigma 09253), 8 
mM 4-iodophenol (Aldrich I10201). 
Solution B – 0.12% (w/w) hydrogen peroxide in water. 
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2.1.2 Antibodies 
Table 2.1 shows a list of antibodies along with their suppliers and dilutions 
used for different applications. 
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Antibody 
 
Species 
 
Source 
Application-
Dilution 
-active caspase 3 rabbit Abcam 
Ab13847 
 
IF-1:100 
Aurora A 
(clone 4/IAK1) 
mouse, 
monoclonal 
BD biosciences 
610938 
 
IF-1:500 
Aurora B 
(clone 6/AIM-1) 
mouse, 
monoclonal 
BD biosciences 
611082 
 
IF-1:200 

INCENP  
(clone 58-217) 
 
mouse, 
monoclonal 
 
Upstate/Millipore  
05-940 
 
IF-1:250 

pericentrin 
 
rabbit 
Covance 
PRB-432C 
 
IF-1:500 
phospho Aurora A 
(Thr288),  
B (Thr232),  
C (Thr198) 
(clone D13A11) 
 
rabbit 
 
Cell Signaling  
2914  
 
IF-1:50 
phospho CENP-A (Ser7) 
(clone NL41) 
 
rabbit 
 
Millipore 
04-792 
 
IF-1:300 
phospho histone H3 
(Ser10) 
 
mouse, 
monoclonal 
 
Abcam 
Ab14955 
 
IF-1:500 
WB-1:1000 
phospho PLK1 (Thr210) 
(clone Poly6186) 
 
rabbit 
 
Biolegend 
618601 
 
IF-1:100 

RASSF1A 
(clone eB114-10H1) 
 
mouse, 
monoclonal 
 
eBioscience 
14-6888 
 
IF-1:100 

RASSF7 
 
rabbit 
  
Aviva System 
Biology 
ARP34390_T100 
 
IF-1:100 
IHC-1:50 
WB-1:1000 
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Antibody 
 
Species 
 
Source 
Application-
Dilution 

RASSF8 
(clone 2G1) 
 
mouse, 
monoclonal 
 
Abnova 
H00011228-M01 
 
IF-1:200 

- tubulin 
(clone DM1A) 
 
mouse, 
monoclonal 
 
Sigma 
T9026 
 
IF-1:250 

 tubulin 
(clone TUB 2.1) 
 
mouse, 
monoclonal 
 
Sigma 
T4026 
 
WB-1:2500 

 tubulin 
(clone GTU-88) 
 
mouse, 
monoclonal 
 
Sigma 
T6557 
 
IF-1:100 

-V5 
 
mouse, 
monoclonal 
 
Invitrogen 
R960-25 
 
IF-1:200 
 
 
Antibody 
 
 
Species 
 
 
Source 
 
Application- 
Diluition 
-mouse Alexa Fluor 488  
goat 
Molecular Probes 
A11001 
 
IF-1:500 
-mouse Alexa Fluor 568  
goat 
Molecular Probes 
A11004 
 
IF-1:300 
-rabbit Alexa Fluor 488  
goat 
Molecular Probes 
A11008 
 
IF-1:500 
-rabbit Alexa Fluor 568  
goat 
Molecular Probes 
A11011 
 
IF-1:300 
-rabbit-HRP goat Pierce WB-1:5000 

-mouse-HRP 
 
goat 
 
Sigma 
A2554 
 
WB-1:5000 
Table 2.1: List of antibodies used. Where known, clone and catalogue numbers of 
primary antibodies are given. Dilutions are of original supplied stocks. For the conditions 
of antibody utilisation, refer to main text. Abbreviatios: IHC: immunohistochemistry, IF = 
immunofluorescence, WB = Western Blotting. 
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2.1.3 Plasmids 
Table 2.2 shows a list of antibodies used during the current project. 
Plasmid names Details Internal database 
number 
Mouse RASSF7 Used for In situ hybridisation 305 
Mouse RASSF8 Used for In situ hybridisation 304 
Mouse RASSF9 Used for In situ hybridisation 361 
Human RASSF7 clone Used for subcloning RASSF7 cDNA 
into the Gateway entry vectors  
414 
pENTR/human RASSF7 
with stop codon 
Gateway entry vector which contains 
RASSF7 for cloning into N-terminally 
tagged destination vectors 
Not available 
pcDNA/DEST53 
(Invitrogen) 
Gateway destination vector with N-
terminal GFP tag (kindly donated by Dr 
Angelina Felici, IFOM, Milan) 
345 
GFP-human RASSF7 Used for analysing the localisation of 
ectopic GFP-RASSF7 
343 
pcDNA6.2/V5-DEST 
(Invitrogen) 
Gateway destination vector with C-
terminal V5 tag 
318 
pENTR/human RASSF7 
without stop codon 
Gateway entry vector which contains 
RASSF7 for cloning into C-terminally 
tagged destination vectors 
382 
Human RASSF7-V5 Used for analysing the localisation of 
ectopic RASSF7-V5 
344 
Human RASSF8-GFP Used for analysing the localisation of 
ectopic RASSF8 (kindly donated by 
Prof. Farida Latif, University of 
Birmingham) 
346 
Cytoplasmic GFP Used as control for localisation 
analysis of ectopically expressed 
proteins  
39 
Human RASSF7 short 
hairpin RNAi 
(SuperArray Bioscience) 
Used for RASSF7 knockdown 314 
Negative control short 
hairpin RNAi 
(SuperArray Bioscience) 
Used for RASSF7 knockdown 315 
Table 2.2: List of plasmids used. Names, details and, where available, internal 
database  numbers of plasmids are given.  
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2.1.4 RNA interference  
Tables 2.3 and 2.4 show the siRNA (small interfering RNA) 
oligonucleotides and shRNA (short hairpin RNA) used for silencing 
RASSF7 gene expression.    
A 
Symbol Catalogue # Oligo sequence (5’-> 3’) 
RASSF7  KD 1 13242 GGAAGUGGUCAUCGCACUAtt 
RASSF7 KD 2 13338 GGAGAUGCAUGGACAGUGUtt 
 
B 
Symbol Catalogue # Oligo sequence (5’-> 3’) 
Luciferase KD 21204193 CGUACGCGGAAUACUUCGA 
Table 2.3: siRNA oligonucleotides used for transient RASSF7 KD in H1792 cells.  
RASSF7 KD1 and RASSF7 KD2 were purchased from Ambion (A). A control 
oligonucleotide targeting luciferase was purchased from MWG (B). 
 
Symbol Catalogue 
# 
Oligo sequence (5’-> 3’) 
RASSF7 KH09867N TCTCGATCGCACTAGCCCAAGCAATACTTCCTGTCATA
TTGCTTGGGCTAGTGCGATCT 
 Control TCTCGGAATCTCATTCGATGCATACCTTCCTGTCAGTAT
GCATCGAATGAGATTCCCT 
Table 2.4: shRNA used for RASSF7 KD in HeLa cells. RASSF7 shRNA and scrambled 
control shRNA were cloned into pGeneClip/Neo vectors and purchased from SuperArray 
Bioscience. 
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2.2 Methods 
 
2.2.1 Molecular biology techniques 
2.2.1.1 Restriction digests 
Digestion of DNA was carried out with restriction enzymes (Promega or 
NEB) according to the manufacturer’s instructions. The reactions 
contained DNA, 1/10 volume of restriction enzyme buffer, 100 g/ml BSA, 
5U of enzyme per g of DNA and water to the required volume. Most 
enzymes were incubated at 37°C for 1-2 hours. When required, restriction 
enzymes were heat inactivated at 65°C for 15 minutes. 
2.2.1.2 Agarose gel electrophoresis 
Digested DNA , synthesised RNA and polymerase chain reaction (PCR) 
products were loaded into a 0.9% (w/v) agarose Tris-acetate EDTA (TAE) 
gel and run in the presence of 500 ng of ethidium bromide (10 mg/ml) per 
ml of agarose to aid visualisation of nucleic acids. Loading dye (6x, 
Promega) was added to each DNA/RNA sample before loading into the 
wells of the gel. Samples were elecrophoresed at 100-135V for 20-30 
minutes depending on size of DNA/RNA. The DNA/RNA samples were 
analysed under ultra-violet light with  a Spectroline® transilluminator. 
2.2.1.3 Bacterial transformations and plasmid DNA separation 
Plasmids which contained specific  DNA constructs were transformed into 
competent E.Coli cells. A small amount (2 l) of the cloned DNA construct 
was added to 100 l of competent TOP10 cells (Invitrogen) on ice and 
incubated for 10 minutes. Cells were subsequently heat shocked by 
incubating at 42°C for 30 seconds, and then placed back on ice for 2 
minutes. LB media (900 l) was added to the heat shocked DNA-cell 
mixture and this was incubated at 37°C for 1 hour. Different volumes of 
this mixture (20-100 l) were then plated on LB plates that contained the 
appropriate antibiotic selection that the recipient plasmid had resistance 
to. This made it possible to select only the colonies which had integrated 
the plasmids. Plates were grown overnight at 37°C. 
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Single colonies were selected and grown in 5 or 100 ml cultures 
(according to the extraction protocol followed) with the relevant antibiotics, 
in order to highly concentrate the volume of desired DNA. Incubation at 
37°C shaking overnight followed. Cultures were pelletted by spinning at 
4000 x g for 15 minutes, and DNA was extracted using mini-prep kits 
(Quiagen) or Maxi-prep kits (Sigma) according to the manufacturer’s 
instructions. The kits are designed to separate plasmid DNA from 
chromosomal DNA and any other cellular debris  such as lipids and 
proteins. This was achieved by binding the plasmid DNA to the column, 
removing all other cellular component via washing and then eluting the 
clean plasmid DNA.   
2.2.1.4 Subcloning of DNA constructs 
The human RASSF7 gene coding region (approximately 1.2 Kb) was 
amplified from the cDNA  clone (IMAGE: 40032773) isolated from a full 
length human plasmid cDNA library (Geneservice). The clone was 
identified by BLAST searches after having interrogated the protein 
database and its translated product corresponds to the RASSF7 protein 
isoform NP_003466 (RASSF7 A). 
In order to subclone RASSF7 construct, the PCR was used along with 
specifically designed primers for the template DNA (Table 2.5).  
No. Primer name Sequence Notes 
1 F7 fwd. 5’-caccatgttgttgggactggcggcc-3’ Forward primer 
2 F7 rev. 5’-tcacagagcctggggctgg-3’ Reverse primer with 
stop codon for cloning 
into N-terminal GFP 
containing vector 
3 F7 rev. 5’-cagagcctggggctgggctg-3’ Reverse primer without 
stop codon for cloning 
into C-terminal V5 
containing vector 
Table 2.5: Primers used for cloning human RASSF7 construct. The description and 
the sequence of the primers utilised is given. Bold and underlined text indicates the 
sequence being introduced into the forward primer at the 5’ end to enable directional 
cloning. F7 fwd is RASSF7 forward; F7 rev. is RASSF7 reverse. 
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PCR reaction was carried out with 400 ng of DNA template, 1X thermal 
polymerase buffer (Stratagene), 200 M dNTPs, 1 M of each 
oligonucleotide primer, 2.5 U Pfu Turbo polymerase (Stratagene). This 
mixture was usually made up to a total volume of 50 l by using dH2O. 
Table 2.6 shows the cycle for PCR that was used when cloning the 
construct. 
PCR stage Temperature Time Repeat 
1- Denaturation 95°C 2 minutes  
2- Denaturation 95°C 30 seconds  
3- Annealing X°C * 30 seconds  
4- Elongation 72°C 1.5 minutes Go to step 2 (x29) 
Hold 4°C   
Table 2.6 : PCR cycle used. *Annealing temperatures were 58.4°C for primers 1+2 and 
61°C for primers 1+3 (refer to Table 2.5 for primers used). 
The PCR products were subsequently gel extracted according to the kit 
manufacturer’s specifications (Quiagen) and were cloned into the 
pENTR/D-TOPO gateway entry clone using the pENTR Directional TOPO 
Cloning Kit (Invitrogen). TOP10 supercompetent cells (Invitrogen) were 
transformed with 2ul of TOPO Cloning reaction using standard 
transformation techniques. RASSF7 containing entry clones were 
sequenced  and transferred to the destination vector backbones by mixing 
the DNAs with the Gateway® LR ClonaseTM II enzyme mix (Invitrogen). The 
destination vectors were green fluorescent protein (GFP) containing 
pcDNA-DEST53 (Invitrogen) for N-terminal fusion to RASSF7 and V5 
epitope containing pcDNA/V5-DEST (Invitrogen) for C-terminal fusion to 
RASSF7. The resulting recombination reactions were then transformed 
into E.Coli bacteria and GFP-RASSF7 or RASSF7-V5 expressing clones 
selected. To check for successful clones with integrated PCR products, 
digestions of the cloned DNA were used, employing BGRI restriction 
enzyme (NEB), for band size estimations. This method was useful in 
identifying positive clones prior to sequencing. DNA sequencing was 
performed via MWG Biotech using vector-specific primers, in order to 
confirm correct DNA sequences of all constructs cloned. 
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2.2.1.5 In Situ Hybridisation (ISH) 
ISH RNA probe synthesis   
Mouse RASSF7 (Genebank accession number: BC011131), mouse 
RASSF8 (Genebank accession number: BC115779)  and mouse RASSF9 
(Genebank accession number: BG175058) DNA containing plasmids (10 
g ) were linearised approximately 500 bp downstream of the appropriate 
promoter using the correct enzyme in the right buffer according to the 
guidelines set out by the suppliers (Table 2.7). Gene-specific antisense or 
sense digoxigenin (DIG)-labelled cRNA probes were made using 1g of 
linearised plasmid DNA and the DIG RNA Labelling Kit (Roche 11 175 025 
910) (Table 2.7).  
Probe Restriction enzyme RNA polymerase 
RASSF7 sense STU I (Promega) SP6 (Promega) 
RASSF7 sense AHD I (NEB) T7 (Promega) 
RASSF8 sense ECONI (NEB) T7 (Promega) 
RASSF8 sense PSTI (Promega) SP6 (Promega) 
RASSF9 sense ALU I (NEB) SP6 (Promega) 
RASSF9 sense BGL II (NEB) T7 (Promega) 
Table 2.7: List of restriction enzymes and RNA polymerases utilised for producing 
the in situ riboprobes. 
The RNA probes were ethanol precipitated in the presence of LiCl and 
resuspended in 20 l of DEPC treated water. RNase Inhibitor (Roche) was 
added to a concentration of 0.1 unit/μl. The probes were subsequently 
vortexed and heated to 80°C for a couple of times to fully resuspend the 
RNA. Agarose gel electrophoresis was performed in order to evaluate and 
compare the presence and the amount of RNA probe obtained. The 
probes were stored at -80°C until used. 
Specimen preparation for ISH and sectioning 
In order to carry out ISH, mouse embryos (E15.5 or E10.5) or adult tissues  
were fixed in 4% PFA at 4°C for approximately 16 hours, dehydrated and 
infiltrated with paraffin wax heated to 60°C through a tissue processor 
(Leica). The samples were then embedded in excess wax in square blocks 
which acted as a support during sectioning, with the help provided by Iryna 
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Withington. Sequential series of sagittal sections (7m thick) were cut 
manually with a conventional microtome (Leica), floated onto a water bath 
and then recovered onto uncoated slides (Fisher Scientific), dried 
overnight and finally stored at 4°C till used. Prior to initiating the ISH, some 
of the embryonic sections were haematoxylin and eosin (H a E) stained to 
verify the integrity of the internal organs (see section 2.2.2.1) 
ISH on mouse slices 
After rehydration, the sections were fixed in freshly prepared 4% PFA for 
30 minutes, washed in PBS and permeabilised for 15 minutes at room 
temperature (RT) with 25 µg/ml proteinase K (Roche 03 115 836 001) in 
PBS. After additional washes in PBS, the sections were post-fixed for 15 
minutes with freshly prepared 4% PFA, washed with 2X SSC  and Tris-
glycine buffer for 5 and 30 minutes respectively, and finally serially 
dehydrated in ethanol and air dried for 30 minutes. The sections were 
subsequently incubated in hybridising solution containing the appropriate 
digoxigenin- labelled riboprobe diluted 1:50 in a total volume of 500 l per 
section. Each section was covered by parafilm and hybridised overnight at 
60°C. To remove the excess probe, the sections were washed  in 5X SSC 
at RT 3 times for 15 minutes each, in post-hybridisation buffer at 55°C for 
40 minutes, in 2X SSC at RT for 15 minutes, and treated with RNAse A 
solution at 37°C for 15 minutes to digest away any excess unbound 
riboprobe. Sections were rinsed in 2X SSC at RT for 15 minutes, washed 
at a higher stringency in post-hybridisation buffer at 55°C for 20 minutes 
and then washed twice in 2X SSC with rocking at RT for 15 minutes each 
time. The sections were incubated at 4°C overnight with alkaline 
phosphatase (AP) labelled anti-digoxigenin Fab fragments (Roche 11 093 
274 910) diluted 1:500 in 1% blocking medium. After 4 hours washes in 
PBS and 3 washes of 10 minutes in NTMT, the staining reaction for 
alkaline phosphatase was performed with the AP chromogenic substrate 
BM purple (Roche 11 442 074 001) at RT in the darkness. Progress of the 
staining was followed using a dissection microscope. The positive signal 
was visible as a dark purple staining and once developed, the reaction 
was stopped for the in situs and the corresponding negative controls, by 
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washing in PBS with 0.5 M EDTA for 5 minutes. The slides were 
subsequently dehydrated and stored in DPX mounting medium at RT for 
following analyses. Pictures were taken using a Nikon digital camera on a 
Leica microscope (David Tosh’s laboratory, University of Bath). 
 
2.2.2 Histological methods 
2.2.2.1 H & E staining  
Slides of 7 mm wax embedded organ sections were washed in histoclear 
clearing solution (National Diagnostics) 2 x2 minutes to remove wax. The 
slides were then hydrated in 100% (v/v) ethanol (2 x 1 minute), in 95% 
(v/v) ethanol (1 minute), 90% (v/v) ethanol (1 minute), 70% (v/v) ethanol (1 
minute), 50% (v/v) ethanol (1minute). Washes in MilliQ water for 1 minute 
followed before staining in haematoxylin (provided by Iryna Withington, 
University of Bath) for 15 minutes. Slides were then washed in running tap 
water for 3 minutes to avoid non-specific binding of haematoxylin. Washes 
in 1% (v/v) concentrated hydrochloric acid (HCl) in 70% (v/v) ethanol for 
30 seconds,  in 1% (v/v) ammonia (NH3) in 70% ethanol for 1 minute and 
in 70% (v/v) ethanol for 30 seconds followed. Filtered eoosin (provided by 
Iryna Withington, University of Bath) was then used for 5 minutes to 
counterstain the slides. Prior to mounting, slides were dehydrated in 70 % 
(v/v) ethanol (3 seconds), in 95% (v/v) ethanol (5 seconds), in 100% (v/v) 
ethanol  (2 x 1 minute) and in histoclear (2 x 2 minutes). Sections were 
mounted using DPX mount overlaid with a plastic coverslip (Millipore). 
Pictures were taken using a Nikon digital camera on a Leica microscope 
(David Tosh’s laboratory, University of Bath). 
2.2.2.2 Immunohistochemistry (IHC) 
Paraffin-embedded sections of mouse tissues and human xenograft 
tumours were kindly donated by Dr Jason Gill (University of Bradford). The 
samples were deparaffinised and rehydrated in histoclear (2 x 5 minutes) 
and decreasing concentrations of ethanol (100%, 95%, 90%, 70%, 50%) 
(v/v) for 1 minute each and PBS (1 x 5 minutes). Antigen retrieval of the 
sections followed by submerging them into boiling sodium citrate buffer in 
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the microwave for 20 minutes. The samples were then allowed to cool for 
45 minutes. A wash in PBS for 5 minutes followed. Tissue sections were 
then circumscribed with a hydrophobic barrier pen (Vector Laboratories), 
in order to keep reagents localised on tissue sections. The samples were 
washed in TBS plus 0.025% (v/v) Triton X-100 with gentle agitation. The 
slides were subsequently blocked for 2 hours at RT. Primary antibody 
rabbit -RASSF7 or rabbit serum (kindly given by David Tosh’s laboratory, 
University of Bath) were then diluted 1:50 in TBS with 1% (w/v) BSA 
(Vector laboratories) and incubated with the sections overnight at 4°C. 
Washes in PBS (1 x 2 minutes) and TBST (2 x 5 minutes) preceded the 
quenching in peroxidase solution (0.3% (v/v) H2O2 in TBS) for 15 minutes 
at RT. After washing in PBS, sections were incubated for 1 hour  at RT 
with biotinylated secondary antibody (anti rabbit IgG) (Vector Laboratories) 
diluted in goat serum (Vector Laboratories) and PBS, prepared according 
to the instructions contained in Vectastain Elite®ABC kit (Vector 
Laboratories PK-6101). After removing the excess of secondary antibody, 
the antigen-antibody complexes were detected using immunoperoxidase 
system (Vectastain Elite ® ABC Kit, Vector Laboratories) and 
Diaminobenzidine (DAB) staining according to manufacturer’s instructions.  
 
2.2.3 Cell culture techniques 
All cell culture media and media supplements were purchased from 
Sigma, unless otherwise specified. 
2.2.3.1 Cell line maintenance 
All cell lines were grown at 37°C under 5% CO2. A549 (human lung 
adenocarcinoma, already present in the lab), Caco2 (human colorectal 
adenocarcinoma, already present in the lab), COS-7 (monkey kidney 
fibroblast, already present in the lab), H1792 (human lung adenocarinoma, 
kindly provided by Prof. Farida Latif, University of Birmingham), HeLa 
(human cervix carcinoma, kindly provided by Prof. Farida Latif, University 
of Birmingham), HepG2 (human liver carcinoma, kindly provided by Dr 
David Tosh, University of Bath), PANC-1 (human pancreatic cancer, kindly 
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provided by Dr David Tosh, University of Bath), OVCAR (ovarian 
carcinoma, purchased from Cancer Research UK), T293 (human 
embryonic kidney, already present in the lab)  cells were maintained in 
DMEM (Dulbecco’s modified Eagle’s medium, Lonza BE12-614F), with 
10% fetal bovine serum (FBS, Sigma F9665), 1% penicillin/ streptomycin 
and 1% glutamine. PC12 rat pheochromocytoma cells (kindly provided by 
Prof. Sue Wonnacott) were cultured in DMEM medium supplemented with 
10% heat-deactivated donor horse serum (Sigma), 5% FBS, 50 U/ml 
penicillin and 50 g/ml streptomycin, 2 mM glutamine. Human THP-1 
monocytic leukaemia and Jurkat leukemic T cells (kindly provided by Prof. 
Stephen Ward, University of Bath) were maintained in DMEM-F12 medium 
containing 10% fetal calf serum, 1% penicillin/ streptomycin and 1% 
glutamine. SH-SY5Y human neuroblastoma cells  (kindly provided by Dr 
Momna Hejmadi, University of Bath) were cultured in DMEM-F12 medium 
with 15% FBS, 1% non essential amino acids, 1% penicillin/ streptomycin, 
2 mM glutamine. 
If required for subsequent immunoblotting analysis, cells were washed 
with ice-cold PBS then 1 ml ice-cold RIPA buffer was added and incubated 
with the cells for at least three minutes. The lysates were then scraped off, 
collected and sonicated on ice for 20/30 seconds, in 3 separate intervals. 
The lysates were subsequently centrifuged for 10 minutes at 12,000 x g at 
4°C. The supernatants were then removed and utilised for Western 
blotting.   
2.2.3.2 Cell cycle synchronisation 
To increase the number of cells in M phase, HeLa cells were grown in T75 
(Fisher Scientific 3123-075) tissue culture flasks and treated with 75 ng/ml 
nocodazole (Sigma) containing growth medium for 18 hours at 37°C. 
Mitotic cells were then dislodged from the tissue culture flasks by agitation 
(“Mitotic shake-off “) as recommended in (Soares et al., 2007). Detached 
mitotic cells (70-90%) were then collected, spun down (1000 x g, 3 
minutes) and resuspended in 1 ml cold RIPA buffer. Cells were then 
sheared by sonication on ice for 20/30 seconds, in 3 separate intervals. 
The lysates were centrifuged for 10 minutes at 12,000 x g at 4°C. The 
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supernatants were removed and utilised for subsequent Western blotting 
analysis. 
2.2.3.3 Exposure to hypoxic conditions 
To expose cells to hypoxic conditions, cultures in T25 tissue culture flasks 
(Fisher Scientific 3103-025) were placed in a humidified 37°C multigas 
incubator with 5% CO2/ 95% nitrogen (kindly provided by Dr Momna 
Hejmadi, University of Bath) for 3 hours and 18 hours. Residual 02 levels 
were monitored regularly and were found to be consistently less than 
0.1%. Some samples were subject to hypoxia stress for 18 hours followed 
by 24 hours recovery in normoxic conditions (21% 02). Control cultures, 
maintained under normoxic conditions, were processed in parallel. Protein 
extraction followed as described at the end of section 2.2.3.1, but with 300 
l ice-cold RIPA buffer.  
2.2.3.4 Transfection and gene silencing 
Plasmid transfection  
Hela cells were seeded at 2 x 105 cells per 6 well plate well (Fisher 
Scientific 3810-006) containing antibiotic free medium one day prior to 
transfection. On the day of transfection, 3.8 g of plasmid DNA were 
incubated with 240 l of Opti-MEM® Reduced Serum Medium (Invitrogen 
31985-062) for 5 minutes at RT. Concomitantly, 9.6 l of LipofectamineTM 
2000 (Invitrogen 11668-019) were incubated with 240 l of Opti-MEM® for 
5 minutes at RT. The two solutions were then mixed and incubated for 20 
minutes at RT. The transfection mixture was added to cells in fresh 
antibiotic free medium for 6 hours at 37°C and then replaced with fresh 
growth medium. When over-expressing a RASSF7 construct, transfected 
cells were fixed 24 hours after transfection and treated as for 
immunofluorescence studies (see section 2.2.3.6) 
When silencing RASSF7 gene expression via pGeneClip/Neo plasmid 
containing either RASSF7 specific or scrambled shRNA sequence, 
transfected cells were put in selection with 1.2 mg/ml G418 (Sigma 
G8168) 24 hours after transfection for 14 days. Cells were then counted 
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and analysed. The experiment, which was repeated 5 times, was also 
reproduced as described above, except that the seeding of 2 x 105 HeLa 
cells was carried out after selection. The analysis was performed via either 
immunofluorescence studies (see section 2.2.3.6) or Western blotting. In 
the latter case were treated as described at the end of section 2.2.3.1, but 
with 100 l ice-cold RIPA buffer.  
Transfection of siRNA oligonucleotides 
H1792 cells were plated at 5 x 104 cells per well of a 6 well plate in 2 ml of 
antibiotic free medium one day prior to transfection. On the day of 
transfection 10 l of 20 M siRNA oligonucleotide were diluted in 175 l 
Opti-MEM® Reduced Serum Medium (Invitrogen) for 5 minutes at RT. 
Concomitantly, 4 l of OligofectamineTM (Invitrogen 12252-011) were 
incubated with 15 l of Opti-MEM® for 5 minutes at RT. The two solutions 
were combined and incubated for 20 minutes at RT. The transfection 
mixture was added to cells in fresh antibiotic free medium at 37°C. The 
results were assayed 3 days later, when cell lysates were collected from 
some samples as described at the end of section 2.2.3.1, but with 100 l 
ice-cold RIPA buffer.  
2.2.3.5 Soft agar growth assay 
The experiment was set up 24 hours after transfecting H1792 cells with 
siRNA oligonucleotides. All solutions were kept in a 42°C waterbath. Equal 
amounts of  2X DMEM and 1.4% (w/v) agar (Sigma) were mixed, 2 ml of 
the solution were put into each well of a 6 well plate and allowed to set at 
RT. Transfected H1792 cells were then trypsinised and 5 x 104 cells per 
well were diluted with 1 ml of 0.35% (w/v) agar (½ 1X DMEM, ¼ 2X DMEM 
and ¼ 1.4% agar). The cells were then plated on top of the previously 
formed agar layer. This second layer was allowed to set. Finally, equal 
amounts of  2X DMEM and 1.4% (w/v) agar were mixed once again, 2 ml 
of the solution were put on top of the first two solidified agar layers into 
each well and allowed to set at RT. Cells were cultured at 37°C for two 
weeks and 200 l 1X DMEM were added once or twice a week to avoid 
drying out. Colonies were photographed with a Zeiss microscope digital 
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camera and the average number of colonies greater than 50 m was 
calculated.  
2.2.3.6 Immunofluorescence studies 
Cells were grown on glass coverslips (Fisher Scientific MNJ-500-0104) in 
6 well plate wells. Cell medium was then removed from cells and cells 
were rinsed once with PBS. Cells were then differently processed 
according to the protocol followed:  
1) Cells were fixed with 4% PFA at RT for 30 minutes. Washes in PBS 
followed and the permeabilisation was carried out with 0.1% Triton X-100 
at RT for 20 minutes. Non specific binding sites were then blocked by 2% 
blocking solution at RT for 2 hours prior to adding the primary antibody 
diluted in 2% blocking solution, and incubating at 4°C overnight. Primary 
antibodies were: anti-active caspase 3, anti-Aurora A, anti-Aurora B, anti-
INCENP, anti-phospho CENP-A, anti-phospho Aurora, anti-phospho 
histone H3, anti-phospho PLK1, anti-RASSF8 and anti--tubulin (for 
diluitions refer to Table 2.1). After 3 x 15 minutes washes, cells were 
incubated with the secondary antibody, diluted in 2% blocking buffer, at 
RT in the dark for 1 hour. Washes in PBS followed again to remove any 
unbound antibody. Nuclear staining was performed with 1 g/ml  DAPI 
(4’,6-diamidino-2-phenylindole) (Sigma) at RT for 20 minutes in the dark, 
followed by a quick wash in PBS. 
2) Cells were fixed and permeabilised with cold methanol at RT for 5 
minutes and subsequently  blocked with 1% BSA/ 3% normal goat serum 
(NGS) in PBS at RT for 2 hours. The incubation with the primary antibody 
diluted into the blocking solution followed at RT for at least 1 hour. Primary 
antibodies were: anti-pericentrin, anti--tubulin, anti-RASSF1A and anti-
RASSF7 (for diluitions refer to Table 2.1). Appropriate species-specific 
fluorophore conjugated secondary antibodies and DAPI were also diluted 
in blocking solution. Incubation with secondary antibodies and 1g/ml 
DAPI were for 20 minutes at RT in the dark. Two washes of 5 minutes 
each in 0.2% BSA/ O.6% NGS/ PBS followed all antibody incubations with 
further 2 washes in PBS alone. Anti-RASSF7 antibody required antigen 
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retrieval to unmask the epitope, which involved EDTA treatment (1mM, pH 
8) for 1.5 hours at 37°C before blocking. 
In both cases, negative controls were conducted in parallel, either by 
omitting the primary antibodies or by replacing  the primary antibody with 
the pre-immune serum used at the least diluted concentration of the 
corresponding antibody. 
Cells were finally mounted in Mowiol (Merck 475904), visualised using a 
Zeiss LSM 510 confocal microscope (Bioimaging Suite, University of 
Bath), and images were captured and processed using LSM image 
browser software.  
2.2.3.7 Fluorescence-Activated Cell Sorting (FACS) 
RASSF7 KD and control HeLa cells were grown onto 10 cm tissue culture 
dishes (SLS T155318) in the presence of G418. Adherent cells were 
removed from plates by trypsinisation. Cells were washed once in PBS, 
fixed in cold 70% (v/v) ethanol/ PBS and stored at -20°C until analysed. 
On the day of analysis, ethanol-fixed cell samples were washed with PBS, 
centrifuged for 3 minutes (1000 x g) and resuspended in 500 l of freshly 
prepared propidium iodide buffer for 30 minutes at RT. DNA content 
frequency was acquired using a FACS Canto benchtop cytometer (Becton 
Dickinson) (Bioimaging Suite, University of Bath), counting 1 x 106 cells 
per sample. Cell doublets were excluded from the FACS data using 
doublet discrimination gating: FSC-H/FSC-W gate followed by an SSC-
H/SSC-W gate and then a PE-H/PE-A gate. Cell cycle stages were 
automatically gated by the software, according to the DNA content of the 
cell population. 
2.2.3.8 Microtubule re-growth assay 
RASSF7 KD and control HeLa cells were grown on coverslips in the 
presence of G418. Cells were washed with PBS and incubated with 300 
ng/ml of the depolymerising drug nocodazole dissolved in growth medium 
at 37°C for 1 hour (Ma et al., 2008). Cells were then shifted on ice for 30 
minutes and two quick washes in cold PBS followed. The treated cells 
were fixed with 4% PFA 0, 5, 15, 30, 60 minutes after adding pre-warmed 
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nocodazole free medium at 37°C. The subsequent immunofluorescence 
staining with the microtubule marker -tubulin made it possible visualise 
the microtubule growth at different time points. The experiment was 
repeated twice.  
 
2.2.4 Protein biochemistry techniques 
2.2.4.1 Protein quantification 
Protein concentrations of cultured cells were estimated with Comassie 
(Bradford) protein assay (Pierce) using a BSA standard curve. Comassie 
Reagent (250 l) was added to each of the wells of a 96-well plate 
containing standard or appropriate samples (5 l). The solutions within the 
wells were mixed with a plate shaker for 30 seconds and the plate was 
subsequently incubated at RT for 10 minutes. The measurement of the 
absorbance at 595 nm was performed with a Spectra Rainbow Thermo 
microplate spectrophotometer (Tecan). Results were analysed using 
Microsoft Excel to determine unknown protein concentration estimations. 
2.2.4.2 SDS – Poly-Acrylamide Gel Electrophoresis (SDS-PAGE) 
Proteins were separated on the basis of mass by electrophoresis in a 
polyacrylamide gel under denaturing conditions. SDS containing sample 
buffers were used to denaturate 25 g of protein in precleared lysates, and 
then heated at 95°C for 5 minutes. SDS is an anionic detergent that 
disrupts nearly all non covalent interactions in native proteins. DTT was 
also included in the sample buffer to reduce disulfide bonds. The SDS 
complexes with the denatured proteins were then electrophoresed on a 
polyacrylamide gel in the form of a thin vertical slab. Vertical gels were of 
1.5 mm thickness and were prepared using acrylamide/bis-acrylamide 
(30% (w/v) acrylamide) (ProtoGel- National Diagnostics ECR 210 010P) 
and gel buffers previously described. Polymerisation of the gels was 
induced by the addition of 10% (w/v) ammonium persulphate (APS, 
Sigma) and N,N,N,N’-tetramethylethylenediamine (TEMED). The gels 
were composed of two layers: a 12% resolving gel (pH 8.8) that separated 
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the proteins according to size; and a lower percentage stacking gel (pH 
6.8) that insured the proteins simultaneous entry into the separating gel at 
the same height. The composition of the resolving and stacking gels is 
given in Table 2.8. Samples were loaded onto the gels with SpectraTM 
Multicolor Broad Range Protein Ladder (Fermentas). The gels were run at 
100 V for about 1.5 hours.  
Solution Resolving Gel Stacking Gel 
30% acrylamide 3 ml 850 l 
Resolving gel buffer 2.5 ml - 
Stacking gel buffer - 1.25 ml 
dH20 2 ml 1.875 ml 
10% APS 50 l 20 l 
TEMED 4 l 5 l 
Table 2.8: Volumes of solutions used for making SDS-PAGE gels. Volumes given are 
for one mini gel. 
2.2.4.3 Transfer of proteins to nitrocellulose membrane  
Electrophoretically size separated proteins were subsequently transferred 
from SDS-polyacrilamide gels to membranes. Gels were immersed along 
with eighteen pieces of filter paper and one nitrocellulose membrane 
(Whatman), in transfer buffer. The transfer process was performed by 
placing nine pieces of filter paper, the nitrocellulose membrane, the gel, 
and finally the last nine pieces of filter paper on the electrophoretic 
apparatus. Air bubbles were carefully removed. Transfer of proteins was 
completed by running the electrophoretic apparatus at 54 mA per gel for 
110 minutes. Following the transfer, nitrocellulose membranes were briefly 
incubated with Ponceau S stain for confirming the presence of transferred 
proteins. 
2.2.4.4 Western blotting 
Immunodetection of specific proteins transferred onto nitrocellulose 
membranes was performed via Western blotting. Membranes were 
washed in TBST to remove all Ponceau S stain and then incubated in 
blocking buffer for 1 hour at RT. Membranes were then incubated with the 
primary antibody diluted in the blocking solution for 2 hours at RT or at 4°C 
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overnight. Membranes were then washed 6 times in TBST, each wash 
lasting a minimum of 5 minutes. The appropriate peroxidise- conjugated 
secondary antibody was then diluted in blocking solution and incubated 
with the membrane for 1 hour at room temperature. Washes followed as 
described after primary antibody incubations. Membranes were then 
incubated for 2 minutes with equal volumes of Solution A and B of the ECL 
Reagent or 5 minutes when using ECL Advanced Reagent (GE-
Healthcare). Lastly, membranes were developed and quantification of 
bands performed using an Optichem detector with associated software 
(Ultra Violet Products) (Geoff Holman’s laboratory, University of Bath). 
 
2.2.5 Statistical analysis 
Means and Standard Deviations (SDs) were calculated and plotted using 
Microsoft Excel. Each experiment was repeated in triplicate unless 
otherwise stated. P < 0.05 was considered significant. Statistical analysis 
was carried out using unpaired Student’s t tests. 
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3 RASSF7 expression in mammalian tissues 
 
3.1 Introduction 
Expression of classical RASSFs 
Alterations in gene expression is a mechanism for loss of tumour 
suppressor gene function in cancer and the most studied aspect of the 
expression of the classical RASSF proteins has been associated with 
hypermethylation of gene promoters and reduced expression during 
tumourigenesis.  
 
The best characterised RASSF1 isoforms, RASSF1A and RASSF1C are 
ubiquitously expressed in normal tissues (Ponting and Benjamin, 1996; 
Yamamoto et al., 1999) as confirmed by Northern blot analysis. The 
expression of the remaining RASSF1 splice variants (RASSF1B, D-G) has 
been either associated to specific cell types (RASSF1B: hematopoietic 
cells, RASSF1D: cardiac cells, RASSF1E: pancreatic cells) or not 
extensively studied (RASSF1F, RASSF1G) (Dammann et al., 2000; 
Burbee et al., 2001). 
Loss of RASSF1A expression is frequently observed in various human 
cancers, in association with promoter hypermethylation (Sekido et al., 
1998; Pfeifer and Dammann, 2005; Agathanggelou et al., 2005). 
Epigenetic inactivation of Rassf1A was found via bisulphite sequencing in 
40% of NSCLC (Agathanggelou et al., 2003), in 72% small cell lung 
cancers (SCLC) (Dammann et al., 2001a; Burbee et al., 2001), in 62% of 
breast cancers (Dammann et al., 2001b), in 60% gastric tumours, in 40% 
ovarian tumours, in 50% prostate tumours (Liu et al., 2002b), in 60% 
bladder tumours and in 52% neuroblastoma (Yan et al., 2003; Tommasi et 
al., 2005) and not surprisingly RASSF1A is reported to be one of the most 
methylated tumour suppressors (Astuti et al., 2001; Harada et al., 2002; 
Yan et al., 2003; Wong et al., 2004; Banelli et al., 2005; Lazcoz et al., 
2006). The association between loss of RASSF1C expression and 
carcinogenesis is more controversial as it was reported only in some 
transformed ovarian and renal cell carcinoma cell lines (Vos et al., 2000; 
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Dreijerink et al., 2001). Thus RASSF1C may have a tissue specific effect. 
Loss of expression of other RASSF1 variants was shown (RASSF1B) or 
predicted (RASSF1D, RASSF1E, RASSF1F, RASSF1G) to be 
concomitant with loss of RASSF1A expression mainly because they share 
the same promoter region (Lee et al., 2001; Burbee et al., 2001; Harada et 
al., 2002; Endoh et al., 2003). 
Northern blot and reverse transcription-PCR (RT-PCR) analyses revealed 
the presence of RASSF2, RASSF3 and RASSF4 transcripts in most 
normal tissues (Tommasi et al., 2002; Vos et al., 2003a; Eckfeld et al., 
2004). RASSF2A, the only RASSF2 isoform with a 5’ CpG island and 
predicted promoter region (Hesson et al., 2005), is reported to be 
methylated in 70% of primary colorectal cancer cell lines (Hesson et al., 
2005; Akino et al., 2005), in primary NSCLC, lung tumour cell lines (Vos et 
al., 2003a; Kaira et al., 2007), gastric cancer and nasopharyngeal 
carcinoma, in which it positively correlates with lymph node metastasis 
(Zhang et al., 2007). Similarly to RASSF2A, CpG island methylation was 
also correlated with abnormally low levels of RASSF4 in breast, lung, 
colorectal and kidney tumour cell lines and in primary lung and breast 
tumours (Eckfeld et al., 2004). On the other hand, RASSF3 was found to 
be transcribed in all human cancer cell lines (including haematological, 
colorectal, lung, melanoma and cervical cell lines) examined (Tommasi et 
al., 2002), which correlates with the absence of methylation in either 
gliomas (Hesson et al., 2004) or colorectal tumour cell lines (Hesson et al., 
2005). 
NORE1A is ubiquitously expressed, whereas NORE1B is predominantly 
expressed in lymphoid tissues, as shown by Northern blotting (Tommasi et 
al., 2002; Vos et al., 2003b). Several cancer cell lines express very low 
levels of NORE1A transcript (promyelocytic leukaemia HL-60, 
lymphoblastic leukaemia MOLT-4, Burkitt’s lymphoma Raji, lung 
carcinoma A549 and melanoma G361 cells) and have absent or down-
regulated expression of NORE 1B (Hela, A549 and G361) (Tommasi et 
al., 2002; Vos et al., 2003b). NORE1A mRNA levels were found to be 
significantly suppressed in pheochromocytoma primary tumours compared 
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with normal adrenal medulla (Li et al., 2005). At a protein level, NORE 
1A/B expression was reported to be severely reduced or absent in 
epithelial-derived adenocarcinomas and SCLCs (Vos et al., 2003b). The 
inactivation of NORE1A commonly results from promoter 
hypermethylation. The aberrant NORE1A promoter methylation is 
frequently found in lung tumour cell lines, primary lung tumours and breast 
tumours (Vos et al., 2003b; Hesson et al., 2003). In contrast, NORE1B 
promoter was found to be unmethylated in all lung and breast cell lines 
and primary tumours examined (Hesson et al., 2003) and gliomas (Hesson 
et al., 2004). However, more recently NORE1B was reported to be 
epigenetically silenced in human hepatocellular carcinoma (Macheiner et 
al., 2006). 
RASSF6 transcript was shown to be present in normal blood and 
numerous tissues analysed including bone marrow where no promoter 
methylation occurred (Hesson et al., 2009). However, reduced transcript 
levels were found in 30-60% of primary tumour tissues in the breast, 
colon, kidney, liver, pancreas, stomach and thyroid gland (Allen et al., 
2007). Given that only a minority of tumour cell lines examined showed 
promoter methylation, Allen and co-workers proposed that loss of RASSF6 
expression in primary tumours may be caused by gene deletions as well 
as epigenetic mechanisms of silencing (Allen et al., 2007). Exceptions to 
this theory are the T and B childhood acute lymphoblastic leukaemias, in 
which RASSF6 was the only highly methylated classical RASSF member 
(Hesson et al., 2009). 
Expression of N-terminal RASSFs 
There is currently limited data in the literature regarding the expression of 
the novel members of the RASSF family.  
Data published during this project showed that RASSF8 has a ubiquitous 
expression pattern in normal human adult tissues, as confirmed by RT- PCR 
(Lock et al., 2010), and is shown to have reduced transcript levels in lung 
adenocarcinoma compared to normal tissue via Real-Time PCR (Falvella 
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et al., 2006) and in male-germ cell tumours via microarray analysis 
(Korkola et al., 2006).  
The expression of Rassf9 has been examined by Northern blot 
hybridisation analysis and RT-PCR in the rat. Rassf9 mRNA transcripts 
were detected in testis, kidney, skeletal muscle, liver, lung, brain heart, 
pituitary gland, adrenal gland and ovary (Chen et al., 1998). So far no 
studies have been undertaken in human samples. 
The major findings on human RASSF10 refer to the methylation status of 
its promoter. The RASSF10 CpG island is highly methylated in thyroid 
cancer (Schagdarsurengin et al., 2009), T-cell acute lymphocytic 
leukaemia (ALL) and leukaemia cell lines (where RASSF10 promoter 
hypermethylation correlated well with low levels of RASSF10 expression) 
(Hesson et al., 2009). However, RASSF10 is unmethylated in normal bone 
marrow where RT-PCR analysis showed RASSF10 to be normally present 
(Hesson et al., 2009). rassf10 showed a particular strong expression in the 
Xenopus tadpole brain (Hill et al., 2010) and also the potential Drosophila 
orthologue CG32150 is expressed in the nervous system (Reeves and 
Posakony, 2005). Following on from this study, Hill et al. reported the 
strong association of RASSF10 promoter methylation with the most 
malignant astrocytomas and with the worst progression free survival and 
overall survival in patients with glioblastoma at the early stage of their 
development (Hill et al., 2010). 
The N-terminal RASSF member this thesis focuses on, RASSF7, was 
previously studied in developing Xenopus embryos. rassf7 expression was 
detected via ISH in the outer epithelial cells of the Xenopus embryo and 
also at a later stage in the tadpole, with a broad expression including the 
brain, eye, ear, branchial arches, and embryonic kidney (Sherwood et al., 
2008).  
The only data referring to RASSF7 expression in organisms other than 
Xenopus derive from microarray studies in which human RASSF7 is 
shown to be up-regulated in cancer. RASSF7 expression is reported to be 
increased in pancreatic ductal adenocarcinoma (Logsdon et al., 2003; 
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Friess et al., 2003; Brandt et al., 2004), pancreatic islet cell tumours (Lowe 
et al., 2007), endometrial cancer (Mutter et al., 2001; Colas et al., 2011), 
where its under-expression correlated with good prognosis (Mhawech-
Fauceglia et al., 2010), and ovarian clear cell carcinoma (Tan et al., 2009) 
relative to normal tissue. Furthermore, RASSF7 is down-regulated by the 
tumour suppressor BRCA 1 (breast cancer 1), suggesting its expression 
would be increased in cancer cells which have lost BRCA 1 function 
(Welcsh et al., 2002). Gene-expression studies have also linked RASSF7 
to hypoxia, a peculiar feature of many solid tumours (Kenneth and Rocha, 
2008). In fact, RASSF7 mRNA levels were found to be up-regulated by 
hypoxia in the MCF7 breast cancer line and in human umbilical vein 
endothelial cells (Camps et al., 2008; Liang et al., 2009). However, prior to 
the present study nothing was known about its expression under normal 
conditions and the consequent functional role of the protein.  Therefore the 
primary aim of the work described in this chapter is to investigate the 
expression of mammalian RASSF7 expression at either a RNA transcript 
or protein level by using different approaches such as ISH and western 
blotting.  
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3.2 Results 
 
3.2.1 In silico analysis 
Initial studies were carried out by interrogating the NCBI database for 
preliminary predictions about the temporal and spatial expression of the N-
terminal RASSF family members in the mouse and human. The 
expression profiles of the selected genes was determined by considering 
those tissues in which the overall number of ESTs (expression sequence 
tags)  was equal or higher than 50000 
(http://www.ncbi.nlm.nih.gov/UniGene/ESTProfile). The frequencies of 
ESTs were expected to give a rough indication of transcript expression 
levels. 
RASSF7, RASSF8, RASSF9 and RASSF10 appeared to be differently 
expressed during development (Figure 3.1). Human and mouse RASSF7 
and RASSF8 transcripts are present from the early stages of 
embryogenesis to adulthood in mouse (Figure 3.1A) and human (Figure 
3.1B). On the contrary, no RASSF9 and RASSF10 ESTs were found for 
the initial developmental stages in mouse (Figure 3.1A) and their presence 
was either negligible or null in human (Figure 3.1B). 
In addition to embryonic stage specific differences, differences were 
observed among the four genes in adult tissues. Different patterns and 
levels of expression in both species were seen (Figure 3.2). Overall, 
RASSF7 and RASSF8 seemed to be widely expressed in mouse (Figure 
3.2A) and human (Figure 3.2B) samples whereas RASSF9 and RASSF10 
were generally less expressed in mouse (Figure 3.2A) and with very few 
transcripts predicted in human tissues (Figure 3.2B).  
Overall, the in silico analysis used as initial guidance for the subsequent 
experiments suggested that RASSF7 and RASSF8 were generally found 
to be broadly transcribed in a wide range of tissues and stages. Human 
RASSF9 and RASSF10 appeared to be less highly expressed. 
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Figure 3.1 
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Figure 3.2 
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3.2.2 RASSF7 expression during developmental stages 
3.2.2.1 ISH on embryonic mouse sections 
To verify if the predictions derived from the in silico analysis about the 
expression pattern of Rassf7 during murine development were correct, 
ISH was carried out on sectioned embryos and adult tissues using a 
Rassf7 in situ probe. The riboprobe should recognise the only mouse 
Rassf7 transcript variant consistently annotated and reported to translate 
into a protein in the VEGA database (Rassf7-001, 
OTTMUST00000056147). 
E10.5 
At this developmental stage relatively high levels of Rassf7 expression 
were seen throughout the embryo including the wall of the brain, neural 
tube and elements of hepatic primordium (Figure 3.3A). Expression was 
also high in regions of the developing heart (Figure 3.3A). Staining was 
seen with the antisense probe but not with the sense control. 
E 15.5 
During late embryogenesis, when most of the organs are distinct and 
easily distinguishable, Rassf7 appeared to be expressed in all tissues but 
at varying levels. Particularly high levels of Rassf7 RNA expression, 
detected by the antisense probe, could be seen in the brain, the gut, the 
heart (Figure 3.3B and 3.4), the lung, and the kidney (Figure 3.3B and 
3.5). A slightly lower expression of Rassf7 was observed in the liver and 
the pancreas (Figure 3.3B and 3.6). 
3.2.2.2 ISH and IHC on adult mouse organ sections 
Rassf7 was expressed in all adult tissues examined. Particularly strong 
Rassf7 expression was seen in the respiratory mucosa delimitating the 
bronchial cavities, the endocrine and exocrine pancreas, and the brain. 
(Figure 3.7).  In the brain there were regions of intense staining coinciding 
with the high presence of neuron cell bodies, as demonstrated by the H a 
E staining (Figure 3.8). 
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Figure 3.3 
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Figure 3.4 
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Figure 3.5 
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Figure 3.6 
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Figure 3.7 
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Figure 3.8 
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As shown in figure 3.8, in both the hippocampus and the cerebellum the 
grey matter strongly stained, apparently without labelling specific neuron 
types. 
Unlike in the embryo though, the level of Rassf7 expression was less 
uniform across the different organs. In the heart, the kidney and the liver 
the RASSF7 RNA staining was weak even if stronger than the 
corresponding sense control (Figure 3.9). 
Expression of RASSF7 protein 
The expression of Rassf7 in the mouse was also tested at a protein level 
by IHC conducted on an adult mouse tissue array kindly donated by Dr 
Jason Gill, University of Bradford. The high and broad expression of 
Rassf7 was confirmed by utilising AVIVA rabbit anti human RASSF7 
antibody, which is able to cross-react with mouse Rassf7. The antibody 
detected the Rassf7 protein in all the analysed samples previously tested 
for Rassf7 transcripts (Figure 3.10). 
Thus Rassf7 is ubiquitously expressed in embryonic and adult mouse 
tissues. 
3.2.2.3 Murine ISH pattern of other N-terminal RASSFs 
To elucidate whether Rassf7 expression pattern during mouse 
development was a distinctive feature of this protein or reflected the 
expression of the other N-terminal Rassf members, hybridisation 
experiments were performed for Rassf8 and Rassf9. Rassf10 was 
investigated as a pseudogene at the time this project was initiated and 
therefore it was not considered. 
In agreement with Rassf7 results, Rassf8 hybridisation signals were found 
to be broadly distributed early in development. At E10.5 the cephalic 
region, the heart and the primitive gut were evenly labelled (Figure 3.11A). 
Rassf8 was ubiquitously expressed also during mid embryogenesis. At 
E15.5, the level of the Rassf8 RNA signal was maintained high, if not 
enhanced, in the major organs, including brain, heart, kidney, liver, lung 
and spinal cord (Figure 3.11B). For this stage no significant differences  
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Figure 3.9 
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Figure 3.10 
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Figure 3.11 
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were observed between the level of expression of Rassf7 and Rassf8 
(Figure 3.3B and 3.11B).    
Expression analysis  was also performed on adult mouse sections as done 
for Rassf7. In these tissues, a faint label with the Rassf8 specific probe 
appeared in the liver, lung and kidney (Figure 3.12, left) but in the case of 
the brain, the heart and the pancreas no Rassf8 hybridisation signals 
above the background were observed (Figure 3.12, right). 
The other N-terminal Rassf gene, Rassf9, exhibited broad distribution in 
late embryogenesis but the intensity of the signal was less than Rassf7 
and Rassf8 (Figure 3.13). ISH analysis on adult mouse tissue was not 
performed for Rassf9 due to time constraints. 
Overall, Rassf7, Rassf8 and Rassf9 are broadly expressed in the mouse 
embryo. In adult mouse tissues, such broad expression is maintained at 
high levels for Rassf7, whereas it seems weaker for Rassf8. 
 
3.2.3 RASSF7 expression in human cell lines 
Since cell lines could represent a useful system to study RASSF7 function, 
an investigation was performed to determine the lines in which RASSF7 
was expressed.  
The RASSF7 antibody used for the mouse IHC was predicted to react with 
human samples and recognise all human protein variants (Figure 4.1) and 
was therefore tested and utilised for probing different mammalian and 
human cell lines. Details of the cell lines used are shown in Table 3.1. All 
immunoblotted lysates showed a major band migrating at the predicted 
molecular weight of RASSF7, 34 kDa, indicating that RASSF7 is 
expressed in all cell lines tested (Figure 3.14).  
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Figure 3.12 
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Figure 3.13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
105 
 
 
Figure 3.14 
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Cell line Species Description 
PC12 Rat Derived from pheochromocytoma of a adrenal medulla 
COS-7 Monkey Immortalised cell line derived from kidney cells 
T293 Human Derived from embryonic kidney 
Jurkat Human Immortalised cell line of T lymphocytes 
OVCAR Human Ovarian carcinoma cell line 
HeLa Human Immortal cervical cancer cells 
Caco2 Human Epithelial colorectal adenocarcinoma 
A549 Human Adenocarcinomic alveolar basal epithelial cells 
SHSY5Y Human Neuroblastoma 
HepG2 Human Liver carcinoma cell line 
PANC-1 Human Non endocrine pancreatic cancer 
THP-1 Human Acute monocytic leukaemia cell line 
Table 3.1: List and description of the cell lysates immunoblotted for RASSF7. 
Details of the cell lines were obtained from the American Type Culture Collection (ATCC) 
website: http://www.lgcstandards-
atcc.org/ATCCCulturesandProducts/CellBiology/CellLinesandHybridomas/tabid/981/Defa
ult.aspx 
Noticeably, most of the human cell lines examined were cancerous and 
still expressed RASSF7. Consistent with this result, IHC studies performed 
on cancer cell lines, grown as human xenografts in mice, showed intense 
staining pattern, often throughout the entire tumour cell (Figure 3.15 and 
3.16). The level of expression could correlate with specific tumour types as 
they appeared to show differential expression patterns (Figure 3.15 and 
3.16). 
Thus RASSF7, unlike RASSF1A, expression, does not appear to be 
down-regulated in cancer cell lines. 
 
3.2.4 Regulation of RASSF7 expression 
Given the findings about Xenopus rassf7 mitotic function (Sherwood et al., 
2008), it is reasonable to wonder if the level of expression of human 
RASSF7 could be determined by the cell cycle stage. However, it should 
be noted that many mitotic proteins can be found also in non-dividing cells.  
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Figure 3.15 
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Figure 3.16 
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Disruption of normal cell cycle controls may lead to abnormal levels of 
proteins, a phenomenon observed in the tumours of various cancers. To 
address if the human RASSF7 protein was itself regulated in a cell cycle 
dependent manner, a human cell line expressing RASSF7 at high levels, 
HeLa (Figure 3.14), was used. HeLa cell lysates were enriched with M 
phase cells through nocodazole treatment (75 ng/ml) for 18 hours followed 
by mitotic shake off. Lysates were then probed for either RASSF7 or 
phospho histone H3 (Ser10) considered as marker for mitotic cells (Figure 
3.17). There was no significant change in RASSF7 protein expression 
levels (Figure 3.17A and 3.17C), whereas the expression of the positive 
control increased as expected (Figure 3.17A and 3.17B), showing that 
RASSF7 expression does not increase during mitosis.   
3.2.4.1 RASSF7 response under hypoxic insult 
Hypoxia, the condition of insufficient oxygen supply to tissues, is 
associated with the metastatic potential of tumour cells and increases the 
expression of genes that also aerobically regulate invasion and 
metastasis. As a result, many solid tumours contain hypoxic regions. 
Hypoxia-inducible genes, such as vascular endothelial growth factor 
(Shweiki et al., 1992), erythropoietin (Huang et al., 1997), and CD105 (Li 
et al., 2003), promote cell survival mainly by facilitating angiogenesis  to 
sustain tumour growth.  
Given the high expression of RASSF7 in numerous cancer cells (Figure 
3.14, 3.15 and 3.16) and the results of previous microarray studies on 
hypoxia induced gene up-regulation (Camps et al., 2008; Liang et al., 
2009), another factor to investigate in relation to RASSF7 protein levels 
could be the effect hypoxia has on RASSF7 expression. 
To determine if RASSF7 protein levels were affected by hypoxia, HeLa 
cells were subjected to hypoxic insult (0.1% Oxygen) for 3 hours, 18 hours 
and 18 hours + 24 hour recovery in normoxic conditions. Then cell lysates 
from normoxic and hypoxic samples were probed for RASSF7. Both acute 
and prolonged hypoxic stress followed by recovery led to a significant 
RASSF7 over-expression compared to respective controls. A small but not 
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statistically significant increase in protein levels was found after 18 hours 
of hypoxic stress without recovery (Figure 3.18). 
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Figure 3.17 
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Figure 3.18 
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3.3 Discussion 
This study sought to fully characterise the expression of RASSF7 in 
mammalian tissues. RASSF7 expression was shown to be ubiquitous in 
the developing and adult mouse and detectable in numerous human 
cancer cell lines. Hypoxia was demonstrated to induce RASSF7 over-
expression at a protein level. 
Rassf7 expression in mouse and Xenopus embryo 
To date RASSF7 expression pattern has been examined exclusively in 
developing Xenopus embryo, where rassf7 has a maternal component and 
whose transcripts were found in neural tissue, epidermis, eye, ear, 
branchial arches and pronepheros. The neural and epidermal expression 
was reported to be maintained also during tadpole stages (Sherwood et 
al., 2008). However, the lack of a suitable antibody did not allow the 
authors to ascertain if that pattern coincided with the protein distribution. It 
was also not known if such expression pattern was evolutionary 
conserved. 
ISH experiments were therefore carried out on embryonic and adult 
mouse sections by using a mouse Rassf7 in situ probe. Rassf7 was seen 
ubiquitously and highly expressed during early embryogenesis, at E10.5, 
where not all organs are properly differentiated. At E15.5, Rassf7 
expression was still broadly ubiquitous and immuno-reactivity was 
maintained at high levels.  
An interesting question, raised by comparing the RASSF7 expression 
pattern in Xenopus and mouse, is why there is a discrepancy between the 
tissue distribution. It is possible that the protein plays different roles in the 
two species. However, given that Xenopus rassf7 exhibits both maternal 
and zygotic expression (Sherwood et al., 2008), it cannot  be excluded 
that rassf7 expression is turned on only in those tissues where the 
maternal protein is exhausted. Another possible explanation is that in the 
early Xenopus embryo some N-terminal rassfs may have a partial 
redundant function and could play the same role of rassf7 in tissues in 
which this protein is not expressed. However, it has to be noted that the 
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stages considered for analysing the expression pattern in the two systems  
may not be comparable, and a more ubiquitous staining may be found in 
tadpoles at later stages. Furthermore ISH was performed on Xenopus 
wholemounts rather than on sections, which may be not sufficiently  
sensitive for detecting low levels of expression in some tissues. 
Rassf7/Rassf8 expression in the adult mouse 
The ubiquitous expression of Rassf7 was found during adult stages, even 
if the level of expression varied, with particularly high levels seen in the 
lung, the pancreas and the brain. In the brain, the intensity of the 
immunoreactivity correlated with the cell density rather than with the cell 
type. An example of this was offered by the dentate gyrus, part of the 
hippocampus formation. No cell type specific staining was detected across 
the three layers of neurons forming this region, therefore the signal was 
determined by the number of cell bodies rather than a subset of cells 
expressing high levels of Rassf7.  
Consistent with the above results, the IHC performed on an adult mouse 
tissue array showed broad expression of Rassf7 protein, thereby 
confirming the ubiquitous presence of Rassf7, as predicted by preliminary 
in silico analyses. Interestingly, the intensity of the staining appeared more 
uniform across the different tissues when compared to the one exhibited 
by the ISH counterparts. This may be due to incomplete fixation of the 
samples used for ISH. In future, quantitative RT-PCR could be used to 
confirm differences in mRNA expression between tissues.  
A comparative study with the other N-terminal RASSFs showed that 
Rassf8 and Rassf9 were broadly expressed in the mouse embryo. Rassf8 
in particular, whose translated product exhibits 37% identity to Rassf7, 
was ubiquitously expressed throughout murine embryos, which raised 
questions over the possible physiological relevance of this expression 
pattern identical to Rassf7. In fact, the two human proteins could have 
redundant functions but preliminary findings published on rassf7 and 
RASSF8 functions (Falvella et al., 2006; Sherwood et al., 2008; Langton et 
al., 2009; Lock et al., 2010) make this hypothesis unlikely. It is possible 
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instead that the members of the N-terminal RASSF group have specific 
distinct functions. A tissue specific role could be indeed suggested for 
Xenopus rassf10, whose striking pattern of expression in the brain was 
observed by Hill et al. (2010).   
RASSF7 expression in human cell lines 
Numerous microarray screenings have shown that RASSF7 is up-
regulated in cancer (Sherwood et al., 2010) but only RNA levels have 
been investigated. The expression of RASSF7 protein in cancer has not 
been studied. 
To develop a better understanding of RASSF7 expression, various 
mammalian cell lysates were probed for RASSF7 via a commercially 
available antibody proved to be suitable for detecting the protein. The 
immunoblotting showed that RASSF7 was expressed in all cell lines 
tested, most of which were derived from human cancers. This result was 
confirmed by immunolabelling different human xenograft tumours grown in 
mice with the same antibody. Several cancer cell types appeared to show 
differential expression and the strong staining did not seem to label 
specific structures within the cells. These data could be even more 
informative if the experiment was done with primary tumour samples and 
normal tissue controls to evaluate possible changes in RASSF7 
distribution and expression. 
Regulation of RASSF7 expression levels 
Another aspect relating to RASSF7 expression is its regulation. RASSF7 
did not exhibit cell cycle dependent changes in the constitutive levels of 
expression, as RASSF7 protein was not increased in mitotic cells. 
RASSF7 protein levels are subject to change though, as they were shown 
to increase in response to hypoxic stress, thus confirming previous 
microarray studies (Camps et al., 2008; Liang et al., 2009). Both acute and 
chronic hypoxic insult followed by recovery in normoxic conditions led to a 
significant over-expression of RASSF7 in HeLa cells. These data suggest 
a role played by this protein to prepare cells to adapt and survive under a 
hypoxic environment. This could be achieved, for example, with an 
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increase of the cell metabolism, namely by increasing glucose transport or 
by raising the levels of glycolytic enzymes.  
Huang and collaborators suggested that the chromatin structure of 
RASSF7 chromosomal region could play a role in the hypoxic regulation of 
gene expression as the genomic positions of RASSF7 and AK123483, 
whose expression is similarly increased by hypoxia, are close (Huang et 
al., 2010). In order to explore the RASSF7 regulation further using 
hypoxia, it would be important to study if RASSF7 is implicated in 
regulating either the upstream or the downstream signaling of the Hypoxia 
Inducible Factor (HIF) pathways, not only in malignant but also in 
physiological conditions.  
It has been proved that the down-regulation of many classical RASSF 
tumour suppressors occurs via promoter methylation (van der Weyden 
and Adams, 2007; Richter et al., 2009; Avruch et al., 2009) and this seems 
to be the case also for RASSF10 (Hesson et al., 2009; Hill et al., 2010). 
However, our collaborators did not observe any methylation for RASSF7 in 
any of the carcer (including leukaemia) cell lines analysed (Hesson et al., 
2009; Recino et al., 2010). Consistent with these data, RASSF7 is 
expressed in various cancer cell lines (shown in this study) so it is 
reasonable to infer that RASSF7 cannot be a tumour suppressor as other 
RASSF proteins. 
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3.4 Conclusion 
The current study has investigated for the first time the expression of 
mammalian RASSF7. RASSF7 was found to be ubiquitously and highly 
expressed in the mouse in a stage and tissue independent manner. 
Human RASSF7 was also seen expressed in every cell lines analysed, 
most of which were cancerous. RASSF7 protein levels were not cell cycle 
dependent but could be up-regulated by hypoxia, a distinctive feature of 
many tumours which is known to cause a large number of gene-
expression changes. The physiological relevance of RASSF7 expression 
pattern has still to be determined, but the broad expression across tumour 
cell lines and the lack of promoter methylation demonstrated in previous 
studies suggest that, unlike other RASSF proteins, RASSF7 cannot act as 
tumour suppressor.  
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4 Cellular distribution of human RASSF7 
 
4.1 Introduction 
Cellular localisation of the classical RASSFs 
RASSF1A represents the best documented RASSF protein in relation to 
its subcellular distribution (Richter et al., 2009). During interphase, it was 
shown that epitope tagged and endogenously expressed RASSF1A 
proteins co-localise with the microtubule network in different mammalian 
cell lines, including A549, LNCaP, HeLa and NIH-3T3 (Liu et al., 2003; 
Song et al., 2004). During mitosis RASSF1A, either tagged or 
endogenous, localises to the centrosomes (prophase) and to the spindle 
fibres and poles (metaphase and anaphase), whereas during cytokinesis it 
relocates to the midbody (Liu et al., 2003; Song et al., 2004). However, 
more recently Guo et al. proved that in HeLa cells endogenous RASS1A 
showed centrosomal localisation throughout the cell cycle (Guo et al., 
2007). Ectopic or endogenous RASSF1A was also demonstrated to be 
recruited to the internalised death receptor TNF-R1 in response to 
TNFstimulation in human osteosarcoma U2OS, lung cancer H1299, and 
monkey kidney COS-1 cell lines (Baksh et al., 2005; Foley et al., 2008). 
The only other RASSF1 isoform whose localisation has been studied is 
RASSF1C. Endogenous RASSF1C localises primarily to the nucleus 
(Song et al., 2004; Kitagawa et al., 2006), where it is anchored in 
promyelocytic leukaemia-nuclear bodies via the binding with the apoptotic 
protein Daxx (Kitagawa et al., 2006). However, RASSF1C was also found 
to localise in the cytoplasm of HeLa cells subjected to ultraviolet (UV) 
irradiation (Kitagawa et al., 2006). Liu and co-workers reported that an 
antibody that reacted equally with RASSF1A, RASSF1B and RASSF1C 
revealed RASSF1 association with mitochondria in interphase cells (Liu et 
al., 2005). The over-expression of RASSF1A causes the rearrangement of 
the microtubules into either circular or bundled perinuclear rings (Dallol et 
al., 2004) and stabilises microtubules from depolymerisation (Liu et al., 
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2003; Vos et al., 2004; Rong et al., 2004; Dallol et al., 2004), similar to 
what was reported for RASSF1C (Rong et al., 2004; Liu et al., 2005).  
Little is known about the other RASSF proteins. Endogenously expressed 
RASSF2 was shown to be nuclear via Western blotting analysis performed 
on nuclear and cytoplasmic fractions of H417 and H720 lung cancer cell 
lines (Cooper et al., 2008). However, epitope tagged RASSF2 was shown 
to be both nuclear and cytoplasmic in gastric cancer JRST cells 
(Maruyama et al., 2008). Ectopic RASSF2 was found to be predominantly 
nuclear also in COS-7, HeLa, 293 and breast tumour cell lines MCF7 and 
HTB19, but only when the putative nuclear localisation signal in its N-
terminal region was not mutated (Cooper et al., 2008).   
The subcellular localisation of RASSF3 and RASSF4 proteins has not 
been determined. 
Endogenous and GFP-NORE1A were seen to localise at the centrosomes 
of human lung epithelial cells (Moshnikova et al., 2006) and, when over-
expressed in cancer A549 and normal cells, NORE1A labelled also the 
microtubules (Moshnikova et al., 2006). In other reports, GFP-NORE1A 
was observed in both nucleus and cytoplasm of transfected monkey COS-
7 cells (Park et al., 2008; Kumari et al., 2010), where it associated to a 
variety of subcellular structures or organelles, including microtubules, 
mitochondria and perinucleus (Park et al., 2008).  
RASSF6 localisation has not been extensively investigated. So far it has 
only been shown that FLAG-RASSF6  localises in both the cytosol and the 
nucleus of HeLa cells (Ikeda et al., 2007). 
Further investigations need to be carried out in order to improve our 
understanding of the localisation of the classical RASSF proteins, but at 
the moment centrosomes and microtubules seem to be their best 
characterised sites of activity. 
Cellular localisation of the N-terminal RASSFs 
Boa, the RASSF8 Drosophila orthologue, was found to co-localise with the 
adherens junction molecule E-cadherin in wing epithelial cells (Langton et 
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al., 2009). In agreement with these data, endogenous human RASSF8 
was observed within the nucleus and at the cell membrane at sites of cell-
cell contact of A549 and H1792 lung cancer cells, where RASSF8 
interacts with E-cadherin (Lock et al., 2010). In both A549 and H1792 cell 
lines human RASSF8 co-immunocolocalised with -catenin, which is a 
subunit of the cadherin protein complex, further confirming the subcellular 
distribution of the protein (Lock et al., 2010).  
Exogenous RASSF9 was found to associate with recycling endosomes in 
EGFP-RASSF9 transfected CHO cells (Chen et al., 1998), but its 
endogenous localisation is not known. 
Recently RASSF10 was shown to be associated with the spindle poles 
during metaphase/anaphase in A549 cells. During late cytokinesis 
RASSF10 was reported to relocate back to the cytoplasm, where it was 
seen to have a diffuse or perinuclear distribution (Hill et al., 2010).  
RASSF7 localisation in Xenopus  
The first attempt to establish RASSF7 localisation was made by Sherwood 
and colleagues in 2008 when a Xenopus N-terminal GFP-, and a C-
terminal HA-fusion constructs were used by injecting Xenopus embryos. 
The authors found that both constructs localised to discrete dots adjacent 
to the nuclei of expressing cells. This staining localised to the 
centrosomes, as indicated by the co-immunolabelling with -tubulin 
(Sherwood et al., 2008).   
The localisation of the human RASSF7 protein has not been studied so it 
has been investigated in the present study by analysing the endogenous 
and ectopic distribution of the protein in human cells via confocal 
immunofluorescence. 
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4.2 Results 
 
4.2.1 Localisation of endogenous human RASSF7 
The availability of a reliable anti-RASSF7 antibody on the market made it 
possible to investigate the subcellular distribution of endogenous human 
RASSF7. The polyclonal antibody used was produced in rabbits 
immunised with a synthetic peptide corresponding to a region of human 
RASSF7 partly overlapping with the first predicted coiled coil domain of 
the protein (Figure 4.1A and 4.1B). Based on protein sequence analysis, 
the antibody should recognise all predicted RASSF7 splice variants 
(Figure 4.1B).  
A 
MLLGLAAMELKVWVDGIQRVVCGVSEQTTCQEVVIALAQAIGQTGRFVLVQRLREKERQLLPQECP
VGAQATCGQFASDVQFVLRRTGPSLAGRPSSDSCPPPERCLIRASLPVKPRAALGCEPRKTLTPEP
APSLSRPGPAAPVTPTPGCCTDLRGLELRVQRNAEELGHEAFWEQELRREQAREREGQARLQ
ALSAATAEHAARLQALDAQARALEAELQLAAEAPGPPSPMASATERLHQDLAVQERQSAEVQGS
LALVSRALEAAERALQAQAQELEELNRELRQCNLQQFIQQTGAALPPPPRPDRGPPGTQGPLPPAR
EESLLGAPSESHAGAQPRPRGGPHDAELLEVAAAPAPEWCPLAAQPQAL 
 
B 
 
Figure 4.1: Human RASSF7 protein variants. RASSF7 A protein sequence (A) and 
schematic diagram of  the domain structure of the three RASSF7 splice variants (B). The 
RA domain has been highlighted in yellow and the two coiled coil (CC) regions in red. In 
bold and blue the peptide sequence used for producing the antibody (ab). 
 
Given the high RASSF7 expression levels shown by HeLa cells via 
immunoblotting (Chapter 3, Figure 3.14), this human cervical cancer cell 
line was used for localisation analysis. Initial studies failed to detect the 
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endogenous protein and it was discovered later that the antibody required 
antigen retrieval to be functional. The specificity of the antibody was 
confirmed by the lack of staining in RASSF7 KD cells (see chapter 5). 
RASSF7 was found to localise to specific structures adjacent to the 
nucleus throughout the cell cycle (Figure 4.2). Double immunolabelling 
with -tubulin showed perfect overlap with the RASSF7, indicating that the 
endogenous protein localises to the centrosomes in both dividing and non 
dividing HeLa cells (Figure 4.3). Thus RASSF7 is a centrosomal protein in 
human cells. 
4.2.1.1 Nocodazole treatment for investigating if RASSF7 
centrosomal localisation is microtubule dependent 
RASSF7 could be an intrinsic component of the centrosome or 
alternatively it could be trafficked to these organelles via the microtubules. 
To see if RASSF7 localisation was maintained when the microtubule 
network was disrupted, HeLa cells were treated with the microtubule 
depolymerising drug nocodazole, which was able to depolymerise most of 
the microtubules within the cells (Figure 4.4A). Following on from the 
treatment, HeLa cells still exhibited RASSF7 immunoreactivity at the 
centrosomes (Figure 4.4B). RASSF7 is therefore a centrosomal protein 
whose localisation is microtubule independent. 
 
4.2.2 Localisation of over-expressed human RASSF7 
The ectopic expression of a gene often provides insight into its role. As 
seen in chapter 3, RASSF7 expression is up-regulated in numerous 
cancer types (Sherwood et al., 2010) and this could potentially lead to the 
mislocalisation of the protein from its original site with direct consequences 
to the protein function. 
To understand if RASSF7 over-expression affected its localisation, two 
differently tagged human RASSF7A splice variant containing constructs 
were engineered with the Gateway cloning system and sequence 
confirmed. Both N-terminal GFP-, and C-terminal V5 fusion constructs 
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were transiently transfected into HeLa cells and immunodetection of the 
tagged proteins followed. 
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Figure 4.2 
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Figure 4.3 
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Figure 4.4 
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4.2.2.1 Localisation of N-terminal GFP and C-terminal V5 tagged 
RASSF7 in HeLa cells 
Transfected cells were found to form one cytoplasmic inclusion at 
moderate levels of N-terminal GFP- and C-terminal V5- tagged RASSF7 
over-expression (Figure 4.5A and 4.5B, arrowheads). However, when the 
level of expression of the ectopic protein was very high, multiple 
cytoplasmic punctuate structures were seen in the cell (Figure 4.5A and 
4.5B, arrows). This phenomenon was not observed when expressing GFP 
alone (Figure 4.5C).  
GFP-RASSF7 and RASSF7-V5 proteins were shown to localise to the 
same structures when co-transfected into the cell (Figure 4.6). In cells 
over-expressing RASSF7 at moderate levels, such structures were 
demonstrated to be centrosomes by the dual labelling experiment with 
either pericentrin or -tubulin, components of the pericentriolar material 
(Figure 4.7 and 4.8).   
No association with the microtubules was observed when RASSF7 was 
exogenously expressed and centrosome spots were still visible in cells 
transfected with fluorescently tagged RASSF7 and immunostained with -
tubulin (Figure 4.9). This does not support a possible microtubule 
stabilising role for RASSF7, as observed for  RASSF1A (Liu et al., 2003; 
Vos et al., 2004; Rong et al., 2004; Dallol et al., 2004). From the data 
presented, it is clear that RASSF7 maintains its centrosomal localisation 
pattern when it is moderately over-expressed.  
 
4.2.3 Cellular localisation of human RASSF8 
RASSF8 is the RASSF protein with the most sequence similarity to 
RASSF7. Given the identical expression pattern shown in the mouse 
embryo (Chapter 3), it is plausible that the two proteins localise to the 
same structures in the human cells. 
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Figure 4.5 
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Figure 4.6 
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Figure 4.7 
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Figure 4.8 and 4.9 
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During the performance of this investigation, Lock and colleagues 
characterised RASSF8 localisation (2010). HeLa cells were stained for 
endogenous RASSF8 with a commercial antibody and examined by 
confocal microscopy. RASSF8 was detected within the nucleus (Figure 
4.10A, arrowheads) and at the cell membrane (Figure 4.10A, arrows) of 
non-dividing cells (in agreement with the work of Lock and colleagues), 
whereas it localised predominantly to the cytoplasm of the cells in M 
phase (Figure 4.10B). Therefore RASSF8 was proved to be neither 
centrosomal nor associated to the microtubules. No specific staining 
above the background was observed for the  negative control (data not 
shown), suggesting that the antibody recognised RASSF8 protein.  
When over-expressed, RASSF8 tended to form aggregates which varied 
in size and number in HeLa cells. Even when expressed at lower levels, 
RASSF8 forming inclusions were not immunolabelled by pericentrin, 
indicating that those structures were not centrosomes (Figure 4.11A). In 
agreement with this result, cells co-transfected with RASSF8-GFP and 
RASSF7-V5 did not show co-localisation (Figure 4.11B). 
Thus, RASSF7 and RASSF8 show a different localisation pattern within 
human cells. 
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Figure 4.10 
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Figure 4.11 
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4.3 Discussion 
In the present chapter human RASSF7 localisation has been analysed. 
Human RASSF7 has been shown to localise to the centrosomes in a 
microtubule independent manner and to maintain its centrosomal 
localisation when over-expressed at moderate levels. It has also been 
demonstrated that human RASSF7 and human RASSF8 do not exhibit the 
same intracellular localisation within the human cells. 
RASSF7 localisation pattern is maintained across species as this protein 
has been found to localise to the centrosomes in Xenopus (Sherwood et 
al., 2008), mouse embryonic fibroblasts (personal communication from 
Nicole Antonio, University of Bath), as well as in the dividing and non- 
dividing human cells examined in the present study. In future, electron 
microscopy could determine where RASSF7 localises within the 
centrosome, and whether it is a component of the pericentriolar material or 
part of the centrioles. 
The centrosomes, as main MTOCs, orchestrate microtubule nucleation 
and spindle assembly during cell division, which involve a complex array 
of centrosome-associated proteins. Xenopus rassf7 has been shown to be 
essential for progression through mitosis and mitotic spindle formation 
(Sherwood et al., 2008).  Likewise, many centrosomal proteins contribute 
to the fine control of the cell cycle, and whose deregulation occurs during 
tumourigenesis. In fact, knocking out Rassf1A in mice causes an 
increased frequency of tumour formation (Tommasi et al., 2005). 
Therefore it is plausible that human RASSF7 plays an equally important 
role in regulating mitosis and cancerogenesis. 
Human RASSF7 is an integral centrosomal component. In fact human 
RASSF7 localisation was maintained when microtubules were lost, in 
contrast to Xenopus rassf7 which localised to the centrosomes in a 
microtubule dependent manner (Sherwood et al., 2008). The discrepancy 
could be well due to the use of a fusion protein in the Xenopus 
experiments. It would be interesting to test this hypothesis by inducing the 
expression of  fluorescently labelled human RASSF7 prior to treating the 
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cells with a microtubule depolymerising drug and establishing if the 
localisation of tagged human RASSF7 is lost. 
Assuming that the subcellular distribution of RASSF7 is related to the role 
it plays in the cell, its mislocalisation could affect its activity. A protein 
could differently localise within the cell according to its levels of 
expression. Such a phenomenon was observed in the RASSF family, 
where the centrosomal NORE1A labelled the microtubules when over-
expressed (Moshnikova et al., 2006). This could be the case also for 
RASSF7, whose levels of expression are up-regulated in numerous 
tumours (Sherwood et al., 2010). However, the over-expression of 
RASSF7, obtained via the transfection of fusion constructs in HeLa cells, 
confirmed the endogenous localisation results, suggesting that RASSF7 
localises to the centrosomes when its expression levels are moderately 
altered. High levels of RASSF7 over-expression could well induce ectopic 
RASSF7 to form aggregates in the cell, which could explain the formation 
of numerous inclusions.  
To mimic the in vivo situation more closely, RASSF7 could be over-
expressed without any tag and preferably in normal cells. Nevertheless, 
the fact that the ectopic RASSF7 behaved in the same way whether it was 
tagged at its N (GFP) or C (V5) terminus and whether it was exogenously 
expressed in HeLa or A549 (data not shown) cells made the result more 
robust. In this respect, a further confirmation could be obtained by 
analysing RASSF7 localisation in HeLa cells subjected to hypoxia 
treatment, that, as shown in chapter 3, induces the over-expression of the 
protein.  
The availability of tagged RASSF7 proteins could be useful in future for 
investigating what RASSF7 protein domains are necessary for its 
localisation and protein interactions. The use of labelled truncated 
versions of RASSF7 could verify if RASSF7 protein interactions are 
mediated by its coiled coil domain, which is a common feature of 
centrosomal proteins (Andersen et al., 2003). 
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Despite the structural and phylogenetic differences between RASSF7 and 
the classical RASSF proteins; RASSF1A, NORE1A and RASSF7 all show 
a similar localisation at the centrosome. However, ectopic RASSF7 does 
not seem to be a microtubule-binding protein as previously seen for 
RASSF1A (Liu et al., 2003) and NORE1A (Moshnikova et al., 2006). 
Microtubule localisation of RASSF1A was proved to occur when the 
expression levels of RASSF1A were not physiological (Liu et al., 2003). 
This result suggests that unlike RASSF1A, RASSF7 does not have a 
microtubule stabilising role. To ascertain if this was the case, it would be 
important to determine if forced expression of GFP-RASSF7 preserves  
microtubule integrity in cells subjected to nocodazole or ice treatment.  
The lack of a stabilising effect in RASSF7 over-expressing cells makes it 
possible to speculate that RASSF7 could promote microtubule 
polymerisation rather than reducing microtubule dynamics as documented 
for RASSF1A (Liu et al., 2003). If that was the case, RASSF7 over-
expression could lead to cytoskeletal problems different to those reported 
for RASSF1A, which led to aberrant centrosome separation and bipolar 
spindle formation (Liu et al., 2003). 
The last section of this chapter aimed to analyse the degree of similarity of 
human RASSF7 and human RASSF8 localisation, given the protein 
sequence homology. Endogenous RASSF8 was found in the nucleus and 
at the cell membrane of interphase HeLa cells, and, at low levels, in the 
cytoplasm of mitotic HeLa cells. When over-expressed RASSF8 forming 
structures did not co-localise with GFP-RASSF7. Recently, Lock and 
colleagues shed light on human RASSF8 cellular distribution, by 
demonstrating that, in both A549 and H1792 cells, RASSF8 
immunostaining co-localised with -catenin at the adherens junction, 
whose formation and function required RASSF8 expression (Lock et al., 
2010). These data confirmed the work published by Langton and 
colleagues, who characterised Boa, the Drosophila RASSF7/8 orthologue, 
showed that it regulates cell-cell adhesion via dASPP interaction and is 
required for normal E-cadherin  localisation (Langton et al., 2009). 
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The data discussed here indicate that human RASSF7 is a centrosomal 
protein whereas human RASSF8 is differently located within the cell. This 
suggests that there may be substantial differences between the functions 
of the two proteins. It is possible that RASSF7 function has diverged from 
RASSF8 during evolution and has developed an independent role. In fact, 
It is already known that while Xenopus RASSF7 is required for completing 
mitosis (Sherwood et al., 2008), Drosophila RASSF7/8 is not required for 
cell cycle progression (Langton et al., 2009) and knocking down human 
RASSF8 produces an increase in proliferation (Lock et al., 2010). RASSF8 
has been proposed as a tumour suppressor gene in lung cancer (Falvella 
et al., 2006), and could well exert this function by controlling the actin 
cytoskeleton organisation and consequently the integrity of the adherens 
junctions (Langton et al., 2009; Lock et al., 2010). Given the up-regulation 
in different cancers and the Xenopus data, it is tempting to speculate that 
human RASSF7 could be instead a centrosomally localised proto-
oncoprotein involved in microtubule dynamics. The function of human 
RASSF7 needed to be studied to test this hypothesis. This will be carried 
out in the next chapter. 
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4.4 Conclusion 
Human RASSF7 was shown to be a resident centrosomal component, 
whose localisation is not microtubule dependent as found in Xenopus. 
Despite localising to the centrosomes as RASSF1A and NORE1A, ectopic 
RASSF7 did not show any association to the microtubules as previously 
reported for RASSF1A and NORE1A. Moreover, human RASSF7 and 
human RASSF8 did not exhibit a similar localisation pattern within the 
human cells. In view of all these differences and despite the homology 
with other members of the family, it is therefore plausible that RASSF7 has 
a distinctive role amongst the RASSF proteins.  
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5 RASSF7 functional analysis 
 
5.1 Introduction 
The classical RASSF proteins have been implicated in a vast range of 
biological processes and are generally regarded as tumour suppressors 
(reviewed in chapter 1). RASSF1A, the best characterised member of the 
family, is involved in regulating microtubule stability, cell cycle progression, 
regulation of apoptosis, cell migration and is part of Hippo tumour 
suppressor network (Hesson et al., 2007; Donninger et al., 2007; Dallol et 
al., 2009a). Some of the classical RASSF members, such as RASSF1A 
and NORE1A, have been shown to bind to RAS proteins (Vavvas et al., 
1998; Vos and Clark, 2006) and therefore may act as RAS effectors. 
Little information is available on the biological properties of the N-terminal 
RASSF proteins [reviewed in (Sherwood et al., 2010)]. RASSF8 was 
identified as a candidate gene involved in leukaemia and lymphoma 
formation in mice (Weiser et al., 2007), may act as a tumour suppressor in 
lung cancer (Falvella et al., 2006), and controls cell-cell adhesion (Langton 
et al., 2009; Lock et al., 2010). RASSF9 has been shown to bind to RAS 
proteins (Rodriguez-Viciana et al., 2004) and could be involved in vesicle 
trafficking (Chen et al., 1998). RASSF10 has been proposed to be a 
tumour suppressor in lymphoblastic leukaemias and glioblastomas 
(Hesson et al., 2009; Hill et al., 2010). 
RASSF7 has been demonstrated to play an important role for cell cycle 
progression and survival in Xenopus (Sherwood et al., 2008), but there are 
no reports on the role of this proteins in other organisms. If such an 
important role was conserved throughout evolution, RASSF7 could be an 
interesting therapeutic target in the case of human pathologies. 
This chapter will try to broaden the current knowledge on the function of 
RASSF7 within human cells by analysing the consequences of RASSF7 
KD via immunocytochemistry and FACS analyses. 
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5.2 Results 
 
5.2.1 RASSF7 depletion prevents anchorage independent 
growth in H1792 cells 
Numerous members of the RASSF family have been shown to be tumour 
suppressors and to inhibit cell growth (van der Weyden and Adams, 2007; 
Richter et al., 2009). In particular, it has been shown that RASSF6 and 
RASSF8 depletion results in an increase of anchorage independent 
growth of the human lung adenocarcinoma cell line H1792 (Allen et al., 
2007; Lock et al., 2010). To understand if RASSF7 functions in a similar 
way, the effect of RASSF7 KD on anchorage independent growth was 
analysed in H1792 cells. The cells were transfected with two different sets 
of double-stranded 21-nt short siRNA constructs, RASSF7 KD1 and 
RASSF7 KD2, which targeted respectively an RA domain coding region in 
exon 2 and a non coding RNA region in the last exon of all RASSF7 
transcripts (Figure 5.1). The results were assayed 72 hours later via 
Western blotting. RASSF7 expression was inhibited by RASSF7 KD2 RNA 
duplexes (Figure 5.2A). In contrast, RASSF7 KD1 did not efficiently knock 
down RASSF7 and this siRNA was used as an additional negative control 
along with the standard siRNA control (Figure 5.2A). H1792 cells showed 
significantly lower colony-forming activity in soft agar (p<0.01) after 
RASSF7 KD2 siRNA treatment as both the size and the numbers of 
colonies resulted drastically reduced (Figure 5.2B and 5.2C). These 
findings suggest that RASSF7 is essential for anchorage independent 
colony formation.  
 
142 
 
Figure 5.1: RASSF7 small interfering (si)RNA target regions. Schematic 
representation of RASSF7 transcript regions targeted by RASSF7 KD1 and RASSF7 KD2 
siRNA constructs. The specific protein domains encoded by exon regions have been 
indicated above each RASSF7 transcript. Blue and empty boxes are exons and lines 
connecting boxes are introns. Blue boxes are coding sequence, whereas empty boxes 
are UTRs. Green boxes: RA protein domains, grey boxes: coiled coil (CC) protein 
domains.  
 
5.2.2 RASSF7 shRNA KD reduces HeLa cell number 
RASSF7 function was also investigated via an alternative KD method. This 
time HeLa cells were used, as they also express RASSF7 (Chapter 3) and 
are easier to analyse than H1792 cells. Plasmids containing either 
RASSF7 specific, which targeted an RA domain coding region in exon 2 
(Figure 5.3), or scrambled shRNA were transfected into HeLa cells and 24 
hours later G418 was added to select for the positive cells.  
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Figure 5.2 
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Figure 5.3: RASSF7 short hairpin (sh)RNA target regions. Schematic representation 
of RASSF7 transcript regions targeted by RASSF7 shRNA. The specific protein domains 
encoded by exon regions have been indicated above each RASSF7 transcript. Blue and 
empty boxes are exons and lines connecting boxes are introns. Blue boxes are coding 
sequence, whereas empty boxes are UTRs. Green boxes: RA protein domains, grey 
boxes: coiled coil (CC) protein domain.  
HeLa cells were efficiently RASSF7 depleted, with more than 70% of the 
protein removed (Figure 5.4A). Consistent with this result, RASSF7 
centrosomal localisation was lost in RASSF7 KD cells (Figure 5.5), which 
confirmed the specificity of the RASSF7 centrosomal staining. After 
culturing the cells  with G418 for 14 days, the difference in cell number 
between control and RASSF7 shRNA tested cells was 2.6 + 0.6 fold 
(p<0.001) (Figure 5.4B and 5.4C). This reduction in cell number cannot be 
explained by the G418 selection process as a significant difference in 
numbers (1.9 + 0.4 fold) was observed also after re-plating selected 
RASSF7 and control KD HeLa cells at the same density. Thus, RASSF7 
KD impairs normal cell growth. 
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Figure 5.4 
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Figure 5.5 
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5.2.3 Phenotypic characterisation of RASSF7 KD cells 
To address why RASSF7 is required for growth, the subsequent 
characterisation following shRNA treatment was conducted in HeLa cells, 
as used previously.  
5.2.3.1 Defects presented by RASSF7 KD cells 
The reduction in cell number observed in RASSF7 KD HeLa cells could be 
caused by increased apoptosis; however, the percentage of active 
caspase 3 positive RASSF7 KD cells was not significantly different from 
controls (Figure 5.6). 
Defects in mitotic cells 
To establish whether the reduction in cell number was caused by defective 
proliferation the effect of RASSF7 depletion was analysed in dividing cells. 
After the completion of selection, shRNAi transfected cells were fixed and 
stained with anti -tubulin antibody (microtubules) and DAPI (DNA) and 
analysed during different mitotic stages. No prominent differences 
between RASSF7 KD and control KD cells were observed  at the onset of 
mitosis (Figure 5.7). However, later on in mitosis, once cells have reached 
metaphase, mitotic aberrations in RASSF7 KD cells became clearly 
evident (Figure 5.8). Loss of RASSF7 resulted in a failure in chromosomal 
congression (Figure 5.8B, left panel), demonstrated by an increase in the 
number of mitotic cells in a prometaphase-like state with no discernible 
metaphase plate (63% compared with 18% in controls, n=300, p<0.01) 
(Figure 5.8B, white arrows), an increase in metaphase cells with lagging 
chromosomes (21.5% compared with 6% in controls, n=300, p<0.01) 
(Figure 5.8B, red arrowhead) and a decrease in metaphase cells with 
correctly aligned DNA (15.7% compared with 75.7% in controls, n=300, 
p<0.001). RASSF7 deficient cells exhibited also spindle defects, with 
spindles showing less pronounced polarisation towards the DNA and a 
more radial organisation of microtubules (Figure 5.8B, red arrows). Finally, 
there was a small increase in the rate of multi-polar spindles (32,6% 
compared with 23.7% in controls, n=300, p<0.05) (Figure 5.8B, white 
arrowheads). 
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Figure 5.6 
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Figure 5.7 
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Figure 5.8 
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All these aberrations may have well contributed to the decrease in the 
number of anaphase cells, which was 5.7% compared with 16.9% in 
controls (n=180, p<0.01). However, despite being reduced in number, 
anaphase cells looked normal (Figure 5.9). 
Defects in interphase cells 
Given that RASSF7 normally localises to the centrosomes (Chapter 4), 
interphase centrosomes were analysed in RASSF7 KD cells by 
immunocytochemistry using an antibody against pericentrin, a component 
of the pericentriolar material. The rate of polycentrosomal cells was 
significantly enhanced when RASSF7 was knocked down (6.5 + 1.5%) 
compared to controls (3.5 + 0.5%) (n=1500, p<0.05) (Figure 5.10). 
Moreover, a conspicuous population (5.3 + 0.7%) of multinucleated cells 
was generated when RASSF7 was knocked down, whereas control 
shRNAi cells had only 2.8 + 0.5% of polyploid cells (n=1500, p<0.01) 
(Figure 5.11). 
These data suggest that RASSF7 KD causes defects in mitosis; this could 
lead to polyploidy and the increase in the number of centrosomes in HeLa 
cells. 
5.2.3.2 Analysis of DNA content of RASSF7 KD cells 
In order to see if the defects caused by RASSF7 KD were able to perturb 
the cell cycle progression, RASSF7 KD and control cells were fixed and 
stained with propidium iodide and their cell cycle stage determined by 
FACS analysis. The lack of RASSF7 did not significantly affect the 
percentage of diploid (2N DNA), dead and dying cells (<2N DNA) (Figure  
5.12). However, RASSF7 depleted cells showed a small but significant 
increase in the number of cells with 4N DNA (24.55 % + 1.35 compared 
with 21.25% + 0.05 in controls, n=3 x 106, p<0.05) (Figure 5.12). The 
number of aneuploid cells (>4N DNA) was not statistically different from 
control cells (Figure 5.12). 
When RASSF7 KD and control HeLa were stained for phospo histone H3 
(Ser10), the number of positive cells in the two samples was statistically 
equivalent (Figure 5.13) indicating that there was no significant difference  
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Figure 5.9 
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Figure 5.10 
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Figure 5.11 
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Figure 5.12 
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Figure 5.13 
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in the number of cells undergoing mitosis between RASSF7 KDs and 
controls. Thus, RASSF7 KD does not appear to cause a delay in mitosis. 
However, the increase in RASSF7 KD polyploidy cells suggests that 
RASSF7 may be required for cells to undergo cytokinesis. 
5.2.3.3 Localisation and activation of mitotic signaling proteins in 
RASSF7 depleted cells 
In order to understand the molecular basis for the mitotic defects 
described in the previous sections, the effect of RASSF7 KD on 
established regulators of mitosis was analysed. Analysis of the activation 
of PLK1 (Barr et al., 2004), using an antibody which recognises its active 
form (-phospho PLK1, Thr210), showed similar staining in RASSF7 KD  
and control cells (Figure 5.14).  
The localisation of RASSF1A, which is also involved in mitosis, to the 
centrosome appeared to be the same in control and KD cells (Figure 
5.15). 
The localisation and activation of Aurora A and Aurora B (Carmena et al., 
2009) was also examined (Figures 5.16 and 5.17). An antibody against 
Aurora A and B and a phospho-specific antibody which recognises the 
active form of Aurora A and B enzymes [-phospho Aurora A (Thr288), B 
(Thr232), C (Thr198)] were used. Aurora A was present at the centrosome 
(Figure 5.16) and Aurora B was present at the kinetochore during 
metaphase (Figure 5.17A) and at the mid-body during cytokinesis (Figure 
5.17B) in both RASSF7 KD and control cells. In the RASSF7 KDs the 
active Aurora staining was present at the centrosomes (Figure 5.18B, 
arrows) where it overlapped with Aurora A staining (Figure 5.19B, white 
arrows), but it was strongly reduced at the kinetochore (Figure 5.18B, 
white arrowhead) where the co-localisation with Aurora B was almost 
undetectable (Figure 5.20A, arrowhead). In fact, only 9.3% of RASSF7 
depleted cells showed strong active Aurora B staining compared with 
83.8% in the controls (n=240, p<0.001). This loss appeared to be 
restricted to metaphase as the activation of Aurora B during cytokinesis 
appeared normal (Figure 5.20B).  
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Figure 5.14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
159 
 
Figure 5.15 
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Figure 5.16 
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Figure 5.17 
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Figure 5.18 
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Figure 5.19 
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Figure 5.20 
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Loss of Aurora B activity was confirmed by the lack of phosphorylation of 
CENP-A (Ser7) (Figure 5.21), a centromere specific histone H3 variant 
phosphorylated by Aurora B during mitosis (Zeitlin et al., 2001). Only 22% 
of RASSF7 KD cells showed strong phospho CENP-A staining compared 
with 93,4% of control cells (n=210, p<0.001), providing further evidence 
that Aurora B is not activated normally in the absence of RASSF7. 
Aurora B activation requires the recruitment of INCENP, inner centromere 
protein (Vader et al., 2006b), but RASSF7 KD did not compromise the 
correct localisation of this protein at the kinetochore (Figure  5.22). 
Overall these data suggest that the expression of centrosomal RASSF7 is 
critical for the correct activation of the mitotic signaling protein Aurora B at 
the kinetochore, whereas it does not seem to affect the localisation/ 
activation of PLK1, RASSF1A and Aurora A. 
5.2.3.4 Microtubule abnormalities in RASSF7 KD cells 
The localisation of RASSF7 at the centrosome and the spindle defects 
seen in the KDs suggest that RASSF7 might have a role in regulating 
microtubules. To test whether RASSF7 is required for microtubule 
polymerisation, microtubule re-growth was studied in RASSF7 depleted 
HeLa cells. Cells were treated with nocodazole to completely 
depolymerise the microtubules and then the cells were released into 
medium at 37°C to allow the microtubules to re-nucleate (Figure 5.23). In 
RASSF7 KD cells initial microtubule nucleation was not affected (5 
minutes) but after 15 minutes microtubule polymerisation was perturbed in 
terms of timing and organisation, with 53% of RASSF7 KD cells showing a 
delay in microtubule re-growth compared with 14% of controls (n=100, 
p<0.001) (Figure 5.23). The microtubules in RASSF7 KD cells appeared 
more bent and looped than controls (Figure 5.23, white arrows). A similar 
delay in microtubule re-growth was seen also at 30 minutes. After 60 
minutes, the number of microtubules in the RASSF7 KD cells resembled 
the controls (Figure 5.23), showing that RASSF7 KD cells eventually 
produce similar numbers of microtubules to control cells. However, the 
microtubule network still appeared quite disorganised, with individual 
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microtubule fibers less straight than the control microtubules (Figure 5.23, 
white arrows). RASSF7 is therefore a key regulator of microtubule growth. 
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Figure 5.21 
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Figure 5.22 
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Figure 5.23 
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5.3 Discussion 
In the current chapter, RASSF7 function was analysed via a dual RASSF7 
RNAi approach. siRNA and shRNA mediated RASSF7 KD were shown to 
impair cell growth in H1792 and HeLa cells respectively. In HeLa cells, 
shRNA induced RASSF7 depletion affected numerous mitotic events and 
led to a little increase in the tetraploid cell population. RASSF7 depletion 
did not affect the localisation of PLK1, RASSF1A and Aurora A, but the 
activity of the mitotic signaling protein Aurora B was found compromised 
and the microtubule growth was defective. 
RASSF7 KD is required for cell growth 
The first approach used for unraveling RASSF7 function involved the use 
of two different sets of small interfering RNA oligonucleotides, only one of 
which specifically inhibited RASSF7 translation. It was found that the 
siRNA duplex capable of knocking down RASSF7 protein affected H1792 
cell growth in soft agar. This result clearly suggests that, unlike RASSF6 
and RASSF8 (Allen et al., 2007; Lock et al., 2010), RASSF7 does not 
seem to restrain cell growth. The fact the RASSF7 is required for growth 
may explain why its expression is not silenced in the cancer cell lines 
analysed in chapter 3. It is plausible that RASSF7 could promote cell 
growth instead. This hypothesis could be tested by over-expressing the 
protein in this cell line in order to see if the colonies formed would become 
bigger and more numerous compared to controls. 
To address why RASSF7 is required for growth, shRNA KDs were carried 
out in HeLa cells. The alternative KD strategy ensured the specificity of the 
phenotype, and HeLa cells were used as they are easier to analyse than 
H1792 cells. Consistent with the data in H1792 cells, shRNA KD of 
RASSF7 caused a reduction in cell number. It is tempting to speculate that 
if RASSF7 controls cell growth, increased levels of RASSF7 could also 
increase the tumourigenicity of cancer cells. If that was the case the 
injection of RASSF7 over-expressing cancer cells into 
immunocompromised organisms, should result in increased tumour 
formation. Such a result would confirm that the misregulation of RASSF7 
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and RASSF8 differently promote cancer progression, as RASSF8 was 
found to suppress tumour growth in vivo (Lock et al., 2010). 
RASSF7 KD causes defects in mitosis 
The cell number reduction in HeLa cells could be caused by increased 
apoptosis, a phenomenon promoted by rassf7 KD in the Xenopus embryo 
(Sherwood et al., 2008). However, the percentage of active caspase3 
positive human RASSF7 KD cells was not significantly different from 
controls. This result was further confirmed by flow cytometry as similar 
sub-G1 populations (which have less than 2N DNA content) were present 
in RASSF7 KD and control cells. It is possible that if the cells had been left 
to grow for longer, a higher cell death rate would have been seen in 
RASSF7 KDs. Another explanation for the reduced HeLa cell number 
could be a defective cell division. While mitotic spindles fail to form in 
Xenopus rassf7 KD cells (Sherwood et al., 2008), their formation in human 
RASSF7 KD cells is not blocked, although they did form abnormally. 
However, loss of RASSF7 was found to produce misoriented and lagging 
chromosomes, a higher rate of multi-polar spindles and a more radial 
organisation of the microtubules. 
RASSF7 KD phenotype partly overlaps with the ones caused by the 
depletion of other centrosomal proteins involved in mitotic progression. 
Misaligned metaphase chromosomes were previously observed in HeLa 
cells following Aurora A siRNA (Marumoto et al., 2003) and PLK1 depleted 
cells had been found to exhibit chromosomes in a rosette-like 
arrangement (Hanisch et al., 2006). PLK1 KD cells exhibited spindles with 
monopolar or abnormally small bipolar microtubule arrays (Hanisch et al., 
2006), and also RASSF1A depletion was seen to cause spindle 
abnormalities (Dallol et al., 2009a). In the examples reported however, the 
chromosomal congression defects detected seem to be less severe than 
the ones observed for RASSF7, and seem to be due to a defective 
centrosome maturation/ separation (Marumoto et al., 2003; Hanisch et al., 
2006). On the other hand, RASSF7 KD mitotic cells exhibited apparently 
normal centrosomes at the opposite poles (data not shown), were able to 
originate microtubule spindles, but were less good at microtubule 
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polymerisation. Nevertheless, more work needs to be done: it would be 
important to test whether in RASSF7 KD cells other centrosomal functions 
are compromised and the centrioles and the pericentriolar material they 
consist of are equally partitioned for each spindle pole. The correct 
distribution of centrioles could be investigated by staining the cells with an 
antibody raised against centrin 3, a component of centriole (Paoletti et al., 
1996). 
RASSF7 KD causes abnormalities in interphase cells 
Both Aurora A and RASSF1A depletions were reported to augment the 
proportion of cells in the earlier stages of mitosis compared to later stages 
(Marumoto et al., 2003; Dallol et al., 2009a), with the majority of RASSF1A 
KD cells failing to proceed into anaphase (Dallol et al., 2009b). Time lapse 
video microscopy could determine the duration of a cell cycle for RASSF7 
KD cells and provide an explanation for the reduced number of anaphase 
RASSF7 depleted HeLa cells, which was a third of the control 
counterparts, in agreement with the Xenopus data (Sherwood et al., 
2008). It would also be interesting to study whether the levels of mitotic 
cyclin B, whose destruction determines the initiation of anaphase and final 
events of mitosis, are maintained high after metaphase and its 
degradation is delayed. RASSF7 KD cells exhibited a two fold increase in 
polyploid and polycentrosomal interphase cells. This could be due to two 
consecutive rounds of genome replication during the same cell cycle or a 
premature exit from mitosis, with subsequent failure to complete 
cytokinesis. The latter was shown to be the case for Aurora A and 
RASSF1A KDs, both resulting in an increase of multinucleated cells 
(Marumoto et al., 2003; Dallol et al., 2009a). 
RASSF7 is over-expressed in numerous cancers (Chapter 3), therefore it 
would be interesting to verify whether the alteration of RASSF7 levels 
results in genomic instability. The karyotyping of the chromosomes could 
help to identify genetic problems leading to disorders and diseases. 
Despite the defects in mitosis, no enhanced phosphorylation of histone 
H3, a marker of mitotic cells, was detected in RASSF7 KD cells compared 
to controls, similarly to what was previously shown for Xenopus rassf7 KD 
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(Sherwood et al., 2008). Given the fact that mitotic defects did not cause 
an increase in mitotic cells, it is possible that the chromosome congression 
defects observed failed to elicit spindle assembly checkpoint activation. 
Several commercial Mad2 (Li and Murray, 1991) antibodies have been 
tested to try and investigate this hypothesis, but none of them were 
suitable for this study (data not shown). If the spindle checkpoint was 
compromised, cells could experience what is known as “mitotic slippage”, 
an aberrant exit from mitosis without sister chromatid segregation and 
cytokinesis. In that case cells could divide also without properly aligned 
chromosomes. This would cause an increase in tetraploid cells in G1, and 
could explain the slight but significant increase in the number of RASSF7 
KD cells with 4N DNA reported with FACS analysis. These cells could 
subsequently arrest in G1, but only if the p53 dependent postmitotic G1 
checkpoint was active (Vogel et al., 2004). Thus it would be important to 
test if RASSF7 KD affects also p53 activation. 
RASSF7 KD effects on mitotic signaling proteins 
The consequences of RASSF7 knockdown on signaling proteins involved 
in mitotic progression were examined. RASSF7 KD did not compromise 
the correct centrosomal localisation of RASSF1A and phospho PLK1. The 
analysis was subsequently moved to the Aurora kinases, which are 
crucially recruited in the control of numerous mitotic events (Nigg, 2001; 
Carmena and Earnshaw, 2003; Andrews et al., 2003). Aurora A was found 
to correctly localise and be phosphorylated at the centrosomes. The CPC 
protein Aurora B (Murata-Hori et al., 2002; Carmena and Earnshaw, 2003; 
Andrews et al., 2003), localised to the inner centromere adjacent to the 
kinetochore and at the midbody as expected. The kinetochore is the site 
where Aurora B exerts is control on DNA condensation, chromosome bi-
orientation and kinetochore-microtubule attachment (Carmena and 
Earnshaw, 2003; Andrews et al., 2003). However, the phospho Aurora 
staining at the centromere of metaphase RASSF7 depleted cells was 
barely detectable, which indicates a lack of activity of the protein. Aurora B 
loss of activity was confirmed by the lack of phosphorylation of CENP-A, a 
centromere specific histone H3 variant phosphorylated by Aurora B at 
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mitosis (Zeitlin et al., 2001) and whose deficiency leads to severe 
chromosome segregation defects (Regnier et al., 2005). Interestingly, 
however, RASSF7 KD did not compromise the correct centromere 
recruitment of INCENP, which is required for Aurora B activation (Vader et 
al., 2006b). The loss of Aurora B activity is likely to contribute to the mitotic 
defects seen in RASSF7 KDs and, consistent with this hypothesis, 
inhibiting Aurora B causes chromosomal congression defects similar to 
those in RASSF7 KD cells (Kallio et al., 2002b; Lampson et al., 2004). 
Notably, cells in which Aurora B function is impaired often proceed through 
anaphase despite the presence of misaligned chromosomes. The loss of 
the spindle checkpoint under these conditions may be due to a lower 
concentration of Mad2 and BubR1, proteins involved in sensing correct 
chromosome attachment, at the kinetochores of Aurora B deficient cells 
(Lens et al., 2003; Hauf et al., 2003). This could explain why the increase 
in the number of tetraploid RASSF7 KD cells is only small.  
Quite intriguingly, Aurora B inactivation was found to be a temporary 
phenomenon restricted to metaphase as the phospho Aurora signal was 
detectable again at the midbody of RASSF7 KD cells undergoing 
cytokinesis. Moreover, given the different activation times for the 
phosphorylation of histone H3 (late G2), a target of Aurora B which was 
found to be active in our experiments, and CENP-A (prometaphase) 
(Zeitlin et al., 2001), it is reasonable to speculate that Aurora B becomes 
inactive during prophase/prometaphase, after which it cannot 
phosphorylate its targets anymore. The activity of other CPC members, 
which have not been checked in the present work, could be compromised 
in RASSF7 KD cells, and could subsequently reduce Aurora B activity on 
its endogenous substrates. This was shown to be the case in Mps1 
deficient human cells, where the CPC protein Borealin was not 
phosphorylated and Aurora B was not active, albeit present at normal 
levels on inner centromeres of chromosomes (Jelluma et al., 2008). 
The localisation of RASSF7 at the centrosome (Chapter 4) and the spindle 
defects seen in the KDs suggest that RASSF7 might have a role in 
regulating microtubules. In accordance with this hypothesis, microtubule 
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growth was found to be affected by the loss of RASSF7 in HeLa cells. 
Microtubule re-growth assay showed that RASSF7 KD microtubules took 
longer to form and were more looped than the control counterparts. This 
demonstrates that RASSF7 is a key regulator of microtubule growth and 
suggests that it could have a role in microtubule polymerisation. This 
function provides also an explanation for the spindle defects seen in 
mitosis. It would be interesting to investigate whether the polarised 
organisation of the microtubules is correctly maintained in RASSF7 
depleted cells and if not, how this could affect mitosis. A possible way for 
looking into this aspect would be to do live imaging of microtubule 
movements and to specifically analyse the kinetochore bound 
microtubules by immunostaining, after cold treating the cells to destabilise 
non kinetochore microtubules. 
Changes induced in the microtubule cytoskeleton of RASSF7 mitotic cells 
were reminiscent of those observed in Aurora B inhibited cells (Kallio et 
al., 2002b), where astral microtubules were remarkably enhanced. 
Interestingly, Aurora B activation requires contact with microtubules 
(Rosasco-Nitcher et al., 2008; Fuller et al., 2008). The spindle formation 
defects derived from RASSF7 KD could therefore stop the microtubules 
from correctly interacting with Aurora B, and cause the failure in Aurora B 
activation, and subsequently in chromosomal congression.  
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5.4 Conclusion 
RASSF7 KD impairs colony forming activity and cell growth in H1792 and 
HeLa cells respectively. Further analysis is needed to understand if 
RASSF7 actively promotes cell proliferation, and whether it has the 
complete opposite role compared to the other RASSF members. The 
characterisation of RASSF7 KD phenotype showed defective mitosis in 
HeLa cells, leading to malorientated and lagging chromosomes, and a 
higher rate of multi-polar spindles with more radial microtubules. 
Eventually such aberrations are the likely cause of the increased numbers 
of polycentrosomal and polynucleated cells. Despite the major defects 
observed, RASSF7 depleted cells do not seem to incur in cell death more 
frequently than controls. RASSF7 depletion also prevents Aurora B 
activation. Aurora B inhibition is known to cause chromosomal 
congression defects similar to those in RASSF7 KD cells and it may 
explain the lack of a pronounced mitotic arrest in RASSF KD dividing cells. 
It is possible that RASSF7 exerts its control on Aurora B activity by 
regulating the microtubules and microtubule re-growth assays showed that 
RASSF7 is an important regulator of microtubule dynamics. 
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6 Final discussion 
 
Proposed working model 
RASSF7 is a member of the N-terminal RASSF family, an evolutionary 
conserved group of RA domain proteins that comprise four vertebrate 
members (Sherwood et al., 2010). So far these proteins have been poorly 
characterised and their biological function is still unclear, but there is an 
increasing amount of evidence that, if misregulated, they may promote 
cancer (Sherwood et al., 2010).  
The current project aimed at investigating the role of the mammalian 
RASSF7, testing the intriguing hypothesis that this protein, as suggested 
by the Xenopus orthologue (Sherwood et al., 2008), could play a role in 
human cell division.   
It has been demonstrated that human RASSF7 is a centrosomal 
component (Chapter 4) and could promote crosstalk between  the 
centrosome  and microtubules, which in turn is required for Aurora B 
function (Rosasco-Nitcher et al., 2008; Fuller et al., 2008) (Figure 6.1). 
RASSF7 appears to control microtubule stability and dynamics during 
formation of a functional mitotic spindle. The down-regulation of RASSF7 
would therefore impair the correct assembly of the mitotic microtubules, 
resulting in Aurora B inactivation and eventually in misalignment of 
chromosomes on the metaphase plate (Chapter 5). Such an important role 
in the cell could justify the broad tissue expression observed in mouse and 
human (Chapter 3) and would be in line with the function of other 
fundamental centrosomal proteins, such as Aurora A (Giet et al., 1999; 
Katayama et al., 2001; Kufer et al., 2002; Tsai et al., 2003). 
RASSF7 interactors are crucial to understand RASSF7 function 
The study of RASSF7 binding partners is required to explain the 
mechanism of action of this protein. RASSF7 could interact with 
microtubules by direct or indirect binding. A fascinating possibility is that 
RASSF7 may interact with microtubules via other microtubule dependent 
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components of the centrosomes. These components comprise elements 
of the cytoplasmic dynein motor, where the dynactin element is required 
for anchoring of microtubules at the centrosomes (Quintyne et al., 1999), 
and are probably involved in mitotic spindle formation and chromosomes 
motility (Vaisberg et al., 1993).  
 
Figure 6.1: Proposed model for RASSF7- Aurora B interaction. RASSF7 would allow 
Aurora B activation and correct completion of mitosis via the stabilisation of the mitotic 
spindle microtubules. 
Potential binding partners for human RASSF7 have been identified via 
large scale yeast two-hybrid studies. These possible interactors include 
CHMP1B (chromatin modifying protein 1B), which is associated with 
endosomal membrane trafficking, and DISC1 (disrupted in schizophrenia 
1), which interestingly interacts with microtubules (Morris et al., 2003; 
Tsang et al., 2006). However, it is crucial to verify these potential protein- 
protein interactions by immunoprecipitation and Western blotting 
techniques. Once this is done, it will be interesting to test if the 
constitutively active/inactive forms of the binding partners are capable of 
attenuating or reversing the mitotic aberrations observed in RASSF7- 
deficient cells. 
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RASSF7 and apoptosis 
During the preparation of this thesis, Takashi and colleagues published 
results demonstrating that RASSF7 physically interacts with 
phosphorylated MKK7 (MAP kinase kinase 7) to negatively regulate pro-
apoptotic JNK signaling in human cells (Takahashi et al., 2011) (Figure 
6.2). The authors showed that RASSF7 normally inhibits apoptosis 
induced by cell stresses, such as UV irradiation, and that its RA domain is 
required for its inhibitory actions. Immuonoprecipitation assays using 
recombinant proteins showed that the same RA domain was also capable 
of binding tightly to active N-Ras, and this interaction was not only 
enhanced following UV irradiation but also necessary to deliver anti-
apoptotic signal in response to short term stresses (Takahashi et al., 
2011).  
Interestingly, prolonged exposure to UV irradiation induced RASSF7 
degradation via the ubiquitin-proteasome pathway in HeLa cells (Figure 
6.2). Other cell stress stimuli, such as glucose depletion or treatment with 
DNA alkylating agents, were shown to induce a temporary up-regulation of 
RASSF7 and if prolonged to determine the ubiquitination of the protein 
(Takahashi et al., 2011). It is tempting to speculate that this observation 
could explain the different levels of RASSF7 expression in HeLa cells after 
the exposure to acute and chronic hypoxic insults (Chapter 3), as RASSF7 
mediated response to stress would not apply to sustained stresses. If this 
was verified, it would be possible to speculate that the high levels of 
RASSF7 proteins shown by HeLa cells chronically exposed to hypoxia and 
then left to recover in normoxic conditions are induced to restore normal 
cellular metabolism after persistent stress conditions. 
Future work is required to establish if there is a link between RASSF7 
induced stress response and RASSF7 role in mitosis.    
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Figure 6.2: RASSF7 inhibits pro-apoptotic JNK signaling. Schematic diagram of the  
relationships among the RASSF7, N-Ras, MKK7 (MAP kinase kinase 7) and Jun (c-Jun 
N-terminal kinase) proteins as proposed by Takahashi and colleagues (2011). Under 
resting or low stress conditions (left), the majority of MKK7 protein exists in its 
dephosphorylated form. RASSF7, in concert with N-Ras, prevents the phosphorylated 
form of MKK7 from accessing and/or activating its downstream substrate JNK. However, 
when stress is prolonged (right), the inhibitory action of RASSF7 on MKK7 is eliminated 
because of degradation of the RASSF7 protein via the Ubiquitin (Ub)–proteasome 
pathway. In the absence of RASSF7, phosphorylated MKK7 activates JNK, triggering 
apoptosis. Adapted from (Takahashi et al., 2011). 
RASSF7 and cancer 
Although gene and protein profiling studies have identified a correlation 
between abundant expression of RASSF7 and cancer development 
(Mutter et al., 2001; Logsdon et al., 2003; Friess et al., 2003; Lowe et al., 
2007; Tan et al., 2009), the lack of mechanistic or functional data has led 
to an incomplete understanding of what role, if any, RASSF7 could have in 
cancer progression. The production of RASSF7 transgenic mouse models 
will probably elucidate if RASSF7 mutants acquire new oncogenic 
activities to promote cancer. 
For now, the results reported in this thesis and the work of Takashi and 
colleagues (2011) may account for the association of elevated RASSF7 
with tumourigenesis. Unlike other RASSF proteins, RASSF7 would exert 
an anti-apoptotic function and would also be responsible for correct 
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completion of mitosis. The two roles could be linked as the MKK7-JNK 
signaling pathway has been associated to cell cycle progression. In fact  
mkk7-/- MEFs display reduced proliferation caused by cell cycle arrest 
(Wada et al., 2004).  
Targeting mitotic regulators allows the interference with specific molecular 
targets that have critical roles in tumour growth or progression. However, 
there is some concern regarding the long term implications of inhibiting 
molecules such as Aurora B in normal cells, although this could limit the 
replication of tumour cells. In view of these considerations, RASSF7 could 
be considered as a possible anti-cancer drug target. In fact, the molecule 
could potentially integrate cellular networks that are essential for tumour 
cell proliferation and viability. If further studies were able to confirm its 
versatile roles in mitosis and apoptosis, inhibiting RASSF7 might provide 
an opportunity to target a larger subset of cancers compared to single 
molecule inhibitors. 
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Figure 3.1: RASSF7, RASSF8, RASSF9 and RASSF10 are predicted to be
differentially expressed during mammalian development. In silico temporal N-Terminal
RASSF expression analysis in mouse (A) and in human (B) according to the NCBI
database (http://www.ncbi.nlm.nih.gov/UniGene/ESTProfile). Only the stages with total
expressed sequence tags (EST) counts exceeding 50,000 were considered.
Figure 3.2: RASSF7 and RASSF8 EST are more frequent than RASSF9 and
RASS10 predicted transcripts in mammalian tissues. In silico spatial N-
Terminal RASSF expression analysis in mouse (A) and in human (B) according to
the NCBI database (http://www.ncbi.nlm.nih.gov/UniGene/ESTProfile). Only the
tissues with total EST counts exceeding 50,000 were considered.
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Figure 3.3: Rassf7 is ubiquitously expressed during mid and late mouse
embryogenesis. In situ hybridisation (ISH) on E10.5 (A, 22x) and E15.5 (B, 8x) mouse
sagittal sections. Both Rassf7 RNA probed (left panel) and negative control (right panel)
are shown. The images are representative of at least three independent experiments.
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Figure 3.4: Rassf7 expression is high during late mouse embryogenesis. High
magnification images of the brain cortex, the gut and the heart of a E15.5 mouse embryo
probed for Rassf7 RNA (left panel) and negative control (central panel) (100x). Haematoxylin
and Eosin (H & E) staining is shown as reference (200x). The images are representative of at
least three independent experiments.
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Figure 3.5: Rassf7 expression is high during late mouse embryogenesis. High
magnification images of the lung and the kidney of a E15.5 mouse embryo probed for Rassf7
RNA (left panel) and negative control (central panel) (100x). H a E staining is shown as
reference (200x). The images are representative of at least three independent experiments.
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Figure 3.6: Rassf7 expression is high during late mouse embryogenesis. High
magnification images of the liver and the pancreas of a E15.5 mouse embryo probed for
Rassf7 RNA (left panel) and negative control (central panel) (100x). H a E staining is shown
as reference (200x). The images are representative of at least three independent experiments.
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Figure 3.7: Rassf7 expression is high in adult mouse organs. The strong signal detected
in the adult mouse lung, pancreas and brain indicates high Rassf7 expression levels. Both
Rassf7 RNA probed (left panel) and negative control (central panel) are shown (50x). H a E
staining is shown as reference (100x). Relevant organ structures are pointed by arrows. The
images are representative of at least three independent experiments.
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Figure 3.8: High Rassf7 expression in the adult mouse brain correlates with
high cell density. High magnification images of the dentate gyrus (pointed by
arrow), a region of the hippocampus (A), and the cerebellum (B) probed for Rassf7
RNA (left panel, 20x). The corresponding H and E staining is shown in the right
panel (50x) for cell number reference.
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Figure 3.9: RASSF7 is weakly expressed in the heart, the kidney and the liver during
mouse adulthood. The low intensity of the staining for the heart, the kidney and the liver
indicates a low Rassf7 expression. Both Rassf7 RNA probed (left panel) and negative control
(central panel) are shown (50x). H a E staining is shown as reference (100x). The images are
representative of at least three independent experiments.
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Figure 3.10: Rassf7 protein is expressed in many organs from an adult mouse.
Immunohistochemistry (IHC) conducted on adult mouse organs (60x) using AVIVA rabbit
anti RASSF7 antibody (A). The signal displayed by the corresponding negative controls,
probed for rabbit serum, was too weak for imaging (as shown in B). Mouse tissue array
kindly donated by Dr Jason Gill, University of Bradford).
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Figure 3.11: Mouse Rassf8 is expressed during mid and late mouse
embryogenesis. ISH on E10.5 (A, 22x) and E15.5 (B, 8x) mouse sagittal sections. Both
Rassf8 RNA probed (left panel) and negative control (right panel) are shown. The
images are representative of at least three independent experiments.
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Figure 3.12: Rassf8 expression in the adult mouse organs. Expression above the
background is shown for the liver, the lung and the kidney (left) whereas the brain, the heart
and the pancreas (right) do not show significant expression. Both Rassf8 RNA probed (first
and third panels) and negative control (second and fourth panels) are shown (50x). The
images are representative of at least three independent experiments.
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Figure 3.13: Rassf9 expression during late mouse embryogenesis. ISH on E15.5
mouse sagittal sections. Both Rassf9 RNA probed (left panel) and negative control (right
panel) are shown (8x). The images are representative of two independent experiments.
Figure 3.14: Expression of RASSF7 protein in different mammalian cell lines. Cell
lysates were probed with AVIVA anti RASSF7 and the protein levels were normalised to
b-tubulin. Data are representative of two independent experiments.
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Figure 3.15: RASSF7 protein is present in a range of human cancer cell types. IHC
conducted on human xenograft tumours grown in mice using AVIVA rabbit anti RASSF7
antibody (left panel) (60x). Negative controls, represented by samples probed for rabbit
serum, (right panel) are shown. For each cell line name and organ of origin are indicated.
Cancer tissue array kindly donated by Dr Jason Gill, University of Bradford.
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Figure 3.16: RASSF7 protein is present in a range of human cancer cell types. IHC
conducted on human xenograft tumours grown in mice using AVIVA rabbit anti RASSF7
antibody (left panel) (60x). Negative controls, represented by samples probed for rabbit
serum, (right panel) are shown. For each cell line name and organ of origin are indicated.
Cancer tissue array kindly donated by Dr Jason Gill, University of Bradford.
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Figure 3.17: RASSF7 levels of expression are not cell cycle dependent. HeLa cell
lysates were enriched with M phase cells through nocodazole treatment (75ng/ ml) for 18
hours followed by mitotic shake off. Lysates were then probed for either RASSF7 or
phospho histone H3 (Ser10) considered as marker for dividing cells. b-tubulin was used as
a loading control (A). Despite the dramatic difference for active H3 expression (B), RASSF7
expression levels are similar in nocodazole treated and untreated cells (C). **p<0.01. The
average results shown derive from three independent experiments. Error bars, Standard
Deviation (SD).
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Figure 3.18: RASSF7 protein is up-regulated under hypoxic conditions and its
expression is maintained higher than the normoxic control during recovery.
Hela cells were subjected to hypoxic insult (0.1% Oxygen) for 3 hours, 18 hours, 18
hours + 24 hour recovery in normoxic conditions. Cell lysates from normoxic and
hypoxic samples were probed for both RASSF7 and b-tubulin, used as a loading
control (A). Both acute and prolonged hypoxic stress followed by recovery led to a
significant RASSF7 over-expression compared to respective controls (B). *p<0.05,
**p<0.01. The average results shown derive from three independent experiments.
Error bars, SD.
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Figure 4.2: Endogenous human RASSF7 localises to specific structures adjacent to
the nucleus in a cell cycle independent fashion. RASSF7 (green) labelling structures are
detectable in both interphase (white arrows) and dividing (white arrowheads) HeLa cells (A).
RASSF7 expression is maintained throughout M phase as shown in B, C and D. Blue:
nuclear staining. The images are representative of three independent experiments.
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Figure 4.3: Endogenous human RASSF7 localises to the centrosomes. Co-localisation of
RASSF7 (red) with the centrosomal marker g-tubulin (green) (white arrows) in HeLa cells. Blue:
nuclear staining. The images are representative of three independent experiments.
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Figure 4.4: Human RASSF7 localisation is maintained after microtubule disruption.
Microtubules were disrupted in HeLa cells when treated with 300ng/ml of nocodazole for one hour at
37°C. Microtubules were stained using a-tubulin (green) (A). Nocodazole treatment did not affect
RASSF7 (red) localisation at the centrosomes (white arrows) which were stained for g-tubulin
(green) (B). Blue: nuclear staining. The images are representative of at least two independent
experiments.
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Figure 4.5: Localisation of ectopic human RASSF7 does not depend on the way the
fusion protein has been engineered. The high over-expression of either N terminal GFP-
(A) or C terminal V5- (B) tagged RASSF7 in HeLa cells causes the formation of
cytoplasmic punctuate structures (white arrows) which vary in number and size within the
cell. Transfected cells over-expressing RASSF7 at moderate levels present one inclusion
(white arrowheads). GFP only transfected cell (C) is shown as control. Green: exogenous
RASSF7. Blue: nuclear staining. The images are representative of three independent
experiments.
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Figure 4.6: Ectopic human RASSF7 localises to the same structures in HeLa cells
despite the differently located tags. GFP-RASSF7 (green) and RASSF7-V5 (red) exhibit
the same localisation (white arrows) when co-transfected. Blue: nuclear staining. The images
are representative of three independent experiments.
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Figure 4.7: Ectopic human RASSF7 is centrosomal in HeLa cells. Co-localisation of GFP-
RASSF7 (green) with centrosomal markers, pericentrin (red, A) and g-tubulin (red, B, C)
(white arrows) in both interphase (A, B) and diving cells (C). Blue: nuclear staining. The
images relative to interphase cells are representative of at least three independent
experiments. Only one transfected mitotic cell was found and imaged in all the specimens
analysed.
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Figure 4.8: Epitope tagged human RASSF7 localises to the centrosomes in HeLa cells.
Co-localisation of RASSF7-V5 (green) with the centrosomal marker pericentrin (red) (white
arrows). Blue: nuclear staining. The images are representative of at least three independent
experiments.
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Figure 4.9: Over-expressed human RASSF7 does not co-localise with microtubules. The
white arrow indicates the centrosome. Green: GFP-RASSF7, red: a-tubulin, blue: nuclear
staining. The images are representative of at least three independent experiments.
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Figure 4.10: Human RASSF8 localisation. HeLa cells were stained for RASSF8 (green) and
imaged in either interphase (A) or metaphase (B). In interphase, RASSF8 was observed within
the nucleus (white arrowheads) and the cell membrane (white arrows). Blue: nuclear staining.
The images are representative of at least two independent experiments.
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Figure 4.11: Ectopic human RASSF8 localisation. RASSF8-GFP (green) does not co-
localise with either pericentrin (red, A) or RASSF7-V5 (red, B) in HeLa cells. Blue: nuclear
staining. The images are representative of at least two independent experiments.
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Figure 5.2: RASSF7 knockdown prevents H1792 cells from forming anchorage
independent growth colonies. RASSF7 siRNA 2 specifically targeted RASSF7 as shown
by the immunoblot (A). Two weeks after transfecting RASSF7 KD2 in H1792 cells, both the
number and the size of the colonies (white arrows) were affected if compared to control (B)
and the difference is statistically significant (C). **p<0.01 vs Luciferase KD and RASSF7
KD1. Error bars, SD. Scale bars, 100 mM. Results of three independent experiments.
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Figure 5.4: RASSF7 shRNAi knockdown results in reduced numbers of HeLa cells.
Immunoblot of RASSF7 from control and RASSF7 knockdown (KD) cells. b-tubulin was
used as a loading control (A). HeLa cells were seeded at the same density and transfected
with constructs encoding resistance for G418 and shRNAi either targeting or non targeting
RASSF7. After the end for selection for G418, cells were allowed to grow and subsequently
counted (B). The difference in cell numbers between control and RASSF7 depleted HeLa
was 2.6 + 0.6 fold (***p<0.001). The average cell reduction was calculated from five
independent experiments (C). Error bars, SD. Scale bars, 100 mM.
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Figure 5.5: RASSF7 centrosomal staining is lost in RASSF7 KD HeLa cells. Control KD
(A) and RASSF7 shRNAi containing (B) HeLa cells were fixed and co-stained for RASSF7
(red) and the centrosomal marker g-tubulin (green) one day after the completion of G418
selection in transfected cells. In RASSF7 KD cells (B) there is some background staining but
no detectable RASSF7 staining at the centrosomes (white arrows). Blue: nuclear staining.
The images are representative of three independent experiments.
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Figure 5.6: RASSF7 KD did not cause a significant increase in apoptosis.
RASSF7 depletion in HeLa cells did not significantly increase the number of active
caspase 3 positive cells (green, highlighted by arrows) compared with controls
(A), as confirmed by statistical analysis (B). More than 500 cells were counted for
each sample from three independent experiments. Blue: nuclear staining.
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Figure 5.7: Early events of mitosis are not compromised by RASSF7 depletion. The
onset of chromosome condensation occurs normally for both control KD (A) and RASSF7 KD
(B) HeLa cells. Prophase cells were fixed and stained with the nuclear dye DAPI (blue) and
the microtubule marker a-tubulin (green). Images are representative of at least three
independent experiments.
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Figure 5.8: RASSF7 KD by shRNA impairs mitosis in HeLa cells. Metaphase RASSF7 KD
cells (B) exhibit defects in spindle formation (red arrows highlight the more radial microtubules)
and chromosomal congression (white arrows), with an increase in cells which had failed to align
their DNA (left panel) and an increase in cells with lagging chromosomes (red arrowhead).
There was also a small increase in tripolar spindles (white arrowheads). Control KD cell is
shown in A). Cells were fixed and stained with the nuclear dye DAPI (blue) and the microtubule
marker a-tubulin (green). Images are representative of at least three independent experiments.
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Figure 5.9: Late events of mitosis are not compromised by RASSF7 depletion. Anaphase
occurs normally for both control KD (A) and RASSF7 KD (B) HeLa cells. Cells were fixed and
stained with the nuclear dye DAPI (blue) and the microtubule marker a-tubulin (green). Images
are representative of at least three independent experiments.
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Figure 5.10: RASSF7 KD leads to a higher rate of polycentrosomal interphase
HeLa cells. RASS7 KD cells often presented multiple centrosomes when in
interphase, as indicated by arrows. Green: centrosomal marker pericentrin; Blue:
nuclear staining (A). The rate of polycentrosomal non dividing cells was significantly
higher for RASSF7 KD compared to controls as shown by the graph in B). *p<0.05,
more than 500 cells were counted for each individual specimen from three
independent experiments. Error bars, SD.
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Figure 5.11: RASSF7 depletion leads to polyploidy in interphase HeLa cells.
RASS7 disruption frequently resulted in the formation of multinucleated cells (as
indicated by the arrows). Green: microtubule marker a-tubulin; Blue: nuclear staining
(A). The graph shows the percentage of RASSF7 KD cells with abnormal DNA content
compared to control (B). **p<0.01, more than 500 cells were counted for each
individual specimen from three independent experiments. Error bars, SD.
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Figure 5.12: RASSF7 KD caused a slight but statistically significant increase of tetraploid
cells. Cytofluorimetric estimation of control and RASSF7 KD HeLa cell cycle stages. Sub G1, G1,
G2/M and polyploid cells were sorted according to DNA content (<2N, 2N, 4N and >4N
respectively), gated accordingly and then counted. The graph shows the average result of three
independent experiments. *p<0.05. One million events were considered each time. Error bars, SD.
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Figure 5.13: RASSF7 KD did not cause a significant increase in mitotic cells.
RASSF7 depletion in HeLa cells did not significantly increase the number of phospho
histone H3 (Ser10) positive cells (green, highlighted by arrows) compared with
controls (A), as confirmed by statistical analysis (B). More than 500 cells were counted
for each sample from three independent experiments. Blue: nuclear staining.
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Figure 5.14: Active Polo Like Kinese 1 (PLK1) localises to the centrosomes in RASSF7
KD cells. Control (A) and RASSF7 KD (B) cells were stained for phospho PLK1 (Thr210)
(green, white arrows) and DAPI (blue). The images are representative of at least two
independent experiments.
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Figure 5.15: RASSF1A continues being localised in RASSF7 KD cells. RASSF7 KD
HeLa cells exhibit normal centrosomal localisation of RASSF1A (green, white arrows) (B)
as in control cells (A). Blue: nuclear staining.
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Figure 5.16: Aurora A localises to the centrosomes in RASSF7 KD cells. Control (A) and
RASSF7 depleted (B) HeLa cells were stained for Aurora A (green) and DAPI (blue). Images are
representative of at least three independent experiments.
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AFigure 5.17: Aurora B localisation is maintained throughout mitosis in RASSF7 KD HeLa
cells. RASSF7 KD cells show Aurora B (green) localisation at the kinetochore as controls during
metaphase (A) and exhibit Aurora B at the mid body during cytokinesis (B). Blue: nuclear
staining. Images are representative of at least three independent experiments.
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Figure 5.18: There is reduced Aurora kinase activation at the kinetochore of RASSF7 KD
cells. Cells were stained with an antibody recognising the phosphorylated forms of Aurora A
(Thr288), Aurora B (Thr232), Aurora C (Thr198). In a normal control cell (A) phospho Aurora (green)
was detectable at both the centrosomes (white arrows) and at the kinetochore (white arrowhead).
RASSF7 depleted HeLa cells (B) were positive for phospho Aurora at the centrosomes (white
arrows) whereas reduced specific phospho Aurora staining was detectable at the kinetochore (white
arrowhead). Blue: nuclear staining. Images are representative of at least three independent
experiments.
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Figure 5.19: Aurora A is expressed and active at the centrosomes of RASSF7 KD cells. Co-
localisation of Aurora A (red) and phospho Aurora (green). The two signals coincide at the
centrosomes (white arrows) for both control (A) and RASSF7 KD (B) HeLa cells. Blue: nuclear
staining. The images are representative of at least three indipendent experiments.
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Figure 5.20: RASSF7 KD compromises Aurora B activity during metaphase but not
cytokinesis. Aurora B co-localises with Phospho-Aurora at the kinetochore (white arrowheads)
only in control metaphase cells (A). At the end of M phase Aurora B activity at the mid body of
RASSF7 KD HeLa cells is almost comparable to controls (B). Blue: nuclear staining. Images are
representative of at least three independent experiments.
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Figure 5.21: RASSF7 KD causes the reduced phosphorylation of CENP-A, a
prometaphase target of Aurora B. Control (A) and RASSF7 KD (B) HeLa cells were
stained for phospho CENP-A (Ser7) and DAPI (blue). Phospho CENP-A localises to the
kinetochore (white arrows) only in control cells. Images are representative of at least
three independent experiments.
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Figure 5.22: INCENP, which is required for Aurora B activation, is correctly
recruited to the kinetochore in RASSF7 KD cells. Control (A) and RASSF7 KD (B)
HeLa cells were stained for INCENP and DAPI (blue). Images are representative of at
least three independent experiments.
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